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Neurotrophic factors are small secretory proteins with important functions both in the 
nervous system and in peripheral tissues. Glial cell line-derived neurotrophic factor (GDNF) 
is best known for its ability to support the survival of midbrain dopaminergic neurons and 
enteric neurons. Also, GDNF is essential for the development of kidney and testis. It has been 
shown that both the absence and excessive amounts of GDNF protein negatively regulate 
kidney morphogenesis, highlighting the importance of proper spatiotemporal regulation of 
GDNF. Despite the wealth of knowledge regarding GDNF functions both in and outside the 
nervous system, relatively little is known about the trafficking mechanisms of GDNF.  
GDNF is synthesized as a precursor protein, proGDNF. In this thesis, we characterized 
the cellular localization and secretion of two GDNF splice variants, pre-(α)pro-GDNF and 
pre-(β)pro-GDNF, that differ in their pro-regions. Both precursor forms were shown to be 
secreted from cell lines. However, while (α)pro-GDNF co-localized mainly with the Golgi 
markers, the (β)pro-GDNF was found primarily in the secretogranin-II positive vesicles of 
the regulated secretory pathway. In accordance, the two splice isoforms responded 
differently to KCl-induced depolarization that is known to trigger the secretion of 
neurotrophin family members in neuronal cells. Only (β)pro-GDNF and corresponding 
mature GDNF were secreted activity-dependently, whereas (α)pro-GDNF and its 
corresponding mature GDNF were secreted via the constitutive secretory pathway. In 
addition, we determined which enzymes are responsible for the proteolytic cleavage of 
proGDNF into mature GDNF.  
To elucidate, whether secreted proGDNF has any biological activity, the recombinant 
cleavage-resistant proGDNF mutant protein was expressed in mammalian CHO cells and 
next purified from the media. Our results demonstrate that proGDNF is biologically active. 
Furthermore, similarly to mature GDNF, proGDNF can signal via the GDNF receptor 
α1/RET receptor tyrosine kinase complex and activate downstream MAPK and AKT 
pathways. Interestingly, proGDNF is not able to activate RET via the GFRα2 receptor.   
Finally, we identified a novel sorting receptor for GDNF and its receptors. Our results 
show that SorLA, a member of the vacuolar protein sorting 10-p domain receptor family, can 
internalize GDNF and GFRα1. While GDNF is subsequently degraded in lysosomes, GFRα1 
is recycled back to the cell membrane. In the presence of SorLA and GFRα1, also RET is 
internalized and directed to early endosomes. By regulating the availability of GDNF and its 
co-receptors, SorLA can inhibit GDNF-induced neurotrophic activity in SY5Y cells. 
Moreover, SorLA seems to regulate intracellular localization of GFRα1 in hippocampal 
neurons.   
In summary, results of this thesis characterize the cellular regulation of GDNF 
regarding its secretion, processing, internalization and subsequent degradation. 
Furthermore, this is the first time that biological functions of the GDNF precursor protein 
proGDNF are described. Our findings indicate that the trafficking of GDNF is very different 
from that of other neurotrophic factors, and in contrast to apoptotic proneurotrophins, 
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The nervous system has been of great interest to mankind for thousands of years, 
but modern neuroscience as a separate field of study was established only during 
the last century. Despite its “young” age, significant development of methods and 
tools have exponentially increased the amount of knowledge of how the nervous 
system works. Nevertheless, deciphering the precise regulation of molecular 
mechanisms within neurons and neuronal circuits continues to challenge scientists 
worldwide.  
The following literature review aims to give an overview of what is currently 
known about the regulation of neurotrophic factors, concentrating on the best-
studied neurotrophin family members, the glial cell line-derived neurotrophic factor 
(GDNF) and its receptors. 
1. Discovery and classification of neurotrophic factors 
Neurotrophic factors (NTFs) are small secretory proteins with a broad range of 
functions in the development and maintenance of the nervous system. NTFs act by 
binding to their cognate receptors on the cell surface and can support for example 
the survival, migration, and differentiation of neurons, as well as modulate neuronal 
connectivity.  
The first NTF was discovered and purified by Rita Levi-Montalcini, Viktor 
Hamburger, and Stanley Cohen back in the 1950-s. These scientists elegantly 
demonstrated that when certain mouse tumors were implanted in developing chick 
embryos, they released a soluble diffusible factor that induced extensive neurite 
outgrowth from cultured sensory and sympathetic ganglia (reviewed in Levi-
Montalcini, 1964). This factor was soon found to be highly expressed in snake venom 
and male mouse salivary gland, and this discovery enabled the biochemical 
purification and functional characterization of the protein (Cohen and Levi-
Montalcini, 1956; Cohen, 1960). The potent molecule was called nerve growth factor 
(NGF), which is the founding member of the neurotrophin protein family and the 
best studied neurotrophic factor so far. 
Based on their experimental data, Levi-Montalcini and Hamburger proposed a 
hypothesis, currently known as the classical “Neurotrophic Factor Hypothesis,” 
which in short states that during neuronal development neurons are born in excess, 
and target-derived neurotrophic factors are necessary for the proper formation of 
neuronal connections. NTFs are released by the targets in very low concentrations, 
and neurons of the same type compete for the supply. Successful neurons survive 
whereas others undergo programmed cell death (Hamburger and Levi-Montalcini, 
1949). This hypothesis, supported today by massive amounts of experimental data, 
holds true for NGF both in the peripheral and the central nervous system (Bothwell, 
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2014). However, in the case of other neurotrophic factors, for example, brain-
derived neurotrophic factor (BDNF) and neurotrophin-3 (NT-3), there is evidence 
suggesting that neurotrophic factors may function differently from what was 
postulated in the original hypothesis. Thus, neurotrophic factors should be 
considered as a heterogeneous group of trophic molecules based on the function and 
mode of action (Conner et al., 1998). 
Based on the structure of the ligands, NTFs are broadly classified in the 
following manner: 
1) Neurotrophins  
2) GDNF family ligands  
3) Neurokines  
4) MANF and CDNF protein family 
Neurotrophins and GDNF family ligands will be described in more detail in 
sections 2 and 3 of the introduction, respectively. Neurokines or neuropoietic 
cytokines are small molecules that act as monomers, signaling via common cytokine 
receptor components. Members of the neurokine protein family include ciliary 
neurotrophic factor (CNTF), interleukin 6 (IL-6), cardiotrophin 1 and 2, and 
leukemia inhibitory factor (LIF). In the nervous system, CNTF and other neurokine 
family members promote the survival of motor neurons (Sendtner, 2014). In 
addition, these factors play a role in metabolism and lipid homeostasis and are 
therefore candidates for treating obesity and obesity-related metabolic diseases 
(Pasquin et al., 2016).  
Mesencephalic astrocyte-derived neurotrophic factor (MANF) and its 
homologue CDNF (cerebral dopamine neurotrophic factor) are members of the 
most recently discovered neurotrophic factor family (reviewed in Lindholm and 
Saarma, 2010). Although the receptor for MANF and CDNF has not yet been 
discovered, evidence indicates that these proteins may have a unique mode of action 
compared to other NTFs. Crystal structures of MANF and CDNF revealed that both 
proteins have an amino-terminal saposin-like domain for possible interactions with 
lipids or membranes, and a carboxy-terminal domain that may protect cells against 
endoplasmic reticulum (ER) stress (Lindahl et al., 2017). So far, both proteins have 
been shown to support the survival of midbrain dopaminergic neurons, and CDNF 
will be used in Phase I/II clinical trial for the treatment of Parkinson's disease 
starting in September 2017 (Herantis Pharma Press Release 23.3.2017, 
http://herantis.com/release/herantis-pharmas-clinical-study-with-cdnf-in-parkinsons- 
disease-authorized-in-sweden/?lang=fi). Furthermore, MANF is an important 
regulator of endocrine islet beta cells and a potential therapeutic candidate for the 
treatment of diabetes mellitus (Lindahl et al., 2014).     
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2. Neurotrophins and their receptors 
While working with NGF, Rita Levi-Montalcini observed that although NGF was 
critical for the developmental survival of neural crest-derived peripheral sensory 
neurons, it did not support the survival of the cranial sensory ganglia, hinting the 
possible existence of another protein with trophic function (Levi-Montalcini, 
1964). At the beginning of 1980-s, brain-derived neurotrophic factor (BDNF) was 
purified from pig brain (Barde et al., 1982), and nucleotide sequence analysis 
revealed that BDNF was structurally similar to NGF (Leibrock et al., 1989). At 
present, there are four members in the mammalian neurotrophin protein family: 
NGF, BDNF, neurotrophin 3 (NT-3) (Hohn et al., 1990; Jones and Reichardt, 1990; 
Maisonpierre et al., 1990b; Rosenthal et al., 1990), and neurotrophin 4 (NT-4, also 
known as NT-4/5) (Berkemeier et al., 1991; Hallböök et al., 1991; Ip et al., 1992). 
Similarly to most growth factors, neurotrophins are first synthesized as precursor 
proteins (proneurotrophins) that undergo proteolytic processing to generate 
dimeric mature protein forms (Seidah et al., 1996). Mature neurotrophins signal 
via the members of tropomyosin-related kinase (Trk) receptor family as well as p75 
neurotrophin receptor (p75NTR). While p75NTR is a common low-affinity 
receptor for all neurotrophins, their binding to the Trk receptors is more ligand-
specific: NGF binds preferentially to TrkA, BDNF, and NT-4 to TrkB, and NT-3 to 
TrkC (Klein et al., 1991a, 1991b, 1992; Lamballe et al., 1991) (Figure 1). Ligand 
binding initiates phosphorylation of Trk receptors and regulates cell growth and 
survival by activation of downstream signaling pathways (reviewed by Reichardt, 
2006).  
 
Figure 1. Mature neurotrophins, proneurotrophins, and their preferred 
receptors. While mature neurotrophins (i.e., mNGF) bind either a specific high-affinity 
Trk receptor or common low-affinity p75NTR, proneurotrophins signal via a receptor 
complex comprising of p75NTR and either Sortilin or SorCS2. Figure adapted from Gibon 
and Barker, 2017. 
4 
 
For a long time, proneurotrophins were considered inactive precursor molecules 
and the proposed role of the pro-domain was to ensure proper folding and 
secretion of the mature NTF (Suter et al., 1991). In 2001, however, Lee and 
colleagues demonstrated for the first time that proneurotrophins are secreted, 
biologically active proteins that bind with high affinity to p75NTR and induce 
apoptosis in cultured neurons (Lee et al., 2001). Since then, many groups have 
investigated the function of those proteins and currently it is known that 
proneurotrophins bind a receptor complex comprising of p75NTR and either 
sortilin or SorCS2 (members of the vps10p domain protein family that will be 
discussed in section 1.5 of this thesis) (Figure 1), and modulate complex signaling 
regulating synaptic activity, pruning and network reorganization (Nykjaer et al., 
2004; Teng et al., 2010; Costa et al., 2017; Gibon and Barker, 2017). 
2.1. Expression and structure of neurotrophins 
Neurotrophins have a wide variety of functions in the peripheral and central nervous 
systems as well as in non-neuronal tissues. These include regulating neuronal 
development, differentiation, survival, and plasticity of certain neuronal 
populations (Bothwell, 2014). Furthermore, neurotrophins modulate retinal, 
cochlear and heart development, and participate in muscle development and 
function. BDNF, for example, has been shown to regulate the regeneration of 
myogenic progenitor cells in vivo (Clow and Jasmin, 2010).  
The expression of neurotrophin encoding genes, bdnf in particular, is tightly 
regulated, allowing precise temporal and spatial expression of the protein. BDNF is 
the most abundantly expressed neurotrophin in the central nervous system (CNS) 
and has been detected in the hippocampus, cerebral cortex, amygdala, and 
hypothalamus (Hofer et al., 1990; Ernfors et al., 1992; Conner et al., 1997). BDNF 
expression levels increase substantially after birth (Katoh-Semba et al., 1997). 
Human bdnf gene comprises nine exons, eight of which are noncoding 5′ exons, 
each controlled by a distinct promoter that is induced by different stimuli (Figure 
2A). For instance, promoter IV can be induced by neural activity, calcium influx, and 
activation of either NMDA receptor or cAMP-responsive element-binding protein 
(CREB). All promoters are linked by alternative splicing to exon IX encoding the 
protein and the 3′ untranslated region (UTR) (West et al., 2014). Since there are two 
polyadenylation sites in the bdnf 3′UTR, each transcript can exist in two forms, one 
with a short and the other with a long 3′UTR, generating a total of 34 possible 
transcripts in humans (Pruunsild et al., 2007) (Figure 2A). 
Several groups have reported that in neurons BDNF mRNA is distributed both 
in somatic structures and in dendritic compartments, where it can undergo local 
translation (reviewed in Edelmann et al., 2014). Recent work by Tongiorgi and 
colleagues suggests that spatial segregation of BDNF mRNA variants depends rather 
on sequences located in the 5′UTR region of BDNF mRNA than in the 3′UTR as 
proposed before. More specifically, neuronal activity drives relocation of transcripts 
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encoding exons 2, 4 or 6: exon 4 containing transcripts localize to proximal 
dendrites and exon 2 or 6 containing transcripts to the distal dendrites (Tongiorgi 
and Baj, 2008; Baj et al., 2011). All in all, though various stimuli regulate the 
transcription of bdnf and the transcripts differ in stability and localization, in the 
end, all of them give rise to the same BDNF protein (West et al., 2014) (see Figure 
2A). 
To add up to the complexity, BDNF is also regulated at the translational level. 
There are multiple conserved sequences in the 3′UTR of bdnf mRNA, and several 
RNA binding proteins such as tristetraprolin and microRNAs have been identified 
that bind to these regions and regulate the expression of BDNF protein either 
positively or negatively (Kumar et al., 2014; Varendi et al., 2014).  
NGF is expressed in both neuronal and non-neuronal cells of the peripheral 
nervous system (PNS) and CNS (Sofroniew et al., 2001). Similarly to BDNF, NGF 
expression can be regulated by neuronal activity as well as stimuli related to 
inflammation. Four different splicing patterns have been identified in mouse ngf 
gene consisting of five exons and a single polyadenylation site. The gene structure 
and synthesis of NT-3 and NT-4 is quite similar but their expression sites are very 
different: while NT-3 is highly expressed in the developing CNS, the levels of NT-4 
are highest in testis, skeletal muscle, and spinal cord but relatively low in the CNS. 
Both genes comprise three exons and three (NT-3) or four (NT-4) polyadenylation 
sites, giving rise to multiple mRNA transcripts. Unlike BDNF and NGF, the 
expression of NT-3 and NT-4 is not induced by neuronal activity (West et al., 2014).  
 
 
Figure 2. The structure of BDNF gene, NGF homodimer, and proNGF 
homodimer. A) The schematic structure of bdnf with 5′UTR, protein-encoding region 
(exon IX) and 3′UTR with two alternative polyadenylation (pA) sites. Exons inducing bdnf 
mRNA translocation to dendrites are marked with an asterisk. All transcripts give rise to 
identical BDNF protein B) The crystal structure of mature NGF, with one monomer 
colored blue and the other purple. C) Predicted structure of proNGF dimer, the pro-region 
is depicted in red and furin cleavage site is shown. The figures are modified from 
Maynard et al., 2016 (A); Butte et al., 1998 (B); Paoletti et al., 2011 (C). 
3'UTR
* * *





High-resolution crystal structures have been determined for all neurotrophins, 
and analysis of the structural data revealed a novel type of protein fold, referred to 
as a cysteine-knot structure (McDonald et al., 1991; Robinson et al., 1995; Butte et 
al., 1998). Highly conserved cysteines form three disulfide bridges that stabilize two 
pairs of antiparallel β-strands in each neurotrophin subunit (Figure 2B). In addition 
to neurotrophins, a similar folding pattern has been observed in other growth 
factors, for example in GDNF family ligands,  and platelet-derived growth factor 
(PDGF) family members (McDonald and Chao, 1995).  
Attempts to model the structure of the neurotrophin pro-domain indicated that 
the pro-region is largely disordered as it contains features typical of an intrinsically 
unfolded region (Anastasia et al., 2013). Crystallization of pro-NGF has proved 
difficult due to its dynamic nature (Feng et al., 2010). Nevertheless, a recent study 
provides evidence that pro-domain of NGF assumes globular conformation in 
solution (Paoletti et al., 2011) (Figure 2C).  
2.2. Trafficking and processing of neurotrophins 
Like neuropeptides, neurotrophins are synthesized as preproproteins in the 
endoplasmic reticulum (ER). The pre-region is cleaved off co-translationally, and 
next, the proneurotrophins ranging from 210 to 270 amino acids in length dimerize 
via the mature region and can undergo post-translational modifications (i.e., 
glycosylation, amidation) while being transported through the Golgi complex and 
packed into the secretory vesicles (Bradshaw et al., 1993). Glycosylation of the NGF 
pro-domain and trimming of the oligosaccharide chains have been shown to be 
important for the precursor to exit ER and subsequent processing and secretion of 
the protein (Seidah et al., 1996b).  
Two major secretory pathways exist in the cell, and these are the constitutive 
pathway, present in all cell types, and the regulated pathway that is employed by 
excitable cells like neurons. In the constitutive pathway, vesicles release their cargo 
by default when reaching the plasma membrane, whereas large dense core vesicles 
used by the regulated secretory pathway need elevated Ca2+ for exocytosis. The 
secretion mechanisms of neurotrophins have been studied extensively. In neurons, 
NGF and NT-4 are predominantly secreted via the constitutive pathway but can also 
be found in the secretory granules of the regulated pathway in both axons and 
dendrites of the CNS neurons (reviewed in Leßmann and Brigadski, 2009). In 
cultured hippocampal neurons, removal of the pro-region is essential for the 
regulated secretion of mature NGF (Lim et al., 2007).  
Neuronal BDNF and NT-3 are secreted mainly in an activity-dependent manner 
with similar efficiency (Mowla et al., 1999; Brigadski et al., 2005). The precise 
molecular mechanism determining which proteins in the trans-Golgi network 
(TGN) are directed to either of the two pathways described or secreted via other, 
unconventional secretory pathways, remains largely elusive. It is suggested that 
sequence information within the prodomain is necessary for protein sorting (Ma et 
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al., 2008), and this is partly true for BDNF. Vps10p domain receptor family member 
sortilin has been reported to guide BDNF to the activity-dependent secretory 
pathway by interacting with BDNF prodomain (Chen et al., 2005). A single-
nucleotide polymorphism (SNP) in bdnf gene leading to a substitution of valine to 
methionine at codon 66 (Val66Met) can alter the binding affinity to sortilin and 
compromise the trafficking of proBDNF (Chen et al., 2008) (Figure 3). Importantly, 
more than 25% of the human population is either homozygous or heterozygous for 
this mutation that is strongly associated with deficits in episodic memory, reduced 
hippocampal volume and a higher risk of depression (Egan et al., 2003).   
In addition to sortilin, carboxypeptidase E (CPE) has been shown to bind BDNF 
and direct the protein to the regulated pathway (Figure 3). Unlike sortilin, CPE 
interacts with the mature domain of BDNF (Lou et al., 2005). This interaction may 
be necessary for the activity-dependent secretion of mature BDNF that has 
undergone proteolytic processing in the trans-Golgi network.  
Cleavage of the pro-domains is highly regulated and can occur in multiple 
places along the secretory pathways or in the extracellular space, depending on the 
cellular context and the expression of proteases. Proneurotrophins contain 
conserved dibasic amino acid sequences in their prodomain and a consensus motif 
(K/R)-(X)-(K/R) - (R), where X is any amino acid, is recognized by the proprotein 
convertase (PC) family members (Figure 3). There are nine members in the 













Figure 3. Potential sites of post-translational modifications in BDNF 
precursor protein. BDNF pre-, pro- and mature domains are drawn in scale. 
Different members of the proprotein convertase (PC) family can cleave BDNF in 
addition to subtilisin/kexin, and furin. BDNF can also be cleaved by matrix 
metalloproteinases (MMP) and plasmin. In addition, a putative N-glycosylation site, 
carboxypeptidase E sorting signal, and the position of the Val66Met single nucleotide 
polymorphism (SNP) are shown. Figure adapted from Lessmann and Brigadski, 2009. 
 
All PC-s are initially synthesized as inactive zymogens that are activated by 
cleavage of the prosegment. PCs differ in expression, and subcellular localization: 
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ubiquitously expressed membrane-bound furin and PC7 are activated in the TGN, 
soluble PC1/3 and PC2 are expressed mainly in neurons and activated specifically in 
dense core secretory granules. PC4, PCSK9, PACE4, and PC5/6A are secreted via 
the constitutive pathway, and the latter two interact with heparan sulfate 
proteoglycans via their cysteine-rich domains (reviewed in Seidah et al., 2008). 
PCs can hydrolyze proneurotrophins either in the Golgi apparatus, in the TGN or in 
the lumen of the secretory vesicles, to release the mature protein and the prodomain.  
If proneurotrophins are secreted, they can be cleaved extracellularly by serine 
protease plasmin or by selective matrix metalloproteinases (MMP3, MMP7, and 
MMP9) (Lee et al., 2001; Mizoguchi et al., 2011) (Figure 3). Cultured hippocampal 
neurons, for instance, secrete a substantial proportion of proBDNF compared to 
mature BDNF and cleavage of proBDNF by plasmin is essential for the expression 
of late-phase long term potentiation and hence hippocampal plasticity and 
formation of memory (Pang et al., 2004; Barnes and Thomas, 2008). 
After secretion, neurotrophins signal by binding to their preferred 
transmembrane Trk receptor tyrosine kinase and elicit signaling cascades 
promoting survival and differentiation, BDNF-TrkB signaling also modulates 
synaptic plasticity (Costa et al., 2017). When high concentrations of mature 
neurotrophins engage with the p75NTR receptor, a stress kinase c-Jun is activated, 
leading to activation of the apoptotic pathway (Teng et al., 2010). Once the ligand is 
bound to either of the receptors, the activated complex is quickly internalized. 
Interestingly, Yang and colleagues showed that proBDNF could be cleaved after 
being internalized in complex with p75NTR and yield mature BDNF that can either 
activate endocytosed TrkB or be recycled back to the cell surface (Yang et al., 2009).  
A characteristic feature of the neurotrophins is their dynein-dependent 
retrograde transport in signaling endosomes. In this way, neurotrophins exert many 
of their functions including regulation of neuronal survival and specification, 
modulation of both axonal and dendritic growth, and regulation of the degree of 
connectivity between neurons by promoting postsynaptic density formation 
(Zweifel et al., 2005; Bronfman et al., 2014). Neurotrophins are degraded in 
lysosomes, and unexpectedly, trafficking of BDNF to the lysosome requires the 
cytoplasmic tail of sortilin - the same sorting receptor that regulates BDNF secretion 
(Evans et al., 2011). 
2.3. Biological functions of proneurotrophins 
Historically, pro-domain containing precursor proteins have been considered 
biologically inactive. As already mentioned, the pro-region was suggested to contain 
information needed for proper folding, intracellular trafficking and protection from 
proteolytic degradation of the protein and these assumptions were shown to be true 
for proneurotrophins (Suter et al., 1991; Seidah et al., 1996b; Paoletti et al., 2011). 
Moreover, the pro-domain was thought to be involved in the inactivation of the 
mature domain, but studies investigating the role of proneurotrophins proved 
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otherwise. The biological activity of proneurotrophins was first demonstrated in 
2001 and in subsequent years, several groups intensively studied the functions of 
proneurotrophins and the role of the pro-region of neurotrophins as well as other 
growth factors (Lee et al., 2001; Hillger et al., 2005; Hempstead, 2006; Bradley et 
al., 2010; Costa et al., 2017). 
To date, proNGF and proBDNF have been characterized thoroughly, proNT-3 
to a lesser extent and nothing has been reported on a role for proNT-4. Two main 
findings concerning proneurotrophins except proNT-4 are the following: they can 
be secreted, and they all bind with high affinity to p75NTR via their mature domain 
(Lee et al., 2001; Hasan et al., 2003; Bruno and Cuello, 2006; Yang et al., 2009; 
Yano et al., 2009). In addition, despite low sequence homology of the pro-domains, 
proNGF, proBDNF and proNT-3 but not proNT-4 can bind to sortilin via their pro-
region (Leibrock et al., 1989; Jones and Reichardt, 1990; Maisonpierre et al., 1990a; 
Nykjaer et al., 2004; Teng et al., 2005; Yano et al., 2009). Signaling via a receptor 
complex comprising of p75NTR and sortilin, proneurotrophins can induce 
apoptosis in different neuronal populations as well as in oligodendrocytes (Costa et 
al., 2017). Recently another member of the vps10p sorting receptor family, SorCS2, 
was shown to mediate the actions of proneurotrophins when in complex with 
p75NTR. ProNGF and proBDNF can initiate growth cone retraction, while proNT-3 
modulates the proliferation of cerebellar neurons via this complex (Deinhardt et al., 
2011; Anastasia et al., 2013; Zanin et al., 2016). 
The levels of proneurotrophins change during development. While proNGF is 
expressed at low level in non-injured or young animals, and the levels are 
upregulated in aging rodents, the amount of proBDNF decreases during aging and 
in adult mouse brain, where the mature form dominates (Fahnestock et al., 2001; 
Al-Shawi et al., 2008; Yang et al., 2009). ProNGF levels are increased upon injury 
and in patients suffering from Alzheimer's disease (Fahnestock et al., 2001; 
Harrington et al., 2004). In rat cortical neurons, proNGF secretion occurs in an 
activity-dependent manner (Bruno and Cuello, 2006). Its function on the cell 
surface depends on the availability of signal-mediating receptors (Ioannou and 
Fahnestock, 2017). It is important to mention that in addition to interacting with 
p75NTR and sortilin, proNGF can also bind to TrkA, although with much lower 
affinity than NGF (Fahnestock et al., 2004). In this way, proNGF can exhibit 
neurotrophic activity similarly to the mature form (Clewes et al., 2008; Masoudi et 
al., 2009). Recent work analyzing the effects of proNGF and NGF in PC12 cell line 
suggests that proNGF can be trophic in the presence of TrkA, p75NTR, and sortilin 
but when TrkA levels are reduced, proNGF activity shifts from survival signaling to 
induction of cell death (Ioannou and Fahnestock, 2017).    
ProBDNF can be released from cultured hippocampal neurons in response to 
depolarization similarly to mature BDNF (Yang et al., 2009). The electrical signal 
triggering their secretion differs in that mature BDNF secretion is regulated by high-
frequency stimulation while proBDNF responds to low-frequency stimulation (used 
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to induce long-term depression (LTD)) (Nagappan et al., 2009). Since proBDNF can 
be cleaved by proconvertases in the secretary vesicles, also the isolated pro-peptide 
can be secreted from neurons (Lee et al., 2001; Dieni et al., 2012). The effects of 
secreted proBDNF are opposite to those of mature BDNF. While BDNF elicits 
survival and differentiation signals and is needed for neurogenesis and long-term 
potentiation (LTP), proBDNF binds to a complex of p75NTR and sortilin or sorCS2, 
to promote cell death, growth cone retraction and LTD (reviewed in Costa et al., 
2017; Kojima and Mizui, 2017). Nevertheless, similarly to proNGF's ability to signal 
via TrkA, proBDNF can bind to and activate TrkB receptor with a slightly lower 
affinity compared to mature BDNF, suggesting that proBDNF could also participate 
in trophic signaling (Fayard et al., 2005). Generation of pro-region specific 
antibodies revealed that in the brain, the expression levels of BDNF N-terminal 
propeptide are greater than that of proBDNF (Dieni et al., 2012). Further studies 
investigating the biological activity of this fragment showed that BDNF propeptide 
acts as a monomer and can elicit LTD similarly to proBDNF protein (Mizui et al., 
2015; Zanin et al., 2017). Moreover, when analyzing the structure of recombinant 
Val66 and Met66 propeptide variants, a shift in conformation from β-strand to 
helical conformation was observed in the Met66 propeptide. This conformational 
change was suggested to account for the enhanced ability of the Met-type BDNF 
propeptide to bind to SorCS2 and promote growth cone retraction in a p75NTR-
dependent manner (Anastasia et al., 2013).  
ProNT-3 is secreted activity-dependently and induces cell death in superior 
cervical ganglion neurons by signaling via p75NTR and sortilin (Yano et al., 2009). 
Also, proNT-3 can bind to a complex of p75NTR and SorCS2 expressed in cerebellar 
granule cells to modulate Ca2+ homeostasis and mitochondrial potential as well as 
to regulate cell cycle exit of these cells (Safina et al., 2015; Zanin et al., 2016).  
In conclusion, proneurotrophins are biologically active ligands with important 
cellular functions. Although proneurotrophins are best known for promoting cell 
death, they can also induce survival signals in Trk-dependent manner and should 
not be considered solely apoptotic molecules.   
2.4. General characterization of neurotrophin receptors 
As mentioned at the beginning of section 2, neurotrophin receptors include p75NTR 
of the tumor necrosis factor (TNF) superfamily and members of the Trk receptor 
family.  
p75NTR was initially identified as a low-affinity receptor for NGF, but in the 
following years, it was shown to bind all neurotrophins with the similar affinity via 
the cysteine-rich domains (CRDs) in its extracellular domain (Rodriguez-Tébar et 
al., 1990; Rodríguez-Tébar et al., 1992; Baldwin and Shooter, 1995). Today, the pan-
neurotrophin receptor p75NTR is also known as a high-affinity receptor for 
proneurotrophins (Lee et al., 2001; Yano et al., 2009). p75NTR is widely expressed 
in both central and peripheral neurons and glia of the developing nervous system 
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(Ernfors et al., 1991). For example, in the CNS it is mainly found in the striatum, 
some brainstem nuclei and the cholinergic neurons of the basal forebrain, the latter 
continue to express high levels of p75NTR through adulthood (Pioro and Cuello, 
1990). Importantly, p75NTR expression increases in neurons, macrophages, 
microglia, astrocytes, and Schwann cells in response to injury, seizures and 
neurodegenerative diseases. In non-neuronal tissue, p75NTR is detected in heart 
and muscle (Meeker and Williams, 2015).  
Structurally, p75NTR comprises the extracellular domain with four CRDs, 
transmembrane domain and the intracellular domain (ICD)(He and Garcia, 2004) 
(Figure 4). Two domains have been identified in the p75NTR ICD: a Chopper 
domain in the juxtamembrane region that is able to induce cell death when bound 
to the membrane (Coulson et al., 2000; Underwood et al., 2008) and a C-terminal 
region that resembles the death domain present in TNF receptor (TNFR) and the 
Fas antigen, used for mediating apoptotic signals. p75NTR undergoes a two-step 
regulated intracellular proteolysis whereby it is first cleaved by the α-secretase 
TACE/ADAM17 and subsequently by presenilin-dependent γ-secretase, releasing 
the ICD of p75NTR to the cytosol for signaling (Skeldal et al., 2011). The ICD of 
p75NTR receptor does not contain catalytic activity but is able to recruit a number 
of cytosolic signaling adaptor proteins and promote downstream signaling 
(Kraemer et al., 2014).  
p75NTR has been attributed numerous functions that modulate survival, 
differentiation or death of the cell depending on whether p75NTR is expressed 
independently or in association with different co-receptors on the plasma 
membrane and which ligand it binds to (Meeker and Williams, 2015) (see Figure 4). 
Strikingly, for a long time, there was no consensus whether p75NTR signals as a 
monomer or a dimer (He and Garcia, 2004; Feng et al., 2010). Results of a very 
recent publication demonstrate that on the cell surface p75NTR can co-exist both as 
a monomer or a trimer (Anastasia et al., 2015).  
Binding of neurotrophins results in p75NTR mediated activation of the nuclear 
factor-κB (NF-κB) and c-Jun N-terminal kinase (JNK) pathways, inducing cell 
death. When co-expressed with the Trk receptors, p75NTR can enhance the binding 
affinity between neurotrophins and the Trk receptors, supporting survival and 
growth signaling via an unknown mechanism since the direct interaction between 
p75NTR and Trk receptors has not been demonstrated (Hempstead et al., 1991; 
Esposito et al., 2001). When in complex with the vps10p domain receptors sortilin 
or sorCS2, p75NTR mediates proneurotrophin signaling. The interaction of p75NTR 
and sortilin occurs via the extracellular domains of the receptors (Skeldal et al., 
2012). ProNGF induces apoptosis of the sympathetic as well as basal forebrain 
neurons when it binds to the complex of p75NTR and sortilin (Lee et al., 2001; 
Nykjaer et al., 2004). ProBDNF signaling via p75NTR/SorCS2 can induce long-term 
depression (LTD) in hippocampal neurons, while proNT3 reduces proliferation of 
cerebellar cells through the same receptor complex (Gibon and Barker, 2017). 
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Finally, p75NTR interactions with the Nogo receptor and Lingo-1 regulate cell 
growth. Myelin-derived ligands Nogo, MAG, and MOG bind to the receptor 
complex, activating RhoA and leading to growth cone collapse, neurite retraction 














Figure 4. Neurotrophin receptor p75NTR and its co-
receptors. Figure adapted from Meeker and Williams, 2015.  
 
There are three members in the Trk family of tyrosine kinase receptors: TrkA, 
TrkB, and TrkC. The expression patterns of Trk receptors do not overlap 
significantly: TrkB is primarily expressed by both neuronal and glial cells of the CNS, 
while TrkA and TrkC can be found mainly in neurons of the PNS and less in the CNS. 
Each Trk receptor selectively binds to different neurotrophin family members with 
nanomolar affinity. TrkA is the preferred receptor of NGF but can also be activated 
by NT-3 and NT-4, TrkB binds BDNF and NT-4, and TrkC is the receptor for NT-3 
(Klein et al., 1991a, 1991b, 1992; Lamballe et al., 1991).  
Trk receptor family belongs to the receptor tyrosine kinase (RTK) superfamily. 
They are type-1 transmembrane receptors with a large, heavily glycosylated 
extracellular domain followed by a single-pass transmembrane domain and an 
intracellular tyrosine kinase domain. The extracellular domain comprises one CRD, 
three N-terminal leucine-rich repeats (LRR), another CRD and two 
immunoglobulin-C2 (Ig) domains. Binding of the ligands occurs via the second Ig 
domain, triggering receptor dimerization and consequent trans-activation of the 
kinase domain, followed by activation of signaling pathways. In addition to direct 
activation by neurotrophins, Trk receptors can be intracellularly transactivated in 
vivo by epidermal growth factor (EGF), glucocorticoids and zinc (reviewed in 
Deinhardt and Chao, 2014).  
Major pathways activated by the phosphorylation of the tyrosine residues in the 
intracellular kinase domain of Trk receptors include i) the mitogen-activated 
protein kinase - extracellular signal-regulated kinase (MAPK-ERK) pathway 
mediating neuronal survival and differentiation, ii) the phosphatidylinositol 3-
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kinase – protein kinase B (PI3K – AKT) pathway modulating retrograde survival 
signals, and iii) the phospholipase Cγ1 – protein kinase C (PLCγ1 - PKC) pathway 
through which TrkB is involved in synaptic transmission and long-term potentiation 
(LTP) (Reichardt, 2006). Also Src signaling pathway can be induced by active Trk 
receptors (Reichardt, 2006).  
Trk signaling may be compromised by truncated isoforms of TrkB and TrkC 
lacking the tyrosine kinase domain. These splice variants can form heterodimers 
with full-length monomers and have dominant negative effects, sequester 
neurotrophins, and signal independently (Eide et al., 1996; Fenner, 2012). Upon 
ligand engagement, Trk receptors are quickly internalized and can either undergo 
recycling or degradation, or form signaling endosomes that are retrogradely 
transported and mediate signaling from axons to cell soma and dendrites (Grimes 
et al., 1996; Ginty and Segal, 2002; Barford et al., 2017).  
2.5. Trafficking of neurotrophin receptors 
Trk receptors are synthesized at the ER, and their expression can be triggered by 
neuronal activity similarly to their ligands. TrkB mRNA has been shown to 
translocate to the dendrites for local translation in response to BDNF and neuronal 
activity (Tongiorgi et al., 1997; Tongiorgi and Baj, 2008). Trk receptors are 
glycosylated post-translationally and transported to the cell membrane by 
microtubule-dependent kinesins (Deinhardt and Chao, 2014). More specifically, the 
interaction of TrkB cytoplasmic region and kinesin-1 is mediated by a complex 
comprising of collapsin response mediator protein-2 (CRMP-2), a small GTPase 
Rab27 and its effector Slp1 (Arimura et al., 2009). In sensory neurons, anterograde 
transport of the Trk receptors is facilitated by sortilin (Vaegter et al., 2011).  
Both plasma membrane and intracellular membranes contain asymmetrically 
distributed clusters of sphingolipids and cholesterol are called lipid rafts. They are 
suggested to be important for cell adhesion, axon guidance, and synaptic 
transmission by forming a signaling hub for transmembrane receptors with adaptor 
and signaling proteins (Simons and Ikonen, 1997; Ikonen and Simons, 1998; Tsui-
Pierchala et al., 2002b). Despite abundant literature characterizing the lipid rafts in 
in vitro settings, there has been a long debate whether they exist in vivo. In a recent 
publication, lipid rafts were detected for the first time in vivo when the structure of 
the biological membranes was analyzed by small-angle neutron scattering (SANS) 
(Nickels et al., 2017).  
NTF receptors can localize to lipid rafts before ligand binding (i.e., GDNF 
receptor α family members) or move to these microdomains upon ligand 
engagement. TrkA and p75NTR are concentrated in caveolae-containing lipid rafts 
at the plasma membrane. Moreover, caveolin-1 and caveolin-2 differentially 
regulate Trk signaling and subsequent cell differentiation (Spencer et al., 2017). 
TrkB, in turn, translocates to lipid rafts of the intracellular compartments in 
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response to BDNF in a tyrosine kinase Fyn-dependent manner (Pereira and Chao, 
2007).  
Internalization of the Trk receptors can occur in two different ways: one is 
clathrin and dynamin dependent, whereas the other is an actin-dependent 
macropinocytotic process. Both types of internalization can take place in axons but 
also in the cell body. After internalization of the activated ligand-receptor complex, 
Trk receptors continue signaling from early endosomes, and small Rab GTPases 
regulate the dynamics of intracellular trafficking (Grimes et al., 1996; Bronfman et 
al., 2014). Some endosomes are recycled, others are sorted to late endosomes and 
lysosomes. TrkA receptor contains a post-endocytic recycling signal in its 
juxtamembrane domain, and hence it is recycled back to the plasma membrane 
more efficiently than TrkB or TrkC. Furthermore, in developing sympathetic 
neurons, somatic TrkA can be endocytosed in the absence of NGF and resides in 
endosomes in cell soma.  
NGF signaling at distal axons triggers the anterograde transport of endocytosed 
TrkA and exocytosis of the receptor into axon growth cones (Ascano et al., 2009). 
This process whereby an endocytosed receptor is anterogradely transported from 
somatodendritic compartments to axon terminals is called transcytosis (Horton and 
Ehlers, 2003). When the Trk receptors are expressed in distal axons, target-derived 
ligand engagement leads to the internalization of the signaling complex and 
retrograde transport of the signaling endosome (Ye et al., 2003; Howe and Mobley, 
2005).  
Rab5 and Rab7 have been implicated to be important for guiding the signaling 
endosome retrograde transport. For example, the signaling endosome containing 
BDNF-TrkB receptor undergoes a conversion from Rab5-positive early endosome 
to Rab7-positive late endosome, and the retrograde transport depends on an 
adaptor protein snapin linking TrkB to dynein and microtubules (Deinhardt et al., 
2006; Bronfman et al., 2014; Barford et al., 2017). It is not well understood, what 
happens to the signaling endosome when it has reached cell soma. Suo and 
colleagues showed recently that TrkA containing signaling endosomes were active 
at the cell soma for up to 25 hours, with persistent signaling inducing transcriptional 
changes by controlling nuclear transactivation of genes such as CREB (Suo et al., 
2014) (Figure 5). Instead of subsequent degradation, the signaling endosome was 
exocytosed on the soma membrane and later re-internalized (Suo et al., 2014). By 
this mechanism, some signaling endosomes are thought to switch compartment 
identity from Rab7-positive late endosomes to Rab11-positive recycling endosomes, 
but further studies are needed to confirm this hypothesis (Barford et al., 2017).  
The degradation of Trk receptors occurs mainly in lysosomes. As mentioned 
before, due to a particular recycling signal, TrkA is preferentially sorted to the 
recycling pathway and thus escapes lysosomal degradation, while TrkB is sorted 




Figure 5. Model for the retrograde transport of Trk receptors and 
neurotrophins. Target-derived neurotrophins bind to Trk receptors expressed in 
distal axons. Activated TrkA can induce axon extension via Erk1/2 and PI3K signaling 
pathways. Alternatively, the signaling complex of NGF-TrkA is internalized, and, 
subsequently, retrogradely transported to convey trophic signals to the cell body. Figure 
adapted from Ginty and Segal, 2002.  
 
The rate of degradation is decreased when TrkB interacts with a recently 
identified regulator Slitrk5 that targets the receptor to recycling endosomes (Song 
et al., 2015). Trk receptor turnover and degradation can also be regulated via 
ubiquitination and deubiquitination, but the exact mechanisms and outcomes 
behind these processes remain unresolved (Sánchez-Sánchez and Arévalo, 2017).  
Despite the wealth of knowledge regarding p75NTR functions, detailed 
characterization of its cellular trafficking remains to be studied. Before reaching the 
cell surface, p75NTR is glycosylated posttranslationally as it possesses both N-
glycosylation and O-glycosylation sites, and its activity can be regulated by 
neurotrophins (Skeldal et al., 2011). 
Similarly to Trk receptors, p75NTR concentrates to lipid rafts in response to 
neurotrophins, implicating the importance of this membrane microdomain in 
p75NTR signaling. When exposed to NGF or BDNF, p75NTR is internalized in a 
clathrin-dependent manner in PC12 cell line but with slower kinetics compared to 
TrkA. Clathrin-dependent endocytic pathway targets p75NTR to retrograde 
transport (Deinhardt et al., 2007). In motor neurons, p75NTR internalization 
mechanism is site-specific: in soma p75NTR is endocytosed in the absence of the 
ligand in a clathrin-independent manner while in axons the two pathways co-exist. 
After internalization, p75NTR undergoes proteolytic processing, giving rise to C-
terminal fragments that are critical for signaling. P75NTR continues to signal in 
recycling endosomes but is also detected from multivesicular bodies targeted for 
exosomal release (Escudero et al., 2014). In motor neurons, p75NTR is recycled both 




The significance of p75NTR retrograde transport is not well understood. A few 
recent studies indicate that retrograde transport of p75NTR in complex with either 
BDNF or proNT3 can lead to apoptosis in sympathetic neurons (Hibbert et al., 2006; 
Yano et al., 2009).   
3. GDNF family ligands 
GDNF family ligands (GFLs) include GDNF, neurturin (NRTN), artemin (ARTN) 
and persephin (PSPN). They are distant members of the TGF-β superfamily due to 
a conserved pattern of seven cysteine (Cys) residues in their primary sequence 
(Airaksinen and Saarma, 2002) (Figure 6). All GFLs are synthesized as precursor 
proteins, containing a signal sequence and a pro-region similarly to neurotrophins. 
Interestingly, GDNF is the only member of the GFLs that is known to be glycosylated 
(Lin et al., 1993; Piccinini et al., 2013) (see Figure 6). GFLs are biologically active as 
homodimers and signal preferentially via a receptor complex comprising one of four 
cognate co-receptors known as GDNF family receptor-α (GFRα), and 


















Figure 6. Schematic representation of GDNF family ligands (GFLs). All four 
GFL members encode a signal sequence marked with light green, followed by a pro-
region (yellow) of variable length. The mature domain of GFLs is highly conserved, 
containing seven cysteine residues depicted as black lines. N marks putative N-linked 
glycosylation sites found in GDNF.  
 
In addition, GFLs bind to heparin and their signaling can be mediated by 
alternative receptors like neuronal cell adhesion molecule (NCAM) and syndecan-3 
(Paratcha et al., 2003; Bespalov et al., 2011). GFLs are involved in the development, 
differentiation and maintenance of multiple neuronal populations including 
dopaminergic, sensory, motor, sympathetic, parasympathetic and enteric neurons 
(Airaksinen and Saarma, 2002). Outside the nervous system, members of the GFLs 
are important for example in kidney development, regulation of spermatogenesis 
and lung pathophysiology (Moore et al., 1996; Davies et al., 1999; Meng et al., 2001; 





3.1. Glial cell line-derived neurotrophic factor (GDNF) 
GDNF is a founding member of the GDNF family ligands that was initially 
discovered as a survival factor for dissociated rat embryonic midbrain dopaminergic 
neurons (Lin et al., 1993). Over the years, numerous other functions have been 
attributed to this NTF and those will be discussed in section 3.1.3, but to name a few, 
GDNF is critical for the development of kidney and the enteric nervous system. 
Moreover, it modulates survival, migration, and differentiation of several neuronal 
populations such as sensory, sympathetic and motor neurons (reviewed in 
Airaksinen and Saarma, 2002). In line with that, GDNF-deficient mice completely 
lack the enteric nervous system, and kidneys, and they die shortly after birth. 
Notably, whereas the knockout animals have deficits in dorsal root ganglion, 
sympathetic and nodose neurons, their midbrain dopamine neurons do not differ 
from wild-type (wt) littermates (Moore et al., 1996; Pichel et al., 1996). These results 
suggest that GDNF is not a critical survival factor for embryonic development of 
dopaminergic neurons. 
In the brain, GDNF expression has been detected in several regions including 
parvalbumin positive interneurons of the striatum, hypothalamus, hippocampus, 
cerebellum and olfactory bulb (Trupp et al., 1997; Golden et al., 1998, 1999; Hidalgo-
Figueroa et al., 2012). A recent study, where a transgenic mouse model with GDNF 
overexpression from the native locus was used, confirmed the reported expression 
pattern (Kumar et al., 2015). Outside the CNS, GDNF is expressed more abundantly 
and is found in sensory neurons, sciatic nerve, developing kidney, ovary, 
gastrointestinal tract, testis, heart, lung, and liver for example (Suter-Crazzolara and 
Unsicker, 1994; Trupp et al., 1995; Suvanto et al., 1996; Kumar et al., 2015).  
GDNF is initially synthesized as a 211 amino acids long precursor protein which 
is cleaved, yielding a mature form of 134 amino acids (Trupp et al., 1995) (Figure 6). 
Mature homodimeric GDNF binds preferentially to the GFRα1 receptor and 
activates the transmembrane RET receptor (Jing et al., 1996; Treanor et al., 1996) 
or NCAM (Paratcha et al., 2003). In vitro studies suggest that GDNF can also bind 
to GFRα2 co-receptor and signal via RET (Baloh et al., 1997; Jing et al., 1997; 
Sanicola et al., 1997; Cik, 2000). Compared to other GFLs, GDNF contains a long N-
terminal region rich in basic amino acids that form a consensus heparin-binding site 
(Alfano et al., 2007). In addition to heparin, GDNF can bind to a heparan sulfate 
proteoglycan syndecan-3 (Bespalov et al., 2011). Binding to polysaccharides 
decreases the diffusion of GDNF and may be necessary to concentrate the ligand at 
certain locations of the extracellular space.  
3.1.1. GDNF expression and structure 
According to the traditional view, the genomic structure of human gdnf includes 
large 5′UTR, three exons and over 2kb long 3′UTR (Grimm et al., 1998). However, 
this gene locus was recently re-analyzed, and the results revealed the existence of 6 
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exons that can be alternatively spliced to generate 5 GDNF isoforms, which all yield 
an identical mature GDNF protein (Airavaara et al., 2011).    
The gene is driven by at least one inducible promoter containing a TATA-box, 
located upstream of exon 1 (Tanaka et al., 2000). The promoter activity can be 
induced by various agents such as phorbol ester, fibroblast growth factor 2 (FGF2) 
and cyclic adenosine monophosphate (cAMP) (Grimm et al., 1998). Furthermore, 
GDNF expression can be upregulated by neurotransmitters like dopamine and 
serotonin, antidepressants, and pro-inflammatory molecules (reviewed in Saavedra 
et al., 2008). In addition to promoter induction, GDNF levels can be regulated by 
several miRNAs that bind to specific regions in the evolutionarily conserved 3′UTR 
and repress GDNF translation (Kumar et al., 2015). 
 Five human GDNF mRNA transcripts have been identified, but only two of 
them are well characterized (Airavaara et al., 2011). In addition to the wild-type 
transcript described in the seminal paper by Lin et al, alternative splicing gives rise 
to a shorter GDNF variant, which contains an in-frame 78bp deletion (Lin et al., 
1993; Suter-Crazzolara and Unsicker, 1994; Trupp et al., 1995; Grimm et al., 1998). 
This deletion results in the loss of 26 amino acids and a single amino acid change in 
the pro-region of the shorter transcript. The two splice isoforms are called pre-
(α)pro-GDNF and pre-(β)pro-GDNF or GDNFFL (full-length) and GDNFΔ78, 
respectively (Wang et al., 2008) (Figure 7). These splice variants are expressed 
slightly differently in tissues outside the CNS, with the shorter isoform being more 
abundant in kidney and the longer isoform in lung (Suter-Crazzolara and Unsicker, 
1994).   
As mentioned before, GDNF is a distant member of the TGF-β superfamily and 
structurally very similar to TGF-β2 and bone morphogenetic protein-7 (BMP-7) 
(Eigenbrot and Gerber, 1997). GDNF monomer has a central α-helix called the heel 













19 aa 32 aa
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134 aa  
 
Figure 7. Pre-(α)pro-GDNF and pre-(β)pro-GDNF differ in the length of the 
pro-region. 
 
Three intramolecular disulfide bridges support the monomeric structure. 
Negatively charged amino acids at the tip of finger two were determined important 
for binding to GFRα1/RET complex, but insufficient to activate GFRα2/RET (Baloh 
et al., 2000). Two GDNF monomers dimerize in a head-to-tail fashion, and the 
dimer is stabilized by an interchain disulfide bond (Eigenbrot and Gerber, 1997). 
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Notably, this GDNF structure lacked the N-terminal region that is very mobile by 
nature, and was cleaved off in crystals. 
3.1.2. Cellular regulation and processing of GDNF 
The most common isoform of GDNF is synthesized as a 211 amino acids long 
inactive preproprotein. The pre-region that is cleaved off immediately after 
synthesis contains a signal sequence that targets the protein to the secretory 
pathway. In the ER and Golgi compartments, GDNF is folded and glycosylated. 
Although human GDNF contains two putative N-glycosylation sites at N49 and N85, 
only N49 seems to be in use (Piccinini et al., 2013). Glycosylation increases the 
stability of GDNF but at the same time regulates its processing as glycosylation-
deficient GDNF mutant (N49A) does not undergo proteolytic cleavage in contrast to 
the wild-type glycosylated protein (Piccinini et al., 2013). Proteolytic processing 
mechanisms that convert precursor proGDNF to the mature form are not well 
understood. GDNF has a putative furin cleavage site (KRLKR) that can be 
recognized by members of the proprotein convertase (PC) family (Lin et al., 1993), 
but the specific enzymes responsible for the propeptide cleavage have not been 
determined. As different PCs are distributed in several organelles as well as at the 
cell surface, the cleavage of proGDNF can possibly take place anywhere between the 
TGN and the extracellular space (Seidah et al., 2008). In addition to the best-
characterized furin cleavage site, additional processing sites have been predicted in 
GDNF primary sequence that could give rise to several neuropeptides (Immonen et 
al., 2008; Bradley et al., 2010). 
Interestingly, two of the predicted neuropeptides are specific for (α)pro-GDNF 
(Immonen et al., 2008). Although the predicted neuropeptides have not been 
detected in vivo, the activity of synthetic neuropeptides derived from GDNF 
sequence has been studied. Characterization of the synthetic 11-mer called Brain 
excitatory peptide 2 (BEP-2) in rats and Dopamine neuron stimulating peptide 11 
(DNSP-11) in humans indicated that it could induce synaptic excitation in rat 
hippocampus and support the survival of dopamine neurons (Immonen et al., 2008; 
Bradley et al., 2010). Curiously, the putative PEP-3 and PEP-4 neuropeptides are 
located at the very N-terminal region of mature GDNF (Immonen et al., 2008). 
Recent N-terminal amino acid sequence analysis revealed the existence of two N-
terminal sequences. Surprisingly, the novel cleavage site is located only six amino 
acids downstream of the conventional furin cleavage site and partially overlaps with 
the predicted PEP-3 (Piccinini et al., 2013). Whether the fragment of PEP-3 is 
released and functional in vivo remains to be studied. 
In contrast to neurotrophins, relatively little is known about the role of GDNF 
pro-region. It has been suggested to play a role in GDNF secretion efficacy as a 
construct encoding only the mature GDNF was retained mostly within the cell 
(Grimm et al., 1998). In addition, the two splice isoforms may be secreted via 
different mechanisms, as the (β)pro-GDNF was detected mainly in the TGN 
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compartment and was secreted less efficiently than (α)pro-GDNF (Wang et al., 
2008). Further studies by the same group showed that (α)pro-GDNF, but not 
(β)pro-GDNF, interacted with the sorting protein SorLA via the pro-domain, and 
was secreted in an activity-dependent manner as a result of this interaction (Geng 
et al., 2011). Nevertheless, Piccinini and colleagues demonstrated that presence of 
the pro-region was not an absolute requirement for proper folding and secretion of 
GDNF. They showed that human GDNF lacking the pro-domain could be detected 
from CHO media as a consequence of transient overexpression, though in smaller 
quantities compared to wild-type GDNF (Piccinini et al., 2013). To my knowledge, 
there is just one publication where proGDNF was found to be the predominant form 
of GDNF in aging rodent brains (Sun et al., 2014). While proGDNF was shown to be 
secreted from primary astrocytes in response to lipopolysaccharide (LPS) 
stimulation, the authors did not characterize the potential functions of the precursor 
protein (Sun et al., 2014). In addition, the in vivo specificity of the proGDNF 
antibody should have been characterized more thoroughly. Therefore, further 
studies are needed to clarify the possible biological activity of proGDNF. 
When mature GDNF is released from the cell, it binds preferentially to the 
cognate GFRα1 receptor to elicit neurotrophic signaling via RET RTK. Subsequently, 
RET is activated, and the ternary signaling complex is internalized. Notably, GDNF 
can be internalized by GFRα1 also in the absence of RET (Vieira et al., 2003). 
Endocytosed GDNF is either degraded or similarly to neurotrophins, retrogradely 
transported to convey the survival signal over long distances. In motoneurons, for 
example, a significant portion of internalized GDNF escapes degradation and is 
transported not only to the cell soma but also to the dendrites, where it accumulates 
in the multivesicular bodies at postsynaptic sites of afferent synapses and can 
undergo transsynaptic transcytosis (Rind et al., 2005). Dorsal root ganglion neurons 
can also retrogradely transport both GDNF as well as its family member NRTN in 
vivo (Leitner et al., 1999). In sympathetic neurons of the superior cervical ganglion, 
in contrast, GFLs are not retrogradely transported due to fast degradation of 
activated RET in these neurons (Leitner et al., 1999; Tsui and Pierchala, 2010).  
 
3.1.3. GDNF functions in and outside the nervous system 
The pioneering study characterizing the function of GDNF demonstrated the ability 
of this neurotrophic factor to support the survival of cultured embryonic midbrain 
dopaminergic neurons (Lin et al., 1993). Since midbrain dopaminergic neurons of 
GDNF knock-out animals are indistinguishable from wild-type littermates, GDNF 
does not seem to be critical in the development of these neurons (Moore et al., 1996; 
Pichel et al., 1996; Kopra et al., 2015). However, as conventional GDNF-deficient 
mice do not survive to adulthood, it was long unclear whether GDNF has any effect 
on postnatal and mature dopaminergic neurons in vivo. To date, results of four 
studies, where either RET or GDNF is ablated specifically from dopaminergic 
neurons, have been published. Only one of the reports found GDNF to be critically 
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important for the survival of the catecholaminergic neurons (Pascual et al., 2008). 
Results of other studies indicate that GDNF signaling is not required for the 
developmental survival of these neurons but may be required for the maintenance 
of adult dopamine neurons (Jain et al., 2006b; Kramer et al., 2007; Kopra et al., 
2015). In addition, in a very recent report, GDNF was proposed to be an essential 
modulator of striatal dopamine homeostasis (Kopra et al., 2017). The authors 
demonstrated that GDNF could regulate the localization and protein levels of the 
dopamine transporter (DAT) and thus affect the rate of dopamine reuptake. 
Furthermore, mice with no GDNF in their brain displayed decreased hyperactivity 
in response to amphetamine (Kopra et al., 2017).  
In the ventral tegmental area (VTA) of the mesolimbic system, GDNF is 
proposed to be an important protector of dopaminergic neurons against excessive 
alcohol consumption and addiction caused by the drugs of abuse (Messer et al., 
2000; He et al., 2005; Barak et al., 2015; Koskela et al., 2017). Taken together, these 
results highlight the importance of GDNF in controlling the homeostasis of 
dopamine neurons and elucidate the therapeutic potential of this neurotrophic 
factor in neuropsychiatric and neurodegenerative disorders that are often a 
consequence of abnormal functionality of the dopaminergic system. 
In addition to being a dopaminotrophic factor, GDNF regulates synapse 
formation in hippocampal neurons together with GFRα1 and NCAM (Ledda et al., 
2007). Furthermore, GDNF is required for the differentiation of ventral precursor 
cells to inhibitory gamma-aminobutyric acid (GABA) expressing neurons and for 
the migration of these interneurons from the medial ganglionic eminence to the 
cortex (Pozas and Ibáñez, 2005; Canty et al., 2009; Perrinjaquet et al., 2011). Results 
by the same research group demonstrate the importance of GDNF signaling also in 
the development and function of the olfactory bulb (Marks et al., 2012). Finally, 
according to a recent publication, GDNF expressed by Purkinje cells functions as a 
survival factor for cerebellar molecular layer interneurons (Sergaki et al., 2017).  
While NGF is the major survival factor for the developing superior cervical 
ganglion (SCG) neurons in the PNS, these cells also express GFL receptors. ARTN is 
the most potent GFL in supporting the survival of the SCG during development, 
whereas GDNF together with NRTN support only a small subset of these neurons 
(Trupp et al., 1995; Kotzbauer et al., 1996; Baloh et al., 1998b). Parasympathetic 
neurons, in turn, require GDNF during early embryogenesis for proper migration 
and proliferation (Enomoto et al., 2000; Rossi et al., 2000). GDNF is expressed by 
astrocytes and Schwann cells and has been established as an important regulator of 
both developing and adult motor neurons in vivo (Henderson et al., 1994; Yan et al., 
1995). Hence, GDNF is a potential therapeutic candidate for the treatment of 
neuromuscular diseases such as amyotrophic lateral disease (ALS), characterized by 
loss of motor neurons and subsequent progressive muscle atrophy leading to 
paralysis and death in a few years after diagnosis (Zinman and Cudkowicz, 2011).  
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The survival of embryonic sensory neurons depends largely on NGF, but 
postnatally the expression of TrkA is downregulated and, instead, RET is expressed 
in IB4-positive non-peptidergic sensory neurons (Bennett et al., 1996). GDNF can 
act as a trophic factor for sensory neurons, inducing neurite outgrowth and ensuring 
proper target innervation (Trupp et al., 1995; Fundin et al., 1999; Paveliev et al., 
2007).  
As evident from knock-out mice deficient in either GDNF, GFRα1 or RET, 
GDNF signaling is essential for proper survival, migration, and differentiation of 
enteric neuronal precursors (reviewed in Airaksinen and Saarma, 2002). Equally 
important is the role of this signaling complex in kidney development. GDNF knock-
out mice lack kidneys, and this is the main reason for the premature death of the 
pups (Moore et al., 1996; Pichel et al., 1996). Recent work by Kumar et al. showed 
that, perhaps unexpectedly, overexpression of GDNF from its native locus had a 
negative effect on kidney size and maturation (Kumar et al., 2015). This finding 
demonstrates the importance of proper spatiotemporal regulation of GDNF protein 
since only the correct concentration of the neurotrophic factor ensures the 
development of functional kidneys.  
In addition to aforementioned functions, GDNF also participates in the 
regulation of spermatogenesis, and several reports have associated GDNF with 
diabetes (Meng et al., 2000; Mwangi et al., 2011; Abadpour et al., 2017). Diabetes is 
a metabolic disease described by high blood glucose levels as a consequence of 
insufficient insulin secretion by pancreatic beta cells. In type 1 diabetes mellitus, the 
beta cells in islets of Langerhans are attacked by body’s immune system, and one of 
the therapies involves transplantation of donor islets (Mwangi et al., 2011). GDNF 
expression was upregulated in the vicinity of beta cells following islet injury, 
indicating that it could partake in modulating islet survival and repair (Teitelman et 
al., 1998). Moreover, GDNF was shown to increase the function and viability of 
isolated human islets in vitro and alleviate thapsigargin-induced ER stress in 
transplanted islets (Abadpour et al., 2017). In conclusion, pretreatment of isolated 
human islets with GDNF is essential for the survival and functionality of the islets 
post transplantation.  
 
3.1.4. GDNF and Parkinson's Disease 
Parkinson's Disease (PD) is a neurodegenerative disorder affecting over 10 million 
people worldwide. PD incidence increases with age and is slightly more common in 
males than in females (Miller and Cronin-Golomb, 2010). Less than 10% of PD cases 
are young-onset, found in people of 40 years or less. PD is best characterized by 
motor problems caused by the loss of dopaminergic neurons in the midbrain region 
called substantia nigra pars compacta (SNpc). The motor symptoms include 
resting tremor, rigidity, postural instability, and difficulties in walking. Also, non-
motor symptoms such as depression, sleep disorders, cognitive impairment, lack of 
motivation, pain, and constipation have been reported (Rana et al., 2015; Knudsen 
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et al., 2017; Wu et al., 2017). Recent data demonstrate that at the time of motor 
symptoms onset, about 30-40% of neurons in SNpc have lost their functional 
connections and degenerated (Kurowska et al., 2016). However, the disease is 
progressive, and although currently available medication suppresses movement 
symptoms, there is no treatment available that would stop or slow down the 
degeneration of dopaminergic neurons.    
As animal experiments have shown, GDNF can protect and restore the 
dopaminergic function both in vitro and in vivo. Since GDNF receptors GFRα1 and 
RET are expressed by dopamine neurons both in rodents and in human, GDNF is a 
potential drug candidate for the treatment of the PD (reviewed by Tenenbaum and 
Humbert-Claude, 2017). There have been several clinical trials where GDNF protein 
infusion was administered to the parkinsonian patients (Gill et al., 2003; Nutt et al., 
2003; Slevin et al., 2005; Lang et al., 2006), but unfortunately, the promising results 
obtained in preclinical testing were not reproduced. Several factors could explain 
the modest outcome of the clinical trials, and they are thoroughly reviewed by 
Tenenbaum and Humbert-Claude (2017). Shortly, since GDNF protein does not 
pass the blood-brain-barrier and has to be administered intracranially via a 
mechanical pump or using viral vectors, optimal delivery parameters are crucial. 
Since GDNF is a heparin-binding protein, which does not diffuse well in brain tissue, 
developing a biologically active GDNF variant with reduced heparin affinity could 
be useful for improved therapeutic effect. At least, using this approach, a prominent 
functional difference was shown in animal models using NRTN variants (Runeberg-
Roos et al., 2016). Also, the stability of GDNF should be taken into account and 
therefore mammalian glycosylated GDNF could be a better candidate for the clinical 
trials compared to bacterially-produced GDNF used so far (Piccinini et al., 2013).  
At the time of writing this thesis, results from the third GDNF Phase II clinical 
trial conducted in Bristol (UK) with 41 patients are being analyzed. Although the 
primary efficacy endpoint was not met (http://medgenesis.com/news.htm#top-
line), it will be interesting to see, whether GDNF that was administered for the first 
time via an innovative Renishaw delivery system, had any beneficial effect this time.  
3.2. Neurturin 
The second member of the GFL family, NRTN was first discovered as a survival 
factor for the cultured sympathetic neurons (Kotzbauer et al., 1996). Similarly to 
GDNF, NRTN is synthesized as a preproprotein, having a 19-amino-acid signal 
sequence and a 76-amino-acid pro-region (Figure 6). The role of the pro-region is 
not clear, but it seems to be involved in the trafficking and activity of NRTN protein 
(Fjord-Larsen et al., 2005). The pro-domain is followed by a conserved furin 
cleavage site and a 100-amino-acid mature region that is 42% homologous to the 
mature domain of GDNF (Kotzbauer et al., 1996). Mature NRTN homodimer signals 
preferentially via its cognate receptor GFRα2 and RET receptor tyrosine kinase, but 
can also activate RET by binding to GFRα1 (Baloh et al., 1997; Jing et al., 1997; Klein 
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et al., 1997; Suvanto et al., 1997). In addition, a number of other receptors exist: 
NRTN can bind to GFRα2 and NCAM, direct interaction with syndecan-3 has been 
demonstrated, and NRTN’s affinity to heparin is higher than that of GDNF 
(Paratcha et al., 2003; Alfano et al., 2007; Bespalov et al., 2011). NRTN KO mice are 
viable and fertile, but show deficits in enteric and parasympathetic innervation 
(Heuckeroth et al., 1999; Enomoto et al., 2000; Rossi et al., 2000).  
NRTN mRNA is widely expressed in a variety of neuronal and non-neuronal 
tissues both in embryos and adults, indicating a plethora of possible functions for 
this protein all over the organism (Kotzbauer et al., 1996; Widenfalk et al., 1997; 
Golden et al., 1998). Like GDNF, NRTN can modulate the development of the 
kidney, promoting epithelial branching by inducing branch initiation in vitro 
(Davies et al., 1999). In addition, NRTN is expressed in embryonic liver, where it 
has been shown to direct liver bud migration (Tatsumi et al., 2007) and suggested 
to participate in erythropoiesis (Golden et al., 1999). Overexpression of NRTN in 
basal keratinocytes modulates mechanical responsiveness to peripheral stimuli in 
primary sensory neurons (Jankowski et al., 2017). GFRα1, GFRα2 and RET receptor 
are all expressed in lung, but their function in that tissue has remained elusive. 
Recently, Mauffray and colleagues discovered that NRTN is involved in the 
pathophysiology of asthma by influencing inflammatory responses and increasing 
markers of airway remodeling in several mouse asthma models (Mauffray et al., 
2015). Finally, a novel function was demonstrated for NRTN in preventing the 
development of diabetes in a rat model. When NRTN was administered together 
with a glucagon-like peptide 1 receptor agonist liraglutide, metabolic parameters 
and glucose homeostasis were restored in hyperglycemic animals (Trevaskis et al., 
2017).   
Within the nervous system, NRTN is important for a number of neuronal 
populations in addition to sympathetic neurons. Ablation of nrtn gene 
demonstrated a critical role for NRTN in the development and maintenance of the 
enteric neurons of the gut (Heuckeroth et al., 1999). In addition, developing 
parasympathetic and sensory neurons of the dorsal root, trigeminal and nodose 
ganglia require NRTN for survival (Kotzbauer et al., 1996; Heuckeroth et al., 1999). 
Besides being a survival factor for the neurons, NRTN together with GDNF plays a 
critical role in the selective maintenance of herpes simplex viruses (HSV) 1 and 2 
latency, inhibiting viral DNA replication in primary adult sensory neurons of 
peripheral ganglia (Yanez et al., 2017).  
In the CNS, NRTN together with GDNF and IFNγ was recently shown to 
promote the differentiation of cortical neural precursor cells in vivo (Yuzwa et al., 
2016). Furthermore, NRTN can protect embryonic motor neurons and basal 
forebrain cholinergic neurons in vitro (Klein et al., 1997; Golden et al., 2003) and 
dopaminergic neurons in the ventral midbrain both in vitro and in vivo in a 6-
OHDA model of PD (Horger et al., 1998; Akerud et al., 1999). Based on the 
neuroprotective effects on nigrostriatal dopamine neurons, NRTN has been tested 
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in clinical trials as a candidate for the treatment of PD. Unlike GDNF, which has 
been administered to the patients by recombinant protein infusion, NRTN trials 
have been carried out using mainly a recombinant adeno-associated virus serotype-
2 (rAAV2) mediated gene transfer (CERE-120)(Marks et al., 2010; Bartus et al., 
2015). So far, the results of NRTN clinical trials have been inconclusive. On the 
positive side, the surgical procedure is well tolerated, and there are no clinically 
significant adverse events related to AAV2-neurturin. Motor status of patients was 
stable or even modestly improved (relative to baseline) over the course of the open-
label, long-term follow-up (Warren Olanow et al., 2015; Marks et al., 2016). 
Although NRTN gene therapy did not improve the condition of all tested PD patients 
significantly, post-hoc analysis suggested a significant therapeutic effect on early 
stage PD patients (Bartus and Johnson, 2017). Post-mortem brain analysis of the 
PD patients that had received NRTN-gene therapy over 4 years before autopsy 
revealed a mild but persistent NRTN expression level. However, the number of 
NRTN-positive nigral neurons was extremely small (Bartus et al., 2015). It is 
tempting to speculate that if NRTN variants with reduced heparin affinity developed 
by Runeberg-Roos and colleagues were used in future clinical trials with less 
advanced PD patients, NRTN would prove to be a potent therapeutic agent for the 
treatment of the PD (Runeberg-Roos et al., 2016).  
3.3. Artemin 
ARTN was discovered as a result of a database homology search. Protein alignment 
analysis revealed that ARTN has a relatively long pre-pro-region, multiple putative 
furin cleavage sites for removal of the pro-part and the mature region of this factor 
is ~45% identical to those of NRTN and PSPN (Baloh et al., 1998b). Like other GFLs, 
ARTN acts as a dimer and activates RET receptor tyrosine kinase by binding to the 
GFRα3 co-receptor. Baloh and co-workers initially proposed that ARTN could also 
signal via GFRα1 and RET in vitro, but further studies concluded that this 
interaction was not likely to be functional in vivo (Baloh et al., 1998b; Carmillo et 
al., 2005). Similarly to GDNF and NRTN, ARTN can also signal in a RET-
independent manner via GFRα3/NCAM, and bind with high affinity to heparin and 
syndecan-3 (Alfano et al., 2007; Bespalov et al., 2011; Schmutzler et al., 2011).  
ARTN is expressed at a relatively low level both in the brain and in peripheral 
tissues (Baloh et al., 1997; Masure et al., 1999; Quartu et al., 2005, 2007). 
Functionally, ARTN was first identified as a survival factor for sensory and 
sympathetic peripheral neurons in vitro (Baloh et al., 1998b). Ablating GFRα3 or 
ret from mice proved that ARTN-GFRα3 signaling is indeed crucial for the 
migration of sympathetic precursors as well as for the survival of mature 
sympathetic neurons in vivo (Nishino et al., 1999; Enomoto et al., 2001). Since 
GFRα3 is expressed mostly in nociceptive sensory neurons of the dorsal root 
ganglia, there is abundant literature linking ARTN to neuropathies (Orozco et al., 
2001; Merighi, 2016). Furthermore, ARTN seems to play a role in atopic dermatitis, 
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caused by air pollutants and warm environment (Murota et al., 2012; Hidaka et al., 
2016), and is in clinical trials for the treatment of neuropathic pain (Rolan et al., 
2015).  
3.4. Persephin 
The fourth member of the GFL family was identified by homology cloning. PSPN is 
expressed as a 156 aa long pre-pro-form, which is cleaved, yielding a 96 aa long 
mature protein that is 40% identical to the mature regions of GDNF and NRTN 
proteins (Milbrandt et al., 1998). PSPN signals mainly through a receptor complex 
comprising of GFRα4 and RET receptor tyrosine kinase but it can also bind to 
GFRα1 (Milbrandt et al., 1998; Lindahl et al., 2001; Sidorova et al., 2010). PSPN is 
the only member of the GFLs that does not bind to heparan sulfate proteoglycan 
syndecan-3 (Bespalov et al., 2011). 
PSPN is expressed at low levels in the central nervous system of rodents and 
primates (Jaszai et al., 1998; Tomac et al., 2002; Quartu et al., 2005, 2007). 
Similarly to other GFLs, PSPN promotes the survival of ventral midbrain 
dopaminergic neurons in culture and prevents their degeneration after 6-
hydroxydopamine treatment in vivo. Furthermore, PSPN can attenuate ischemic 
neuronal cell death both in vitro and in vivo (Tomac et al., 2002) and it also 
supports the survival of motor neurons in culture and in vivo after sciatic nerve 
axotomy (Milbrandt et al., 1998). Mice lacking PSPN show normal development and 
behavior but are hypersensitive to cerebral ischemia (Tomac et al., 2002).  
In contrast to GDNF or NRTN, PSPN has no survival-promoting effect on 
peripheral neurons, including SCG and sensory neurons in dorsal root ganglion 
(Milbrandt et al., 1998). However, it can promote neurite outgrowth of the SCG 
neurons (Sidorova et al., 2010). PSPN might also contribute to the survival of 
precursor cells during enteric nervous system development since in some patients 
with Hirschsprung's disease (HSCR), a point mutation (R91C) in the mature region 
of PSPN was found to be associated with the HSCR phenotype (Ruiz-Ferrer et al., 
2011). 
Outside the nervous system, PSPN like GDNF, promotes ureteric bud branching 
(Milbrandt et al., 1998) and regulates calcitonin synthesis and release by the C-cells 
in the thyroid (Lindfors et al., 2006). In addition, PSPN was recently found to be 
overexpressed in oral squamous cell carcinomas and to be strongly associated with 
tumoral progression by promoting cell-cycle progression in the G1 phase through 
the RET receptor and the RTK signaling pathway, and by decreasing the expression 




4. GDNF family receptors 
GDNF ligands signal through a tetrameric receptor complex comprising of two 
GFRα molecules and two RET receptors (Durbec et al., 1996; Jing et al., 1996; 
Treanor et al., 1996; Trupp et al., 1996). Each of the ligands binds preferentially to 
a different GFRα receptor: GDNF to GFRα1, NRTN to GFRα2, ARTN to GFRα3 and 
PSPN to GFRα4 (reviewed in Airaksinen and Saarma, 2002) (Figure 8). 
Furthermore, in vitro studies have shown that GDNF can also bind to GFRα2 and 
subsequently activate RET, and neurturin in turn is able to signal via GFRα1 (Baloh 
et al., 1997; Jing et al., 1997; Sanicola et al., 1997; Trupp et al., 1998; Cik et al., 2000). 
Also ARTN and PSPN have been shown to bind to GFRα1 in the presence of RET 
(Baloh et al., 1998b; Sidorova et al., 2010). Since all GFRα receptors are linked to 
the plasma membrane via a glycosylphosphatidylinositol (GPI)-anchor and do not 
contain an intracellular domain, additional receptor is needed to convey the signal 
into the cell. RET is the signaling receptor shared by all the GFLs (Jing et al., 1996; 
Trupp et al., 1996). Interestingly, RET is the only known receptor tyrosine kinase 
that does not bind its ligands directly and requires a co-receptor for activation. 
Importantly, the structure of the extracellular domain of RET in complex with 
GFRα1 and GDNF was recently solved by combining cryo-electron micoroscopy and 
low-angle X-ray scattering (SAXS) data (Goodman et al., 2014).   
In some cells of the nervous tissue i.e. neocortex and hippocampus, GFRα 
receptors are expressed abundantly, but RET protein is not present (Golden et al., 
1999). This observation suggested the existence of RET-independent signaling, and 
indeed, by now, several alternative receptors have been discovered. First, neuronal 
cell adhesion molecule (NCAM) was identified as a co-receptor for GFRα1-3, then a 
heparan sulfate proteoglycan syndecan-3 was shown to bind GDNF, NRTN and 
ARTN (Paratcha et al., 2003; Bespalov et al., 2011; Schmutzler et al., 2011). 
Interestingly, the latter interaction between syndecan-3 and the GFLs does not 
require the presence of either of the traditional receptors GFRα or RET (Bespalov et 
al., 2011). In addition, there is some evidence that GDNF could also signal through 
N-cadherin and integrins and thus protect the dopamine neurons but these 
interactions have not been characterized in detail and will not be discussed in this 
thesis (Chao et al., 2003; Cao et al., 2008; Zuo et al., 2013).  
4.1. GFRα receptors 
There are four members in the GFRα receptor family: GFRα1 (Jing et al., 1996; 
Treanor et al., 1996), GFRα2 (Baloh et al., 1997; Buj-Bello et al., 1997; Jing et al., 
1997; Klein et al., 1997; Suvanto et al., 1997), GFRα3 (Jing et al., 1997; Baloh et al., 
1998a; Masure et al., 1998; Naveilhan et al., 1998; Worby et al., 1998) and GFRα4 
(Enokido et al., 1998; Thompson et al., 1998; Lindahl et al., 2000; Masure et al., 
2000). As mentioned already in section 1.4, each GFRα receptor functions primarily 
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as a dimeric co-receptor for RET receptor tyrosine kinase when ligated to a preferred 
high-affinity binding GDNF family ligand (Figure 8).  
The length of mature GFRα receptors is about 400 amino acids, and they share 
30%–45% sequence identity. GFRαs have three cysteine-rich domains (CRD1, 
CRD2, and CRD3) and a C-terminal extension, except for GFRα4 that lacks CRD1 
(Airaksinen and Saarma, 2002). Leppänen and colleagues solved the crystal 
structure of GFRα1 CRD3, and proposed that CRD2 and CRD3 have a similar 
structure with five α-helices, and five disulfide bridges and the domains are located 
close to each other, whereas CRD1 is linked to CRD2 by a flexible hinge region 
(Leppänen et al., 2004). Mutational analysis indicates that for ligand interaction, 
domains CRD2 and CRD3 are required, while CRD1 has been proposed to stabilize 
the forming complex (Scott and Ibanez, 2001; Virtanen et al., 2005). In the case of 
GFRα1, residues F213, R224, R225 and I229, located in CRD2, are important for 
GDNF binding and further RET activation (Leppänen et al., 2004). Furthermore, 
length of the hinge region seems to be equally important for GFRα1 functioning, as 
the splice variant lacking five amino acids of that area (GFRα1b) binds GDNF with 
higher affinity and promotes stronger RET phosphorylation compared to GFRα1a, 
where exon 5 encoding these amino acids is included (Charlet-Berguerand et al., 
2004). In addition to their cognate ligands and RET, GFRα receptors 1, 2 and 3 bind 
also to NCAM, and this interaction is likely to be mediated by the N-terminal CRD1 
domain (Sjostrand and Ibanez, 2008).  
Analysis of the crystal structure of GFRα1 comprising CRD2 and CRD3 in 
complex with GDNF confirmed the results of earlier mutational studies. The 
fingertips of GDNF and CRD2 of the GFRα1 are essential for the high-affinity ligand-
receptor binding (Parkash et al., 2008). Comparison of the GDNF-GFRα1 crystal 
structure with that of ARTN-GFRα3 demonstrated that the ligand-receptor binding 
site is highly conserved. However, there is a difference in the bend angle of GDNF 
and ARTN, and this feature affects the formation of the ligand-receptor complex and 
further activation of RET (Parkash et al., 2008; Parkash and Goldman, 2009). 
Not much is known about the trafficking of the GFRα receptors. All of them 
contain putative N-glycosylation sites and undergo glycosylation in the Golgi 
complex. Sugar moieties have been suggested to play a role in protein trafficking 
(Hart and Copeland, 2010) but currently, no evidence has been provided for GFRα-
s. TGF-β is crucial for recruiting GFRα1 to the plasma membrane in primary 
neurons, but trafficking of GFRα2 does not depend on TGF-β, indicating differential 
regulatory mechanisms for each of the GDNF receptors (Peterziel et al., 2002).  
GFRα receptors are linked to the cell membrane by a GPI-anchor and thus lack 
the cytoplasmic domain. GPI-anchored proteins along with doubly acylated proteins 
(e.g. cytoplasmic Src-family kinases), cholesterol-linked and palmitoylated proteins 
are enriched in lipid rafts. GFRα receptors are localized to lipid rafts, and upon 
GDNF binding, GFRα1 has been shown to recruit RET to lipid rafts where the 
signaling occurs (Tansey et al., 2000). When RET localization is disrupted using 
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either transmembrane or soluble GFRα1, GDNF-stimulated intracellular signaling 
events, as well as neuronal differentiation and survival, are markedly attenuated 
(Tansey et al., 2000; Pierchala et al., 2006). Interestingly, in the presence of GDNF, 
GFRα1 can activate Src family kinases in lipid rafts also independently of RET 
(Poteryaev et al., 1999). GFRα receptors can be cleaved by the phosphoinositide-
specific phospholipase C (PI-PLC) (Yu et al., 1998), and soluble forms of GFRα have 
been shown to activate RET receptor tyrosine kinase in trans (Trupp et al., 1997). 
Indeed, GFRα1 can be cleaved by neurons and Schwann cells and together with 
GDNF, soluble GFRα1 can recruit RET to the lipid rafts (Paratcha et al., 2001). 
However, since transgenic mice expressing GFRα1 in ret locus did not show deficits 
in enteric or motor neurons, neither in kidney or Schwann cells where trans-
signaling has been implicated in vitro, the physiological relevance of this signaling 
in vivo could be restricted to CNS (Enomoto et al., 2004).  
The tissue expression pattern of the GFRα receptors is very similar to their 
corresponding ligands. During mouse embryonic development GFRα1 and GFRα2 
are highly expressed in the mammalian brain but are also detected in the urogenital 
system, the digestive system, the respiratory system, developing skin, bone, muscle, 
and endocrine glands (Golden et al., 1999). GFRα3 is mostly found in the 
nociceptive sensory neurons and superior cervical ganglion neurons of the 
peripheral nervous system, while GFRα4 is expressed in other organs like thyroid, 
pituitary and adrenal glands (Nishino et al., 1999; Lindahl et al., 2000; Orozco et 
al., 2001). The expression level of GFRα receptors decreases in adult mouse 
compared to the embryo (Golden et al., 1999).  
Soon after the discovery of the four receptor family members, conventional 
knock-out mice were generated for each receptor, and in short, their phenotype was 
rather similar to that of their cognate ligands (Airaksinen and Saarma, 2002). 
GFRα1 knock-out mice die at birth due to uremia similarly to GDNF knock-out 
animals; they lack kidneys and enteric neurons below stomach (Enomoto et al., 
1998; Tomac et al., 1999). GFRα2-deficient animals are viable but have retarded 
growth as well as severely reduced parasympathetic innervation of the lacrimal and 
salivary glands and the myenteric plexus of the intestine (Rossi et al., 1999). Also, 
GFRα2 KO mice show a deficit in parasympathetic innervation of pancreatic islets 
and impaired vagal tone but respond normally to exogenous glucose (Rossi et al., 
2005). GFRα3-ARTN signaling is critical for the migration of sympathetic neurons. 
Thus, not surprisingly, GFRα3 KO mice display abnormal innervation of the entire 
sympathetic nervous system (Nishino et al., 1999; Tanaka et al., 2011). Mice lacking 
GFRα4, created by Lindfors and colleagues, are viable and fertile without any gross 
defects. Further analysis of these mice revealed, however, that they do have reduced 
thyroid calcitonin levels and therefore increased bone formation (Lindfors et al., 
2006).  
There are two GFRα related receptors: GDNF family receptor α-like (GFRAL) 
and GAS-1. GFRAL does not bind GDNF family members but very recently, Hsu and 
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colleagues (Hsu et al., 2017), and three other research teams (Emmerson et al., 2017; 
Mullican et al., 2017; Yang et al., 2017) have  identified GFRAL as the receptor for 
growth differentiation factor 15 (GDF15), and demonstrate that GDF15-GFRAL-

















Figure 8. GDNF family ligands and their receptors. GFLs bind to GPI-
linked GFRα-receptors and signal via RET receptor tyrosine kinase. Complex 
formation is calcium-dependent. Preferred receptors for each GFL are indicated 
with bold arrows, secondary receptors are marked with dotted arrows. GFRα 
receptors (except GFRa4) can mediate GFL signaling also in complex with NCAM. 
Adapted from Kramer and Liss (2015). 
 
4.2. RET 
RET is a RTK superfamily member with essential functions in kidney 
morphogenesis, mediating spermatogonial stem cell maintenance, body weight 
control, and development of the nervous system (reviewed in Mulligan, 2014).  
The gene encoding RET (REarranged during Transfection) receptor tyrosine kinase 
was initially characterized as a gene activated by DNA rearrangement (Takahashi et 
al., 1985). Further studies revealed that the ret gene consists of 20 exons that give 
rise to several splice isoforms (Tahira et al., 1990; Carter et al., 2001; De Graaff et 
al., 2001). For example, alternative splicing of intron 19 generates three splice 
isoforms: RET9, RET43, and RET51 that are identical until Tyr1062 but have a unique 
C-terminal amino acid sequence. RET9 and RET51 are evolutionarily highly 
conserved, most abundantly expressed isoforms of RET protein and therefore best-
studied, RET43 has been detected in low levels only in primates (Tahira et al., 1990; 
Myers et al., 1995; Carter et al., 2001; De Graaff et al., 2001). Recently, it was shown 
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that exon skipping in the 5’ region of the RET gene produces two novel splice 
isoforms RETΔE3 and RET ΔE345, which are found both in human and in lower 
organisms (Gabreski et al., 2016).  
Mutations in the ret gene are linked with several pathologies. Gain of function 
mutations lead to endocrine cancers, including multiple endocrine neoplasia type 
2A and 2B (MEN2A and MEN2B), and familial medullary thyroid carcinoma. 
Germline loss of function mutations, in turn, are strongly associated with 
Hirschsprung's disease (HSCR) and can also be found in patients with congenital 
abnormalities of the kidney and urinary tract (CAKUT) (Mulligan, 2014). HSCR is a 
gut syndrome characterized by the absence of enteric neurons in the distal part of 
the colon and small intestine (Amiel et al., 2008). 
RET is expressed at highest levels during the embryogenesis in neural crest-
derived cells and tissues (Pachnis et al., 1993; Tsuzuki et al., 1995). These include 
dopaminergic, noradrenergic and motor neurons, sympathetic, parasympathetic 
and sensory neurons and the enteric nervous system (Arighi et al., 2005). In adult 
brain, RET mRNA expression is mainly restricted to the midbrain, cerebellum, 
pons, and thalamus (Kramer and Liss, 2015). Outside the nervous system, RET is 
for example expressed by a population of ureteric bud tip cells (Shakya et al., 2005), 
as well as in lung, testis, thyroid and adrenal gland (Tsuzuki et al., 1995). 
Similarly to GDNF and GFRα1 knock-out animals, ablation of the ret gene in 
mice leads to death shortly after birth due to renal agenesis. Moreover, those mice 
lack enteric neurons throughout the digestive tract, and their sympathetic precursor 
cells fail to migrate properly (Schuchardt et al., 1994; Enomoto et al., 2001). To 
address, whether the KO phenotype is splice isoform-dependent, mice 
monoisoformic for either RET9 or RET51 were generated. Both mouse-lines are 
viable with normal kidney, indicating redundant roles for RET isoforms in kidney 
development (Jain et al., 2006a). Since GDNF is a prominent survival factor of the 
midbrain dopamine neurons in numerous in vitro assays, and its signal 
transduction is mediated mainly by RET receptor tyrosine kinase, the role of RET in 
the dopaminergic neurons of adult animals was studied. For that, conditional RET-
KO mouse line was created where RET was specifically ablated from dopaminergic 
neurons (Jain et al., 2006b; Kramer et al., 2007). The first study did not observe 
differences in the survival of dopaminergic neurons in 1-y-old RET conditional 
knock-out mice compared to the age-matched controls (Jain et al., 2006b). 
However, gradual loss of dopamine neurons in SNpc and reduction of dopaminergic 
nerve terminals in the striatum of transgenic mice was reported by the other group. 
The change was observed at nine months and peaked at two years of age, indicating 
that RET signaling is required for maintenance of target innervation of midbrain DA 





4.2.1. RET structure and signaling 
Typically, RTKs are type-1 transmembrane receptors with a large extracellular part 
for interacting with ligands, a single transmembrane helix and a cytoplasmic kinase 
domain for the signal transduction (Figure 9). The extracellular domain (ECD) of 
RTKs commonly contains leucine-rich repeats, immunoglobulin or fibronectin-like 
domains (Lemmon and Schlessinger, 2010). RET, however, differs from other RTKs 
as its ECD comprises of 4 cadherin-like domains (CLD) with a calcium binding site 
between CLD2 and CLD3 and a membrane-proximal cysteine-rich domain (Anders 
et al., 2001). Cadherins are transmembrane proteins that mediate Ca2+ -dependent 
homophilic cell adhesion, and RET is classified as a distant member of the cadherin 
superfamily (Hulpiau and van Roy, 2009). Unlike traditional cadherins with linear 
organization of cadherin domains, RET CLD1-2 forms a clamshell arrangement 
(Kjaer et al., 2010). Functionally, CLD motifs are required for stabilizing RET 
dimers. The presence of calcium ions has been reported crucial for proper folding 
and cell surface expression of RET and necessary for GDNF signaling (van Weering 
et al., 1998; Anders et al., 2001). Taking that into account, it is surprising that the 
novel splice isoforms where either exon 3 (RETΔE3) or exons 3, 4, 5 are skipped (RET 
ΔE345), leading to large deletions in the ECD structure, can still bind to all GFRα 
receptors to similar extent as the wild-type RET (Gabreski et al., 2016).  
The cysteine-rich region is required for protein conformation and ligand 
binding (Amoresano et al., 2005), while the transmembrane (TM) domain of RET 
is essential for dimer association and hence for intracellular signaling (Kjær et al., 
2006). The intracellular part of RET comprises of a 50-residue-long juxtamembrane 
domain, a highly conserved tyrosine kinase domain and a C-terminal tail of 100 
residues. Within the cytoplasmic domain of RET, there are multiple tyrosines (Tyr) 
and one serine (Ser) residue that can become phosphorylated upon activation of the 
RET dimer and facilitate either direct interaction with signaling molecules like Src 
and phospholipase Cγ (PLCγ) or serve as docking sites for numerous adaptor 
proteins which activate downstream signaling pathways, promoting cell growth, 
proliferation, survival or differentiation (reviewed in Ibáñez, 2013; Mulligan, 2014) 
(Figure 9). The structure of the human RET tyrosine kinase domain has been solved 
(Knowles et al., 2006).  
Tyr687 and Ser696 are located in the juxtamembrane region, and both residues 
are involved in cyclic adenosine monophosphate (c-AMP)-mediated modulation of 
RET activity (Fukuda et al., 2002). By creating a knock-in mutant mouse, Ser696 was 
shown to be involved in the migration of the enteric neural crest cells in mouse 
developing gut (Asai et al., 2006). Tyr687 also has an established role in the 
integration of RET and protein kinase A (PKA) signals (Ibanez, 2013). 
Phosphotyrosines Tyr752 and Tyr928 can both activate Signal Transducer and 
Activator of Transcription (STAT3) and downstream Janus kinase (JAK)-STAT 
pathway, resulting in enhancement of proliferation and differentiation. Tyr905 is 
located in the kinase activation loop and is activated upon ligand binding. Structural 
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analysis of the RET kinase domain confirmed that this phosphotyrosine is necessary 
for full kinase activation of the protein (Knowles et al., 2006). Tyr981 binds the proto-
oncogene tyrosine protein kinase Src, thereby promoting GDNF-induced survival 
(Encinas et al., 2004). Phosphorylated Tyr1015 serves as a high-affinity docking site 
for PLCγ and its mutation leads to a decrease in RET signaling (Borrello et al., 1996). 
Kidney defects were found in mice when Tyr1015 of either Ret9 or Ret51 was mutated 
to phenylalanine (Jain et al., 2006a).  
 
Figure 9. Intracellular signaling pathways mediated by RET. 
Adapted from Mulligan, 2014. 
Tyr1062 is the major signaling hub of RET protein and mice with a point mutation 
in Tyr1062 have a severe loss-of-function phenotype (Ibanez, 2013) (see Figure 9). 
Autophosphorylation of Tyr1062, present in all splice isoforms of RET, is required for 
activation of rat sarcoma (RAS)/MAPK and PI3K/AKT pathways. The MAPK 
signaling pathway mediates neurite outgrowth but also contributes to the neuronal 
survival. The PI3K pathway, in turn, is essential for neuronal survival but can also 
stimulate neurite growth. Signaling pathway activated by the Dok proteins regulates 
neuronal differentiation (Ibanez, 2013).  
When Tyr1062 was mutated in mice expressing either RET9 or RET51 selectively, 
defects in kidney branching morphogenesis were observed. However, the phenotype 
was much milder in RET51 mice since presumably the signaling was partly 
compensated by Tyr1096 (Jain et al., 2006a).  
Tyr1096, present only in RET51 isoform, is phosphorylated upon ligand binding, and 
binds growth factor receptor-bound protein Grb2, contributing to RAS/MAPK and 
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PI3K/AKT pathways. Mutation of this residue has been shown to increase the 
activity of an oncogenic MEN2B form of RET (Liu et al., 1996).  
The splice isoform specific amino acid sequence in the C-terminus of the RET 
protein is proposed to be responsible for certain distinct properties of RET9 and 
RET51. Indeed, differences in gene expression induced by RET9 and RET51 have 
been described (Hickey et al., 2009). Furthermore, there is evidence of differential 
binding of RET9 and RET51 to adaptor proteins Shc (Src homology 2 domain-
containing protein), SHANK3 (SH3 and multiple ankyrin repeat domains protein 
3), Enigma, Grb2, and c-Cbl (E3 ubiquitin-protein ligase) that support this idea 
(Mulligan, 2014) and will be further discussed in the next section.  
 
4.2.2. Cellular regulation of RET 
The first translated N-terminal amino acids (1-28) of RET encode a signal sequence, 
which targets the nascent protein to the endoplasmic reticulum (ER). RET 
monomers have 12 putative N-linked glycosylation sites in the extracellular domain, 
and they undergo rapid glycosylation in ER to produce an immature 150 kDa 
glycoprotein (Takahashi et al., 1993a). Proper processing of the precursor protein in 
ER is dependent on calcium as the lack of it negatively affects maturation and 
trafficking of RET to the plasma membrane (van Weering et al., 1998). Next, the 
immature form of RET is further processed within the trans-Golgi network (TGN) 
and secretory pathway, and this results in a mature fully glycosylated plasma 
membrane-localized protein with a mass of approximately 170 kDa (Cosma et al., 
1998). Ret conversion from immature to mature form most likely takes place in the 
acidic trans-Golgi apparatus since the terminal glycosylation of the receptor is pH 
sensitive (Hirata et al., 2010). RET is believed to be synthesized as an inactive 
monomer that can get into contact with ligands and the co-receptors only on the cell 
surface. This is probably correct for the wild-type RET, but a constitutively active 
RET MEN2B mutant can be phosphorylated and interact with Grb2 and Shc already 
in the ER, further activating AKT, ERK, and STAT3 pathways, at least in cellular 
assays (Runeberg-Roos et al., 2007). 
The rate of maturation differs between RET isoforms. Though RET9 is 
expressed at higher levels relative to RET51, the immature form of RET9 
accumulates in a perinuclear region that co-localizes with areas of TGN (Richardson 
et al., 2012). Interestingly, RET9 binds to and co-localizes with Enigma, an adaptor 
protein acting between the kinases and cytoskeleton, with stronger affinity than 
RET51 (Borrello et al., 2002). This finding may partly explain why the majority of 
RET9 protein is retained inside the cell while RET51 matures faster and is localized 
mostly on the plasma membrane (Richardson et al., 2012). RET surface levels can 
also be modulated by protein kinase C (PKC) and high K+ depolarization via 




Differently from neurotrophin receptors, plasma membrane-localized RET is 
found outside the lipid rafts, where it interacts with Shc upon activation (Paratcha 
et al., 2001). RET can be recruited to the rafts by the GDNF-GFRα1 complex, thus 
enabling the association of RET and Src (Tansey et al., 2000; Pierchala et al., 2006). 
Activation of RET results in recognition of the receptor by the endocytic machinery 
of the cell, leading to internalization primarily through clathrin-coated pits 
(Richardson et al., 2006; Crupi et al., 2015). RET localization to endosomes is 
necessary for complete MAPK activation and provides an important link between 
receptor down-regulation and activation of the proliferative signaling cascade 
(Richardson et al., 2006). Interestingly, RET9 and RET51 have been shown to 
assemble unique signaling complexes in cells as well as primary neurons (Tsui-
Pierchala et al., 2002a). Although RET51 is internalized to endosomes more rapidly 
than RET9 (Crupi et al., 2015), and it has been shown to associate more strongly 
with the ubiquitin ligase Cbl than RET9 (Scott et al., 2005), this does not lead to the 
faster degradation of the longer splice variant. On the contrary, a portion of RET51 
escapes degradation and is recycled back to the plasma membrane through a Rab11-
positive recycling pathway, while RET9 is delivered to lysosomes (Richardson et al., 
2012). By this virtue, RET51 is present and active within the plasma membrane and 
cytoplasm longer than RET9 and mediates prolonged ERK1/2 activation compared 
to the shorter isoform (Richardson et al., 2012). In summary, alternative splicing of 
RET protein generates isoforms with notably different localization and trafficking 
properties, which affect their signaling capacities and thus may contribute to 
differences in their biological functions. 
4.3. NCAM 
Neuronal cell adhesion molecule (NCAM) is a transmembrane glycoprotein that 
belongs to the immunoglobulin superfamily. The ectodomain consists of five N-
terminal immunoglobulin-like domains (Ig1-5), followed by two membrane-
proximal fibronectin domains. NCAM is posttranslationally modified and carries an 
unusual carbohydrate – polysialic acid (PSA) - at its Ig5 domain. PSA is a highly 
negatively-charged sugar polymer and may comprise above 90 sialic acid residues 
in postnatal mouse brains, increasing the hydrodynamic radius of their carriers 
dramatically. To date, only eight proteins expressed in vertebrates have been 
identified to undergo polysialylation, neuropilin-2, synaptic cell adhesion molecule, 
and C-C Chemokine receptor type 7 being some examples in addition to NCAM  
(reviewed in Galuska et al., 2017). NCAM is expressed on neuronal cell surface, and 
it is shown to play an important role in neural development, promoting cell adhesion 
and migration, axon pathfinding and synaptic plasticity (Fields and Itoh, 1996; 
Maness and Schachner, 2007). While the role of NCAM in the developing brain is 
rather well studied, a recent review proposed that NCAM could also regulate the 




Alternative mRNA splicing gives rise to three NCAM isoforms: NCAM-180, 
NCAM-140 and NCAM-120, the numbering referring to the molecular weight of the 
isoforms in kDa. NCAM-180 and NCAM-140 are transmembrane proteins, whereas 
the shortest isoform is a GPI-linked receptor similarly to GFRα receptors. Unlike 
RET, NCAM-140 can bind GDNF directly with a Kd of about 5nM (Paratcha et al., 
2003; Nielsen et al., 2009) but for intracellular signaling the presence of GFRα1 is 
required. The interaction site has been identified, and it involves the heel region of 
GDNF and the third Ig domain of NCAM (Sjöstrand et al., 2007; Nielsen et al., 
2009).  NCAM140 also interacts physically and functionally with GFRα via its Ig4 
domain (Paratcha et al., 2003; Sjöstrand et al., 2007). 
According to current understanding, the two receptors seem to interact in cis 
only (Paratcha et al., 2003; Ledda et al., 2007). Interestingly, GFRα1 binding 
decreases NCAM’s ability to trigger homophilic cell-cell interactions and thus 
mediate cell adhesion, a phenomenon that does not depend on GDNF (Ibáñez, 
2010). On the other hand, in the presence of GFRα co-receptor, the binding affinity 
of NCAM and GDNF increases to Kd = 1nM. As a result of this binding, Src-like 
tyrosine kinase Fyn and downstream focal adhesion kinase (FAK) are activated, 
leading to GDNF-stimulated Schwann cell migration and axonal growth of cortical 
and hippocampal neurons (Paratcha et al., 2003). NCAM-140 expression is 
upregulated at presynaptic sites in hippocampal neurons during the early postnatal 
period, and in addition to regulating neurite outgrowth, NCAM can modulate also 
synapse formation together with GDNF and GFRα1 (Ledda et al., 2007). In addition 
to NCAM-140, also NCAM-180 is involved in mediating GDNF signaling (Nielsen et 
al., 2009). So far, there is little evidence of other GFLs signaling through NCAM. 
Schmutzler and coworkers found that NRTN and ARTN are able to signal through 
the complex comprising of their cognate receptor and NCAM independently of RET, 
mediating sensitization of sensory neurons (Schmutzler et al., 2011). In another 
study, overexpressed GFRa4 was shown to interact with NCAM, suggesting that also 
PSPN may use this alternative signaling pathway (Paratcha et al., 2003).  
4.4. Syndecan-3 
Syndecan-3 is one of four members of the syndecan protein family present in 
mammals. Syndecans are transmembrane proteoglycans with a variable 
ectodomain to which one or more glycosaminoglycan (GAG) chains are covalently 
attached. Whereas syndecan-1 and -3 have both heparan sulfate (HS) and 
chondroitin sulfate (CS) chains, the serine-glycine motifs of syndecan-2 and -4 only 
bind the HS chains (Afratis et al., 2017). HS is composed of repeating disaccharides 
of N-acetyl-D-glucosamine and D-glucuronic acid. The HS chains are functionally 
highly important as they interact with multiple biological effector proteins like 
growth factors, chemokines, and extracellular matrix components. In addition, 
recent data demonstrate that also the core region located between the N-terminal 
HS chains and the transmembrane domain of syndecans can bind other proteins 
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such as integrins, receptor tyrosine kinases, and phosphatases (Mitsou et al., 2017). 
Syndecan-3, for example, interacts in this manner with tissue factor pathway 
inhibitor (TFPI) in vascular and cancer cells (Tinholt et al., 2015). The 
transmembrane of syndecans is crucial for the dimer formation, as syndecans can 
apparently form both homo- and heterodimers on the cell surface.  
The cytoplasmic domain of syndecan proteoglycans is rather short, and it is 
divided into three regions. The C1 area interacts with the cytoskeleton and 
modulates syndecan internalization, least conserved V region is responsible for 
syndecan-specific signaling, and the C2 region binds PDZ domain proteins via its 
hydrophobic tail and may be necessary for trafficking and exosome formation 
(Mitsou et al., 2017). When ligated by heparin-binding growth-associated molecule 
(HB-GAM), syndecan-3 can bind Src family kinases (c-Src and Fyn) via its V region, 
make (indirect) contact also with their substrates (cortactin, tubulin), and mediate 
neurite outgrowth and neuronal migration (Kinnunen et al., 1998; Hienola et al., 
2006).   
Syndecans participate in many essential cellular actions such as cell adhesion, 
proliferation, differentiation, and migration. Notably, syndecan-3 is the only 
member of the family expressed by the neural cells (Afratis et al., 2017). Recent work 
suggests an important role for syndecans in tissue regeneration (Chung et al., 2016). 
The expression of syndecans is significantly altered during cancer development and 
progression. Syndecan-3 is associated with pancreatic and prostate cancer, and it 
may play a role in tumor angiogenesis (Afratis et al., 2017). 
Syndecan-3 was first identified as an alternative receptor for GDNF, NRTN, and 
ARTN by Bespalov and colleagues in 2011. The authors demonstrated that GFL 
binding to the HS chains of syndecan-3 led to the activation of the Src kinase and 
promoted cell spreading as well as neurite outgrowth of hippocampal neurons 
(Bespalov et al., 2011). One of the functions of syndecans is to present their binding 
partners to their cognate receptors, thereby promoting efficient signal transduction. 
Therefore, it is speculated that syndecan-3 could function as a co-receptor and 
deliver GDNF to GFRα1/RET or GFRα1/NCAM complex. Alternatively, GDNF-
syndecan-3 complex could activate Src signaling pathway directly (Bespalov et al., 
2011). Taken together, the interaction of GFLs and heparan sulfates is of high 
physiological relevance and potential therapeutic value, but further studies are 
needed to understand this phenomenon in more detail.  
 
5. Vps10p domain receptors (sortilins) 
The mammalian Vps10p domain receptor family includes sortilin, sorting protein 
related receptor with A-type repeats  (SorLA), sortilin-related receptor CNS 
expressed 1 (SorCS1), SorCS2 and SorCS3 (Figure 10). The name vps10p is short for 
vacuolar protein sorting 10 protein identified in Saccharomyces cerevisiae (baker's 
yeast) by Scott Emr and coworkers as a protein responsible for the correct sorting of 
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carboxypeptidase Y to vacuoles (Marcusson et al., 1994). Sortilins are type-1 
transmembrane receptors that contain a highly conserved vps10p-domain (vps10p-
D) at their N-termini, but differently from the protein encoded by the vps10 gene in 
yeast, there is just one copy of the domain instead of two (Willnow et al., 2008). 
Sortilin and SorLA were purified from human brain homogenate by receptor-
associated protein affinity chromatography, while homologous SorCS1, SorCS2 and 
SorCS3 were identified by database mining (Jacobsen et al., 1996; Petersen et al., 
1997; Hermey et al., 1999, 2004; Rezgaoui et al., 2001).  
Sortilin serves as a prototype for the vps10p receptor family as its extracellular 
domain (ECD) comprises the vps10p-D solely. A crystal structure has been solved 
for the ECD of sortilin in complex with one of its ligands neurotensin. The analysis 
of the structural data revealed a novel protein fold made of three structural domains: 
a ten-bladed oval-shaped β-propeller structure with a conical tunnel inside serving 
as a ligand binding site, followed by two cysteine-rich domains (CRDs) that interact 
extensively with the β-propeller segment to stabilize its structure (Quistgaard et al., 
2009).  
Whereas sortilin most likely cannot change its conformation, SorCS1, SorCS2 
and SorCS3 all contain a polycystic kidney disease (PKD) domain and a leucine-rich 
domain between their Vps10p-D and the transmembrane region (Figure 10). The 
presence of the leucine-rich repeat suggests a relatively flexible β-sandwich fold 
common to the E-set superfamily, and it is believed to be important in the formation 
of protein-protein interactions (Kobe and Kajava, 2001).  
SorLa is a large mosaic receptor twice the size of other sortilins that are in the 
range of 100-130 kDa (Willnow et al., 2008). The extracellular domain of SorLA 
comprises the vps10p-D followed by epidermal growth factor (EGF) precursor 
homology domain, a cluster of eleven complement type repeats, and finally six 
fibronectin type III repeats (Jacobsen et al., 1996) (see Figure 10). The intracellular 
domain of sortilins is only 40-80 amino acids long and contains several motifs for 
interaction with cytosolic adaptor molecules that guide the complex trafficking of 
sortilins between the cell surface and various intracellular compartments (Glerup et 
al., 2014b).  
All sortilins are abundantly expressed by the nervous system but can also be 
found in non-neuronal tissues, for example, sortilin and SorLa are expressed in both 
embryonic and adult kidney, lung, and liver. In addition, SorLA has been detected 
in an adult immune system (Glerup et al., 2014b). SorCS1 and SorCS2, which are 
mostly expressed in brain, can be found in adult liver, kidney, heart (SorCS1) as well 
as in adult lung and testis (SorCS2) (Rezgaoui et al., 2001; Hermey et al., 2004). The 
SorCS3 expression seems to be restricted to the nervous system as it has not been 
detected elsewhere (Oetjen et al., 2014). Interestingly, hippocampal expression of 
SorCS1 and SorCS3 but not SorCS2 can be regulated by neural activity, suggesting 

















Figure 10. Vps10p-domain sorting receptors 
(sortilins). Figure adapted from Glerup et al., 2014.   
 
During the last decade, sortilins have emerged as key regulators of intracellular 
protein sorting. Their interactions with neurotrophic factors and their receptors will 
be reviewed in section 1.5.2 of this thesis. Since sortilins are active both in the 
nervous system and several non-neuronal tissues, it is not surprising that many of 
them are linked to neuronal as well as metabolic disorders such as Alzheimer's 
disease (AD) and obesity. AD is a common neurodegenerative disease causing 
progressive dementia. The pathological symptoms often found in AD patients brains 
include neurofibrillary tangles and amyloid plaques. Amyloid plaques are formed 
when amyloid precursor protein (APP) is cleaved by β-secretase into aggregating 
neurotoxic Aβ peptide (reviewed by Willnow and Andersen, 2013). SorLA seems to 
retain APP in the intracellular compartments, thus minimizing the cleavage of the 
protein and subsequent formation of the toxic peptides (Andersen et al., 2005). 
Moreover, overexpression of SorCS1 leads to reduced Aβ levels, but the molecular 
mechanism behind this effect remains to be determined (Reitz et al., 2011).     
Sorl1 encoding SorLA protein has also been linked with obesity in both humans 
and rodents by genome wide association studies (GWAS) (Schmidt et al., 2017). A 
recent study showed that SorLA knock-out mice were protected from diet-induced 
obesity due to enhanced thermogenesis in adipose tissue (Whittle et al., 2015). 
Moreover, soluble SorLA was able to repress thermogenesis by interacting with bone 
morphogenetic protein (BMP) receptors and inhibiting BMP/TGFβ signaling in 
adipocytes (Whittle et al., 2015).  
Ubiquitously expressed sortilin interacts with a plethora of ligands, including 
neuropeptide neurotensin, prosaposin, lipoprotein lipase, and morphogen sonic 
hedgehog (Glerup et al., 2014b; Campbell et al., 2016). Sortilin levels are 
upregulated in several human cancer cells. Furthermore, in lung cancer cells sortilin 
is detected in exosomes in complex with TrkB and epidermal growth factor receptor 
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(EGFR), forming a so-called TES complex (Wilson et al., 2014). According to a 
recent model, sortilin may regulate the biogenesis of exosomes and secreted TES 
complex can activate ErbB signaling and modulate the secretion of angiogenic 
factors (Wilson et al., 2016). The function of SorCS1-3 is less studied, but GWAS 
suggest that SorCS1 is linked to diabetes and SorCS2 to bipolar disorder, 
schizophrenia and ADHD attention-deficit/hyperactivity disorder (Clee et al., 2006; 
Goodarzi et al., 2007; Baum et al., 2008; Ollila et al., 2009; Christoforou et al., 2011; 
Alemany et al., 2015).  
Recent work by Glerup and co-workers confirmed and elucidated the role of 
SorCS2 in BDNF-dependent hippocampal plasticity (Glerup et al., 2016). In 
addition, SorCS2 seems to be essential for the proper development of inner ear hair 
cells (Forge et al., 2017). SorCS3 is detected in postsynaptic densities, where it 
interacts with a glutamate receptor sorting protein PICK1 (Breiderhoff et al., 2013). 
Faulty localization of PICK1 in SorCS3 knock-out animals is proposed to lead to 
altered synaptic plasticity by selective loss of LTD that in turn causes defects in 
spatial learning and fear memory (Breiderhoff et al., 2013).    
5.1. Trafficking of sortilins 
The Vps10p receptor family members are synthesized at ER as inactive precursor 
proteins that undergo proteolytic processing in the TGN to generate active mature 
proteins. The propeptide is believed to block the binding of possible ligands to the 
vps10p-D (Quistgaard et al., 2009). This idea may be correct for sortilin, but SorLA 
contains another binding site within its complement type repeats, and also SorCS3 
precursor protein has been shown to interact with proNGF, indicating that these 
receptors are biologically active before the removal of the propeptide (Westergaard 
et al., 2005; Andersen et al., 2006).  
As the Vps10p protein in yeast has a well-established role in sorting hydrolases 
towards vacuoles, it was proposed that the vertebrate homologues of Vps10p would 
have a similar function. Indeed, sortilin and SorLA have been shown to localize 
mostly intracellularly in perinuclear regions and in the TGN (Jacobsen et al., 2001; 
Nielsen et al., 2001). In neurons, sortilin and SorLA show a vesicle-like staining in 
the soma but are also detected in the axons, dendrites and the nerve terminals 
(Willnow et al., 2008). In the case of SorCS1, differently localized splice isoforms 
make the trafficking analysis rather complicated: while SorCS1a isoform is almost 
completely intracellular, other splice variants are localized at the cell surface 
(Nielsen et al., 2008). SorCS2 and SorCS3 can be found at the TGN as well as at 
plasma membrane. Sortilin, SorCS1, and SorCS3 can be secreted via the activity-
dependent pathway, while SorLA and SorCS2 follow the constitutive secretory 
pathway (Hermey et al., 2004; Nykjaer et al., 2004; Schmidt et al., 2017). At the cell 
surface, all sortilins can be shed with different kinetics, and soluble forms are 
released to the extracellular space (Hermey et al., 2006). It is estimated that up to 
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10% of sortilin and SorLA can be found on the cell surface, but the proteins are 
quickly internalized through clathrin-coated pits to the endosomes.  
Trafficking of the sorting receptors is assisted either directly or indirectly by 
adaptor proteins. Internalization of sortilin is mediated by its tyrosine-based motif 
(Nielsen et al., 2001), whereas the dileucine motif in the cytoplasmic tail of SorLA is 
recognized by an adaptor protein 2 (AP-2) (Nielsen et al., 2007). Internalized 
sortilin and SorLA are transported back to the TGN by retrograde sorting pathways, 
escaping lysosomal degradation and continue shuttling protein cargo between the 
TGN and endosomes (Nielsen et al., 2001, 2007; Schmidt et al., 2017). According to 
the current model, retrograde transport of sortilin and SorLA is assisted by the 
retromer complex, adaptor protein 1 (AP-1) and phosphofurin acidic cluster sorting 
protein (PACS1) (Nielsen et al., 2001, 2007; Schmidt et al., 2007). Anterograde 
transport of the two receptors from the TGN to endosomes is regulated in turn by 
Golgi-localizing, γ-adaptin ear homology domain, ARF-interacting proteins GGA1 
and GGA1, which are monomeric clathrin adaptors, and AP-1 (Jacobsen et al., 2002; 
Schmidt et al., 2007; Herskowitz et al., 2012). The internalization and intracellular 
trafficking of SorCS proteins are not as well characterized as those of sortilin and 
SorLA. All three SorCS homologues contain tyrosine-based motifs similarly to 
sortilin, and AP-2 mediates the internalization of SorCS1 splice variants and SorCS3 
(Nielsen et al., 2008; Oetjen et al., 2014). The adaptor proteins regulating the 
trafficking of SorCS2 have not been identified so far. 
5.2. Interaction of sortilins and neurotrophic factors 
Sortilins are perhaps best known for their ability to modulate trafficking and 
signaling of proneurotrophins. Historically, Anders Nykjaer and colleagues were the 
first to demonstrate that sortilin mediated proNGF induced neuronal cell death by 
forming a complex with the p75NTR receptor (Nykjaer et al., 2004). Upon ligand 
binding, sortilin most likely internalizes proNGF, as sortilin-deficient cells fail to 
uptake proNGF and do not cause cell death (Nykjaer et al., 2004). Next, proBDNF 
was shown to induce apoptosis in sympathetic neurons when bound to the same 
receptor complex (Teng et al., 2005). Interestingly, in addition to internalizing 
proBDNF from the cell surface in complex with p75NTR, sortilin can also regulate 
other aspects of BDNF cellular trafficking. First, sortilin binds to the pro-region of 
BDNF precursor protein and guides it to the regulated secretory pathway (Chen et 
al., 2005b). Intriguingly, sortilin fails to sort the BDNF Met66 variant to the activity-
dependent pathway and these mutant mice display altered hippocampal structure 
and function and are more anxious compared to the wild-type animals (Chen et al., 
2006). Thus, it is tempting to speculate that sortilin-BDNF interaction could serve 
as a molecular model to explain the effect of BDNF mutant in the etiology of anxiety 
and other neuropsychiatric diseases. Second, cytoplasmic region of sortilin has been 
implicated in the lysosomal sorting of mature BDNF (Evans et al., 2011). Last, 
sortilin can also indirectly modulate neurotrophin signaling by interacting with NTF 
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receptors TrkA, TrkB and TrkC, facilitating their anterograde transport (Vaegter et 
al., 2011). 
SorCS2 is the second member of Sortilins that mediates proneurotrophin 
signaling when co-expressed with p75NTR (Deinhardt et al., 2011; Glerup et al., 
2014a). Importantly, SorCS2 processing gives rise to two variants with different 
functions in neurons and glia: single-chain SorCS2 regulates axon guidance in 
developing neurons, while two-chain SorCS2 variant conveys an apoptotic signal in 
peripheral glial cells (Glerup et al., 2014a). Moreover, in the hippocampus, SorCS2 
can either weaken or strengthen the synapses, depending on the availability of co-
receptors and ligands (Glerup et al., 2016). When in complex with p75, SorCS2 can 
modulate LTD by interacting with proBDNF or BDNF propeptide; activity-
dependent interaction with TrkB results in translocation of the BDNF receptor to 
postsynaptic densities to maintain synaptic potentiation (LTP) (Glerup et al., 2016).  
In contrast to the vast amount of work done characterizing the interaction of 
neurotrophins and their receptors with sortilins, just a few studies are describing 
the effects of the sorting receptor family on other neurotrophic factors. First, sortilin 
was shown to bind to the C-terminal site of CNTF and to internalize it from the cell 
surface. In addition, sortilin was able to promote CNTF receptor-mediated signal 
transduction independently of ligand binding (Larsen et al., 2010). Soon after, the 
results by Geng and colleagues indicated SorLA as a sorting receptor for proGDNF, 
targeting the ligand to the regulated secretory pathway without affecting GDNF 
signaling on the cell surface (Geng et al., 2011). A very recent study identified SorLA 
as a trafficking modulator for interleukin-6 (IL-6) and its receptor (IL-6R) in 
astrocytes (Larsen and Petersen, 2017).  
Further studies are needed to elucidate whether sortilins can also regulate other 
neurotrophic factors or their receptors. Considering their expression pattern and 
essential role in the trafficking of secretory proteins, it is tempting to speculate that 




AIMS OF THE STUDY 
Although the requirement of GDNF for normal development and homeostasis is 
well-known, the mechanisms regulating the trafficking of this neurotrophic factor 
are less studied. In addition, the possible biological function of GDNF precursor 
protein proGDNF has remained elusive.  
The primary goal of this thesis focused on the characterization of cellular regulation 
of GDNF. The specific aims were to  
1) Analyze the secretion mechanism of two GDNF splice isoforms (study I) 
2) Determine the enzymes involved in the proteolytic cleavage of GDNF 
precursor protein proGDNF (study I) 
3) Purify recombinant proGDNF and test its biological activity (study II) 
4) Characterize the receptor binding properties of proGDNF (study II) 
5) Investigate the interaction of a sorting receptor SorLA with GDNF and its 





MATERIALS AND METHODS 
Detailed information about materials and methods used in this study can be found 
in the original articles. Summary of the methods is presented in Table 1, and the 
methods that I have used or participated in are marked with a *.  
 
Table 1. Methods used in this thesis. 
Method used in 
Cloning of DNA constructs* I 
Endoglycosidase digestion* I 
Protein processing analysis* I 
RT-PCR* I 
Protein production*  I, II 
Protein purification* I, II 
Cell culture and transfections* I, II, III 
Immunoblotting* I, II, III 
Primary neuronal cultures* I, II, III 
Confocal microscopy* I, II, III 
Immunoelectron microscopy I, III 
GDNF ELISA  I, III 
Immunocytochemistry* I, III 
Protein stability* II 
Heparin affinity chromatography* II 
Sequence alignment (Clustal Omega)* II 
Coomassie gel stainings* II 
Luciferase assay* II 
Kidney explant cultures  II 
Binding assays (SPR, MST)* II, III 
Binding studies in cells* II, III 
Ret phosphorylation assays* II, III 
Internalization assay* II, III 
Immunoprecipitation* II, III 
Tissue preparation III 
Behavioral assays III 
Immunohistochemistry III 
Determination of the levels of dopamine and its metabolites III 
Analyses of tyrosine hydroxylase positive neurons III 
Use of transgenic animals (SorLA KO) III 
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RESULTS AND DISCUSSION 
1. Cellular regulation of two GDNF splice isoforms (I)  
In this study, we characterized the expression, cellular localization, and secretion of 
two GDNF splice isoforms. In addition, we identified the enzymes responsible for 
the proteolytic cleavage of proGDNF into mature GDNF. Previously, it was known 
that alternative splicing of Gdnf gives rise to two splice isoforms, called pre-(α)pro-
GDNF and pre-(β)pro-GDNF (Suter-Crazzolara and Unsicker, 1994; Trupp et al., 
1995). Although additional human transcripts were described more recently 
(Airavaara et al., 2011), to date, these two remain the best-studied isoforms. The 
mRNAs of pre-(α)pro-GDNF and pre-(β)pro-GDNF share an identical signal 
sequence but differ in the length of the pro-region as alternative splicing results in 
the loss of 26 aa and substitution of 1 aa (Gly25Ala) in the β-form (Grimm et al., 
1998) (I, Figure 1, A and B). The mature sequences are shown to be identical for 
both splice variants. GDNF is known to be secreted from the cells, but whether it is 
sorted to the constitutive or regulated secretory pathway, has remained unstudied.  
1.1. Expression of pre-(α)pro-GDNF and pre-(β)pro-GDNF mRNAs in 
the brain and developing kidney 
GDNF is widely expressed in the nervous system as well as in peripheral tissues. 
Previous studies have detected different levels of pre-(α)pro-GDNF and pre-(β)pro-
GDNF mRNAs in the brain and outside the nervous system (Suter-Crazzolara and 
Unsicker, 1994; Trupp et al., 1995). Our results confirm the differential expression 
levels of the two GDNF splice isoforms. We found that pre-(α)pro-GDNF mRNA was 
the predominant form in embryonic and early postnatal mouse brain (I, Figure 1E) 
as well as in primary cultures of postnatal hippocampal neurons (I, Figure 1D). In 
the human adult brain, in contrast, pre-(β)pro-GDNF mRNA was expressed more 
abundantly (I, Figure 1 C). The mRNAs of pre-(α)pro-GDNF and pre-(β)pro-GDNF 
were also detected in the developing kidney, but the levels decreased around birth 
(I, Figure 1F). Differently from what has been reported in the literature, we were not 
able to detect GDNF mRNA in mouse kidney after postnatal day 5 (P5) (Trupp et al., 
1995).      
1.2. Subcellular localization of pre-(α)pro-GDNF and pre-(β)pro-GDNF 
in cell lines and primary neurons 
NTFs are small secretory proteins that are often expressed and secreted in response 
to neuronal activity. However, it is difficult to investigate the trafficking 
mechanisms in vivo, as the levels of endogenous NTFs are usually very low, and, to 
a large extent, the available antibodies fail to detect them specifically. To overcome 
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this problem, transiently overexpressed NTFs can be studied, or, alternatively, NTF 
constructs can be fused with different tags or fluorescent proteins to improve their 
detection. The drawback of adding tags is the possibility that they may interfere with 
protein trafficking and affect, for example, secretion either positively or negatively 
(Piccinini et al., 2013). The chance that a 27kDa green fluorescent protein (GFP) 
may disrupt the cellular regulation of a 30kDa GDNF dimer is even higher. When 
characterizing protein trafficking in cell lines, choice of the suitable expression 
vector is critical. Vectors with strong promoters (i.e., pAAV-MCS) can easily lead to 
the expression of high amounts of exogenous protein that can fill up the intracellular 
organelles and give a false view of the localization and processing of the protein.  
In this study, we characterized the localization of transfected pre-(α)pro-GDNF 
and pre-(β)pro-GDNF in NGF-differentiated neuron-like PC6.3 cell line and 
primary cortical neurons by immunofluorescent staining. Both transiently 
overexpressed splice variants were detected in the Golgi complex and vesicle-like 
structures when analyzed either by confocal or immune electron microscope (I, 
Figures 2 and 3). Interestingly, quantification of splice variant localizations revealed 
that whereas (α)pro-GDNF was distributed more or less evenly between Golgi and 
the vesicles, the majority (~80%) of the protein encoded by pre-(β)pro-GDNF was 
found in vesicle-like structures of the PC6-3 cells (I, Figure 2B). In rat cortical 
neurons, the two splice isoforms co-localized partly with the Golgi marker GM130 
(I, Figure 3B). Furthermore, they were detected both in axons and dendrites, and 
antibodies specific for either the mature region or the pro-segment of GDNF showed 
similar vesicle-like staining patterns (I, Figure 3, A and C). This finding suggests 
that GDNF precursor protein or the cleaved pro-region together with mature GDNF 
can be transported to the cell periphery in primary neurons (I, Figure 3C). 
1.3. Processing and secretion of GDNF precursor proteins 
GDNF is synthesized as a preproprotein. The signal sequence that is cleaved off after 
the protein synthesis targets the nascent polypeptide to the ER, but the role of the 
pro-region has not been studied extensively. Also, it is not known, which enzymes 
are involved in the proteolytic processing of proGDNF into mature GDNF. In the 
case of neurotrophins, members of the proprotein convertase family have been 
shown to cleave off the pro-segment of the proneurotrophins (Seidah et al., 1996a, 
1996b). In addition, plasmin and selective matrix metalloproteinases are involved 
in the proteolytic processing of secreted proneurotrophins (Lee et al., 2001; 
Mizoguchi et al., 2011).  
In order to determine, which enzymes are responsible for the cleavage of the 
GDNF precursor form, we expressed wild-type pre-(α)pro-GDNF and pre-(β)pro-
GDNF cDNAs in CHO and NGF-differentiated PC6.3 cells in the presence or absence 
of furin endoproteinase inhibitor and GM6001, which is a broad-spectrum MMP 
inhibitor (I, Figure 7). In neuron-like PC6.3 cells, also the effect of α2 anti-plasmin 
was studied. WB analysis demonstrated that while GM6001 and anti-plasmin did 
47 
 
not prevent the cleavage of proGDNFs, furin inhibitor reduced the processing to 
some extent. To further analyze the role of furin and other members of the 
mammalian proprotein convertase (PC) family in the proteolytic processing of 
proGDNF, we utilized a Lovo cell-line deficient in endogenous furin activity 
(Takahashi et al., 1993b). Co-expression of human proGDNFs with members of the 
PC family proteins revealed that in addition to furin, PACE4, PC5A, PC7, and, to a 
lesser extent, PC5B can efficiently cleave pro-GDNF into mature GDNF (I, Figure 
7E). Notably, different PCs are activated in various subcellular organelles, furin and 
PC7 can cleave proteins already in the TGN, but PACE4 and PC5A are secreted 
constitutively and can be detected from the cell surface (Seidah et al., 2008). 
Consequently, removal of the GDNF pro-domain can take place either in the TGN 
or upon secretion. Further studies are required to characterize the GDNF processing 
mechanisms in more detail.  
To analyze, whether GDNF can be secreted as a precursor form, we raised an 
anti-pro-GDNF peptide antibody that recognizes the pro-regions of both (α)pro-
GDNF and (β)pro-GDNF (I, supplemental Figure S1). Next, pre-(α)pro-GDNF and 
pre-(β)pro-GDNF cDNAs were transiently expressed in CHO and PC6.3 cells, and 
subsequently detected by immunoblotting or immunofluorescence analysis (I, 
Figures 4 and 5). Using antibodies against the pro-region and the mature-part of 
GDNF, we were able to demonstrate that the two isoforms are secreted from cell 
lines in both pro- and mature forms (I, Figure 4). Furthermore, by mutating the 
putative furin cleavage site, we were able to prevent the cleavage of the precursor 
form substantially and increase the secretion of proGDNF variants (I, Figure 6, C 
and D). This finding is in accordance with a previous report where mutation of the 
furin cleavage site was shown to enhance the secretion of the unprocessed GDNF 
form (Oh-hashi et al., 2009). Notably, we cloned another GDNF mutant with six 
critical positively charged amino acids changed to alanines (named GDNF(6A) in 
study I). This mutated GDNF was efficiently secreted to the cell media and almost 
completely resistant to proteolytic cleavage (Figure 6, C and D). This construct was 
later used for the production of recombinant proGDNF characterized in study II.  
1.4. GDNF splice isoforms respond differently to KCl-induced 
depolarization in neuronal-like cells 
There are two main secretory pathways in mammalian cells, the constitutive 
pathway and the activity-dependent pathway. In the constitutive pathway, present 
in all mammalian cells, small secretory vesicles transport the cargo to the cell 
membrane and release it by default, ensuring a constant supply of the protein. The 
regulatory pathway is characterized by larger dense core vesicles (DCV) that are 
activated in response to stimuli (i.e., electrical activity) and require calcium to 
release the content of the secretory granules (Leßmann and Brigadski, 2009). The 
secretion mechanisms of neurotrophins have been studied in detail, and the results 
show that neurotrophins can utilize both secretory pathways. For instance, NGF and 
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NT4/5 are mainly localized to the vesicles of the constitutive pathway but can also 
be secreted along the regulated pathway (Leßmann and Brigadski, 2009). BDNF 
and NT-3, in turn, are secreted predominantly via the activity-dependent pathway 
in response to KCl-induced depolarization in neuronal cells (Mowla et al., 1999; 
Chen et al., 2004; Brigadski et al., 2005).  
To investigate, which is the preferred secretory route of the proteins encoded 
by pre-(α)pro-GDNF and pre-(β)pro-GDNF, we utilized the NGF-differentiated 
PC6.3 cells and analyzed the secretion of proGDNFs upon depolarization by KCl. 
Western blot analysis of PC6.3 media showed that while the secretion of (α)pro-
GDNF/GDNF did not change much after KCl treatment, the amount of (β)pro-
GDNF/GDNF in the media was clearly increased (I, Figure 8A). This result was also 
confirmed by GDNF ELISA (I, Figure 8B). To assess whether the KCl-dependent 
secretion of (β)pro-GDNF/GDNF was dependent on calcium, we used a calcium 
chelator BAPTA-AM. The presence of BAPTA-AM prevented the secretion of KCl-
induced (β)pro-GDNF/GDNF as well as pro-BDNF-EGFP/BDNF-EGFP (positive 
control) but did not affect the secretion of (α)pro-GDNF/GDNF (I, Figure 8B).  
In addition to analyzing the media samples, we also studied the effect of KCl on 
the intracellular localization of the two GDNF splice variants. The results show that 
(β)pro-GDNF/GDNF were detected predominantly in the secretory vesicles positive 
for secretogranin II (SgII) and Rab3A, which are markers of the regulated secretory 
pathway (I, Figure 9, supplemental Figure S5). Moreover, the areas with strongest 
co-localization of (β)pro-GDNF/GDNF and SgII were found in the distal regions of 
the extensions (I, Figure 9A). In contrast, the co-localization of (α)pro-
GDNF/GDNF with Sg II was weak before and after KCl treatment and the two 
proteins co-localized most strongly in the proximal areas of cells (I, Figure 9, A and 
C). Taken together, these results suggest that the secretory mechanisms of proteins 
encoding pre-(α)pro-GDNF and pre-(β)pro-GDNF are different. The (β)pro-GDNF 
and corresponding GDNF are transported out of the neuronal cell primarily in dense 
core secretory granules of the regulated pathway, and the secretion can be 
upregulated calcium-dependently by KCl-induced depolarization. The secretion of 
(α)pro-GDNF and corresponding GDNF, in turn, seems to occur predominantly via 
the constitutive secretory pathway and is not significantly enhanced in response to 
depolarization. Our results differ from those of Wang et al., where (β)pro-GDNF was 
shown to accumulate in the Golgi and to be poorly secreted in comparison to the 
protein encoding pre-(α)pro-GDNF. The discrepancy could be explained by the fact 
that the other group studied C-terminally hemagglutinin (HA)-tagged cDNAs, 
whereas we used wild-type GDNF cDNAs. Even small tags may interfere with the 
proper sorting and trafficking of GDNF, especially when linked to the C-terminal 
region, which is known to be critical for binding GFRα receptors and activating RET 




2. The biological role and binding profile of proGDNF 
As mentioned before, GDNF is synthesized as a precursor protein, but the possible 
function of the pro-form has remained unstudied. Earlier work indicates that the 
GDNF pro-region may be required for proper folding of the nascent polypeptide and 
it is involved, though not critical, for the secretion of GDNF protein (Grimm et al., 
1998; Piccinini et al., 2013). We and others have shown, that proGDNF can be 
secreted, at least in cell lines and in primary astrocytes (Study I, Piccinini et al., 
2013; Sun et al., 2014). Furthermore, it is possible to detect endogenous proGDNF 
precursor protein from the media of human glioblastoma cells (U87 MG) using 
modified GDNF-ELISA (II, Suppl. Fig. S3), but the amount is not sufficient for 
proper characterization of the protein. 
To date, most information concerning the role of the neurotrophic factor 
precursors comes from the work on proneurotrophins. In contrast to the mature 
neurotrophins, proneurotrophins have been shown to elicit mainly apoptotic signals 
(Lee et al., 2001; Teng et al., 2005; Yano et al., 2009). Nevertheless, recent work 
suggests that the function of proneurotrophins can be regulated by the availability 
of signaling receptors and in the presence of TrkA, proNGF may also possess 
neurotrophic activity (Clewes et al., 2008; Masoudi et al., 2009; Ioannou and 
Fahnestock, 2017).   
In the second study of my thesis, we focused on the characterization of the 
recombinant mammalian proGDNF mutant protein, resistant to proteolytic 
cleavage. Our primary goal was to assess whether proGDNF is a biologically active 
protein and determine its receptor binding profile.   
2.1. Characterization of the proGDNF properties and purification 
In study I, we characterized the processing of GDNF precursor protein and showed 
that members of the proprotein convertase family cleaved proGDNF into mature 
GDNF (see section 1.3 of Results and discussion). Moreover, in order to produce an 
uncleavable proGDNF mutant protein, we cloned a construct, where six basic amino 
acids located at the furin cleavage site and positions 11, 12 downstream of the furin 
site were mutated to alanines. Expression of this construct (called proGDNF6A in 
study II) resulted in enhanced secretion of GDNF pro-form, and, therefore, we 
chose to characterize it further. To confirm earlier findings, the expression of 
proGDNF6A and GDNF wt was compared in HEK293T cells and analyzed by 
immunoblotting using antibodies against the mature as well as the pro-domain of 
GDNF (II, Figure 1B). While GDNF wt was secreted primarily in the mature form, 
the molecular mass of the secreted proGDNF6A suggested that it was resistant to 
endogenous proteases and remained in the pro-form. Notably, when cells were kept 
in serum-containing medium (full medium), the secretion of both GDNF wt and 
proGDNF6A was enhanced. This result is in accordance with an earlier report where 
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GDNF stability was shown to be affected by the extracellular environment (Piccinini 
et al., 2013).  
Next, we analyzed the heparin binding affinity of proGDNF6A. As the N-
terminal region of the mature GDNF is proposed to be critical for binding heparin 
and heparan sulfates (Alfano et al., 2007; Bespalov et al., 2011), we hypothesized 
that proGDNF6A displays weaker binding to heparin. Indeed, proGDNF6A was 
eluted from the heparin affinity column with 0.4-0.7 M NaCl, while elution of GDNF 
wt that was used as a control, only started upon the addition of 0.7 M NaCl (II, 
Figure 1C). Since it has been demonstrated that mammalian GDNF is more stable 
than GDNF produced in the bacterial expression system (Piccinini et al., 2013), 
proGDNF6A was subsequently expressed in CHO cells using a patented QMCF 
Technology developed by Icosagen Ltd. Analysis of the CHO media showed that in 
addition to proGDNF6A, there was also some recombinant mature GDNF present, 
indicating that proGDNF6A underwent proteolytic processing to a small extent. 
Since we introduced a mutation of two arginines to alanines at position 11, 12 of the 
GDNF mature region, the recombinant mammalian GDNF was called GDNF2A to 
distinguish it from wt mature GDNF that was also used in this study. Using three 
chromatography methods (heparin affinity column, size-exclusion chromatography, 
and cation-exchange column), and taking advantage of the slightly different 
biochemical properties of proGDNF6A and GDNF2A, we managed to separate 
fractions that contained primarily proGDNF6A. The purity of the proteins was 
verified by reverse phase chromatography (data not shown) and SDS-PAGE stained 
with Coomassie Brilliant Blue (II, Figure 1D). Taken together, this is the first report 
on the purification of a recombinant, mainly cleavage-resistant proGDNF mutant 
protein, which also shows reduced heparin affinity. 
2.2. Testing the biological activity of proGDNF6A in vitro 
GDNF is a well-known survival factor for several neuronal populations, including a 
subset of sympathetic neurons. To assess, whether the recombinant proGDNF6A is 
biologically active, we tested its effect on postnatal rat superior cervical ganglion 
cultures in comparison with GDNF2A, and NGF, which is the most potent survival 
factor for these neurons. To our surprise, proGDNF6A displayed trophic activity, 
and supported the survival of the SCG sympathetic neurons dose-dependently, 
although it was not as efficient as GDNF2A (II, Figure 2A). Interestingly, we did not 
observe a significant additive effect when GDNF2A and proGDNF6A were applied 
together to primary neurons, suggesting that GDNF and proGDNF might signal via 
the same receptor pool that was saturated by the addition of exogenous ligands (II, 
Figure 2B).  
Next, we tested the effect of GDNF2A and proGDNF6A in tissue culture. For 
that, we used mouse embryonic kidney explants. It has been reported that 
exogenous mature GDNF can induce extra ureteric budding as well as enlargement 
of the definitive ureteric tips (Sainio et al., 1997). After dissecting the explants, 5 nM 
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of recombinant proGDNF6A or GDNF2A was added to the medium, and the tissue 
cultures were maintained for 48 h. The presence of both proteins lead to the 
induction of extra ureteric buds in comparison to control tissues grown in the 
absence of GDNF (II, Figure 2C). Similar results were obtained when using 2.5 nM 
or 3.75 nM ligands (II, Suppl. Fig S1) Importantly, results of this assay also 
demonstrated the relative stability of recombinant proGDNF6A, as it was not 
cleaved during the 48 h culturing period (II, Figure 2D). Based on this result we can 
conclude that the observed morphogenic effect was the result of proGDNF signaling 
and not caused by the cleavage of the prodomain and subsequent activity of the 
mature GDNF.  
These results indicate that the activity of the GDNF precursor form is very 
different from that of proneurotrophins, which are able to cause neuronal apoptosis. 
However, it does not rule out the possibility that proGDNF6A may possess dual 
activity, for instance, in the case of neuronal injury, or during aging.  
2.3. Receptor binding properties of proGDNF6A  
As proGDNF6A displayed trophic activity in the in vitro assays, we speculated that 
it could bind to GFRα1 and signal via RET. It is known from the literature that 
proNGF can interact with the TrkA receptor, although with slightly reduced affinity 
compared to the mature NGF (Clewes et al., 2008). To characterize the binding of 
proGDNF to GFRα1, we used two approaches. Results of the microscale 
thermophoresis (MST) analysis showed that proGDNF6A bound to GFRα1 with the 
Kd ≈ 90 nM (II, Figure 3A). Taking into consideration that the experiment was 
conducted using soluble proteins, this affinity is similar to what has been reported 
for mature GDNF-GFRα1 interaction. Importantly, in the MST settings, we did not 
detect any binding of proGDNF6A to the RET ECD (II, Figure 3A) that is in line with 
earlier data showing that mature GDNF does not bind directly to RET either.  
Next, we radiolabeled proGDNF6A and GDNF2A with 125I and characterized the 
binding abilities of the ligands in more detail in the cellular competition binding 
assays. Human GFRα1 and GFRα2 were transiently expressed on the surface of HEK 
cells, and radiolabeled proGDNF6A or GDNF2A were added to the cells in the 
presence or absence of unlabeled ligands. Results of the binding studies confirmed 
the initial result obtained with MST: proGDNF6A bound to GFRα1 with high affinity 
(II, Figure 3B). Furthermore, using GFRα1 mutant proteins deficient in GDNF 
binding, we were able to demonstrate that the proGDNF binding site is identical to 
that of mature GDNF (II, Figure 3C). This finding was next verified by showing that 
unlabeled GDNF efficiently displaced 125I-proGDNF6A binding from GFRα1 and 
vice versa (II, Figure 3D). All in all, this result is not very surprising. Compared to 
neurotrophins that all possess propeptides of almost the same length as the mature 
region, and may thus sterically hinder the binding sites located in the mature 
domain, the pro-segment of GDNF is less than half the length of the mature region. 
Therefore, it is not likely that it could physically block the C-terminal part (fingers) 
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of the mature GDNF that is required for GFRα1 binding (Baloh et al., 2000; Parkash 
et al., 2008).  
Next, we wanted to study whether the iodinated ligands share similar affinity 
also to GFRα2. Unexpectedly, we were unable to detect binding of proGDNF6A to 
GFRα2, while mature GDNF2A clearly bound to the receptor (II, Figure 4, A and B). 
In line with the initial findings, unlabeled proGDNF displaced GDNF in cells 
expressing GFRα1 but not GFRα2, not even when the unlabeled protein was added 
in concentrations as high as 100 nM (II, Figure 4B).  
Results from earlier studies show that the transmembrane RET receptor can 
stabilize the interaction of GDNF and its cognate GFRα1 receptor (Cik, 2000; 
Leppänen et al., 2004). Indeed, when we transfected HEK cells with the GFRα-
receptors together with RET, the binding affinity of both proGDNF6A and GDNF2A 
to GFRα1 increased (II, Figure 4, C and D). The same effect was evidenced in the 
case of GDNF and GFRα2. Notably, proGDNF6A displayed a weak affinity to GFRα2 
in the presence of RET and was also able to displace GDNF in binding to the complex 
comprising GFRα2 and RET (II, Figure 4, E and F). Together, these results suggest 
that the receptor binding properties of proGDNF6A are slightly different from the 
mature GDNF. While both ligands interact with GFRα1 in a similar manner, their 
affinity to GFRα2 differs significantly.   
2.4. RET activation mechanism by proGDNF6A 
A unifying characteristic feature of the proneurotrophins is their ability to bind to 
the p75NTR. As GFLs signal via a receptor complex consisting of a GPI-linked GFRα 
receptor and RET receptor tyrosine kinase, we wanted to test, whether GDNF 
precursor form could possibly bind to, or activate RET. Although the initial MST 
analysis indicated that proGDNF6A does not bind to the RET ECD, its ability to 
interact with a transmembrane receptor may be different. The analysis was carried 
out in fibroblasts stably expressing wt full-length RET, and we measured the ability 
of GDNF2A and proGDNF6A to phosphorylate RET in the presence and absence of 
soluble GFRα1. The results demonstrate that neither GDNF2A nor PROGDNF6A 
can activate RET alone. However, in the presence of soluble GFRα1, both ligands 
induced phosphorylation of RET (II, Figure 5A).  
Next, we analyzed the time-dependence of RET activation in MG87RET cells 
transiently expressing the GFRα1 receptor. GDNF2A and proGDNF6A were added 
to serum-starved cells that were subsequently lysed 15, 30, 45, or 60 minutes later, 
and subjected to immunoprecipitation. In short, we did not see a difference in the 
phosphorylation pattern of the RET receptor, indicating that GDNF2A and 
proGDNF6A can activate RET to the same extent both in the presence of soluble and 
transmembrane GFRα1 (II, Figure 5B). 
RET is known to contain several phosphorylation sites that lead to the 
activation of different signaling pathways (see Figure 9 of the literature review). To 
monitor, which pathway is induced by GDNF and proGDNF, we utilized a MAPK 
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activation detection system, developed and characterized by Sidorova and 
colleagues (Sidorova et al., 2010). In StratαLuc cells, which express RET and GFRα1, 
GDNF2A and proGDNF6A showed similar efficiency in activating MAPK pathway 
(II, Figure 5C). In contrast, when the ligands were added to the NoStratαLuc cells 
with soluble GFRα2, we observed a dose-dependent MAPK activation with 
GDNF2A, while proGDNF6A had a significantly weaker effect (II, Figure 5C). As 
this phenomenon might have been a result of a prolonged incubation time of the 
samples, leading to the degradation of proGDNF6A, we used an alternative method 
and analyzed the MG87RET cells, induced for 1 h with soluble ligands and co-
receptors. In line with the results obtained using the MAPK-luciferase system, we 
saw that GDNF2A and proGDNF6A induced RET phosphorylation and consequent 
activation of the MAPK as well as AKT pathway in the presence of soluble GFRα1 
(II, Figure 5D). However, proGDNF failed to activate RET and the downstream 
signaling molecules when applied with soluble GFRα2. Notably, proGDNF seemed 
to bind weakly also to a GFRα1 mutant protein lacking domain 1, as evidenced by a 
modest RET phosphorylation level. Domain 1 is proposed to be necessary for the 
stabilization of the ligand-receptor complex (Virtanen et al., 2005). 
Taken together, these results suggest that proGDNF6A can activate RET and 
downstream MAPK and AKT signaling pathways in the presence of wt GFRα1. 
However, the interaction is not as stable as that of mature GDNF and GFRα1. 
Differently from mature GDNF, proGDNF6A is not able to induce RET 
phosphorylation together with soluble GFRα2. This finding may help to explain the 
results of the assays where biological activity of proGDNF6A was assessed (II, 
Figure 2 A-C). Neonatal SCG neurons express higher levels of GFRα2 than GFRα1 
(Nishino et al., 1999), and may thus respond better to mature GDNF. The embryonic 
kidney explants, on the other hand, express solely GFRα1, which both ligands seem 
to activate to a similar extent. 
2.5. Internalization of proGDNF6A 
Finally, we compared the internalization rate of proGDNF and GDNF, using 
radiolabeled ligands and HEK293T cells transiently expressed with i) RET, ii) 
GFRα1, iii) RET+GFRα1, or iv) RET+GFRα1+SorLA. Iodinated proGDNF6A and wt 
recombinant GDNF were added to the cells and incubated on ice for 2 h. 
Subsequently, the plates were moved to a 37° C water bath, and the rate of the 
endocytosis was measured during a 40 minute period. The specificity of the ligand 
uptake was verified by the addition of unlabeled ligand in the longest time-point of 
the assay.  
The results show that GDNF and proGDNF6A are not endocytosed by RET, but 
GFRα1 can mediate the ligand uptake in a very effective manner (II, Figure 6, A and 
B). The latter finding confirms the results presented in an earlier report (Vieira et 
al., 2003). Perhaps surprisingly, in this experimental set-up, the rate of ligand 
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internalization was not enhanced in cells expressing RET+GFRα1, or RET+GFRα1 
+SorLA compared to cells expressing only GFRα1 (II, Figure 6, C and D).    
Further analysis of the internalization is required to fully understand the 
kinetics of GDNF uptake, and the role of different GDNF receptors in this process. 
Regarding the comparison of GDNF and proGDNF6A internalization, we can 
conclude that both ligands are endocytosed possibly via a similar mechanism in 
vitro.  
 
3. Interaction of SorLA with GDNF and its receptors 
The vps10p-domain sorting receptor family members have emerged as important 
regulators of intracellular trafficking. The five receptors (sortilin, SorLA, SorCS1, 
SorCS2, and SorCS3) are abundantly expressed in the nervous system as well as 
non-neuronal tissues like kidney, lung, and heart (Willnow et al., 2008). In the NTF 
field, sortilin and SorCS2 have been identified as co-receptors for p75NTR and this 
receptor complex has been shown to mediate proneurotrophin signaling (Glerup et 
al., 2014b). In addition, a recent report identified SorLA as a trafficking regulator 
for interleukin-6 and its receptor in astrocytes (Larsen and Petersen, 2017). In this 
study, we analyzed the interaction of SorLA with GDNF and its receptors GFRα1 and 
RET and characterized the phenotype of SorLA-deficient mice.   
3.1. Determination of the ligand-receptor binding site 
Vps10p-domain receptors interact with their ligands mostly via the N-terminal 
vps10p-domain (Willnow et al., 2008). SorLA is the largest member of the receptor 
family, in addition to the vps10-p domain, its ECD contains an EGF precursor 
homology domain, a cluster of eleven complement type repeats, and six fibronectin 
type III repeats (Jacobsen et al., 1996) (III, Figure 1D). Using surface plasmon 
resonance (SPR) analysis, we compared the binding of all GFLs to the ECD of SorLA. 
The results revealed that SorLA bound with high affinity to GDNF but not to NRTN, 
ARTN or PSPN (III, Figure 1, A and B). It is known that GDNF is the only member 
of the GFLs with an N-terminal extension, and, to assess, whether this region was 
necessary for the binding, we produced a glutathione-S-transferase (GST) fusion 
peptide comprising GDNF propeptide and the N-terminal part of mature GDNF 
sequence (aa 20-115). This peptide did indeed bind to SorLA, although with lower 
affinity compared to mature GDNF (III, Figure 1C). Importantly, two other peptides 
encompassing the pro-region of GDNF or NRTN solely, failed to bind to SorLA, 
indicating that the N-terminal part is needed for the binding to take place. Thus, our 
results differ from a previous report claiming that SorLA interacts with the pro-
region of (α)pro-GDNF (Geng et al., 2011).   
To determine, whether the vps10p-domain is required for the interaction of 
SorLA and GDNF, the SPR analysis was conducted in the presence of excess SorLA 
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pro-peptide or small neuropeptide neurotensin, both of which are known to block 
the tunnel-like cavity of the vps10-p domain and prevent other ligands from binding. 
GDNF did not bind to SorLA in these assays, suggesting that the interaction of the 
two proteins is mediated by the N-terminal extension of GDNF and the vps10p-
domain of SorLA (III, supplemental Figure S1A and S1B). As the vps10p-domain is 
highly conserved among the sorting receptor family, it would be interesting to test 
in future studies, whether other members of the vps10-p domain receptors can also 
interact with GDNF.   
3.2. Internalization of GDNF by the SorLA-GFRα1 receptor complex 
After characterizing the SorLA-GDNF binding by SPR and also in cells (III, 
supplemental Figure S1C), we were interested, whether SorLA can internalize GDNF 
from the cell surface. Using HEK293 cells, we showed that SorLA was able to 
internalize GDNF (III, Figure 1E). While the rate of endocytosis was not affected by 
the presence of RET receptor,   cells expressing both SorLA and GFRα1 internalized 
GDNF more efficiently than SorLA alone (III, Figure 1E). To understand this 
phenomenon, SorLA and GFRα1 were co-immunoprecipitated (co-IP) and shown to 
form a complex both in the presence and absence of GDNF (III, Figure 2A). 
Subsequent SPR analysis revealed that the two receptors bind directly to each other 
with very high affinity (Kd≈6 nM) (III, Figure 2B, and supplemental Figure S3A). 
Interestingly, SorLA was able to bind to GDNF and GFRα1 simultaneously with the 
same affinity as was seen in the individual binding experiments, indicating the 
possible formation of a ternary complex (III, supplemental Figure S3D). 
After internalization, GDNF did not stay in complex with the two receptors, but 
was co-localized with an early endosome marker (EEA1) and degraded within an 
hour (III, Figure 1, F and G). Inhibition of lysosomes by leupeptin and pepstatin 
restored GDNF immunoreactivity (III, Figure 1G). The combined data demonstrate 
that extracellular GDNF is efficiently endocytosed by the complex of SorLA and 
GFRα1 and targeted to the lysosomes for degradation.  
3.3. Regulation of GFRα1 by SorLA in cell lines and primary neurons 
Next, we investigated whether SorLA affects GFRα1 trafficking. First, we compared 
the rate of internalization, and consequent cellular localization of GFRα1 expressed 
in the presence or absence of SorLA. In HEK293 cells expressing GFRα1 alone, we 
did not observe significant endocytosis of this GPI-linked receptor (III, Figure 2C). 
In the presence of SorLA, in contrast, GFRα1 was efficiently internalized in 45 
minutes with and without GDNF (III, Figure 2C), and both receptors co-localized 
partly with the trans-Golgi marker TGN46 (III, Figure 2F). Furthermore, 
immunoelectron microscopy analysis revealed that SorLa and GFRα1 co-localized 
also in early endosomes and multivesicular bodies (MVBs) (III, Figure 2G). Second, 
we measured the stability of metabolically labeled GFRα1 and found that SorLA 
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prolonged the half-life of GFRα1 (III, Figure 2E; supplemental Figure S3, G and H). 
Together, these results indicate that differently from GDNF, SorLA does not target 
GFRα1 to lysosomes.  
In addition to characterizing the interaction of SorLA and GFRα1, we were 
interested whether SorLA can also interact with other members of the GFRα 
receptor family. Co-IP analysis revealed that SorLA can indeed form a complex with 
GFRα2, GFRα3, and GFRα4, and trigger their internalization similarly to GFRα1 
(III, supplemental Figure S4). Hence, SorLA seems to be a general sorting receptor 
of the GFRα protein family, and future studies will hopefully uncover the functional 
relevance of the other interactions. It would be interesting to assess, for instance, 
whether SorLA can modulate GFL signaling by regulating the availability of the 
GFRα receptors at the cell surface.    
In addition to characterizing the sorting of GFRα1 in HEK293 cell line, we 
wanted to investigate whether SorLA has similar effects on the GDNF receptor in 
neurons. For this purpose, we utilized primary hippocampal (HC) neurons that 
express substantial levels of endogenous GFRα1 and SorLA, but not the RET 
receptor (III, Figure 5C). Comparison of GFRα1 levels and localization in HC 
cultures from wild-type or SorLA knock-out animals indicated that SorLA can 
indeed control the intracellular localization of GFRα1 in primary neurons. While the 
total levels of GFRα1 were not altered in KO neurons, the protein was detected 
primarily at the cell surface close to soma and the initial segment of filaments (III, 
Figure 5, F and E). In accordance, surface-localized GFRα1 was able to bind GDNF, 
but it failed to internalize the ligand efficiently in the absence of SorLA (III, Figure 
5H). In conclusion, these results suggest that SorLA can mediate the endocytosis of 
GDNF/GFRα1 similarly both in HEK293 cells and in primary neurons.  
3.4. Inhibition of GDNF signaling as a result of RET endocytosis by 
the SorLA-GFRα1 receptor complex 
In order to study if SorLA can regulate the RET receptor tyrosine kinase regarding 
its trafficking and interaction with GFRα1, we started by performing co-IP analyses. 
The pull-down experiments demonstrated that SorLA does not inhibit the complex 
formation of GFRα1 and RET. On the contrary, in the presence of SorLA, the RET-
GFRα1 interaction seemed to increase slightly (III, Figure 3A). Notably, in these 
experiments, GFRα1 pulled down only the immature 150 kDa form of RET that is 
detected intracellularly. Next, we showed that RET, in turn, had a positive effect on 
the SorLA-GFRα1 co-IP (III, Figure 3A).  
To analyze whether SorLA is able to regulate the trafficking of RET, we used 
antibodies recognizing the ECD of RET and monitored the internalization of RET in 
HEK293 cells transfected with RET alone, RET and GFRα1, RET and SorLA, or RET 
with SorLA and GFRα1 (III, Figure 3, B and C). Interestingly, RET was efficiently 
internalized only in the presence of both SorLA and GFRα1 and subsequently 
detected in early endosomes (III, Figure 3D).  
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Results of the experiments described above suggested that SorLA could have an 
impact on GDNF signaling. To investigate the possible effects in more detail, we 
used a neuroblastoma cell line Sy5y, which expresses RET, GFRα1, and SorLA 
endogenously. We were able to demonstrate that the phosphorylation levels of 
GDNF-induced Erk and Akt increased as a result of using blocking antibodies for 
SorLA, and consequent inhibition of GDNF/GFRα1 endocytosis (III, Figure 4A). 
Moreover, by inhibiting endogenous SorLA by its propeptide, we saw an increase in 
the cell survival that was comparable to the effect seen upon adding exogenous 
GDNF to the cells (III, Figure 4C).  
In addition to modulating cell survival, GDNF can also affect the proliferation 
and differentiation of SY5Y cells. We showed that SY5Y cells overexpressing SorLA 
proliferate more slowly (III, Figure 4F). Furthermore, the ability of GDNF to induce 
neurite outgrowth was significantly reduced in those cells. Importantly, the excess 
of SorLA did not block the retinoic acid-induced neurite outgrowth that utilizes a 
different signaling pathway (III, Figure 4G). Taken together, these results suggest 
that SorLA can inhibit the neurotrophic function of GDNF most likely by regulating 
the levels of the ligand and controlling the subcellular localization of the GDNF 
receptors.       
3.5. Characterization of SorLA knock-out animals 
SorLA is widely expressed in the CNS of both young and old mice (III, Figure 5A). 
Notably, it is also detected in the midbrain and striatum. Analysis of primary 
dopamine (DA) neuron cultures revealed that SorLA is expressed by the DA neurons 
as well as by the supporting cortical glial cells (III, Figure 6, A and B). In line with 
our previous findings, we were able to demonstrate that SorLA mediated the uptake 
of GDNF to glial cells (III, Figure 6D) and in SorLA KO animals, GFRα1 levels were 
increased on the cell surface of DA neurons (III, Figure 6G). We also showed that 
SorLA significantly inhibited GDNF-induced survival of DA neurons (III, Figure 
6H).  
To assess whether SorLA can regulate GDNF levels in vivo, we used the striatum 
and midbrain homogenates of wild-type and Sorl1 knock-out animals. Results of the 
ELISA analysis showed that GDNF levels were significantly increased both in 
striatum and midbrain of SorLA KO mice (III, Figure 6K). Previous work 
demonstrates that elevated expression of GDNF protein negatively regulates kidney 
morphogenesis (Kumar et al., 2015). Therefore, it was tempting to speculate that 
GDNF excess could potentially disturb also the normal functioning of the DA 
system. This question is relevant also in the light of a very recent publication where 
GDNF was proposed to modulate striatal DA homeostasis (Kopra et al., 2017).  
The overall appearance of the midbrain DA system was indistinguishable in 
SorLA KO and wt mice (III, supplemental Figure S7A). Furthermore, in SNpc and 
VTA, the number of tyrosine hydroxylase (TH)-positive neurons, as well as the 
length of TH+ nerve fiber projecting to the striatum and nucleus accumbens, 
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respectively, were similar (III, Figure 7A-D). Nevertheless, we did observe a 
significant difference in the function of the nigrostriatal pathway, accompanied by 
reduced striatal TH protein levels, slightly reduced DA levels, and no response to 
amphetamine in SorLA-deficient animals (III, Figure 7E-J).  
Next, SorLA KO mice were tested in different behavioral assays. The mice were 
characterized by hyperactivity, as they traveled almost twice the distance in 
comparison with the wt controls when placed in an open field for 40 minutes (III, 
Figure 7I). Moreover, animals lacking SorLA did not respond to amphetamine, most 
likely due to the perturbed activity of the dopamine transporter (DAT) in DA 
neurons. When tested in the elevated plus maze, SorLA knock-outs spent more time 
in the open arms than the control mice, displaying reduced anxiety (III, Figure 7K-
M). Interestingly, analysis of GDNF heterozygote animals in the same paradigm 
revealed that these mice demonstrated increased anxiety, as evident from fewer 
entries and less time spent in the open arms (III, Figure 7, N and O). Together, these 
results suggest that SorLA is an important regulator of GDNF signaling in vivo. The 
characteristic features of the SorLA-deficient mice may reflect the effect of increased 
GDNF activity on the functionality of the DA system. Moreover, SorLA may be a 
novel target for future studies aiming to understand better the molecular 






The goal of this thesis was to characterize the cellular regulation of GDNF, and to 
elucidate the putative function of GDNF precursor protein proGDNF. It is known 
that similarly to other NTFs, GDNF is secreted from the cells. We showed that the 
two GDNF splice isoforms seem to be regulated differently in terms of their cellular 
localization and secretory route (I). Our studies on GDNF processing demonstrate 
that several members of the PC family can cleave proGDNF into mature GDNF (I), 
interestingly, some of which are localized at the cell surface. Also, we found that both 
proGDNF variants can be secreted from cell lines (I, II).  
Characterization of the recombinant proGDNF revealed that the precursor 
protein is biologically active and can elicit typical receptor tyrosine kinase 
downstream signaling pathways via the receptor complex comprising of GFRα1 and 
RET (II). Notably, proGDNF is not as effective as mature GDNF, and its receptor 
binding profile differs from that of the mature form when signaling via GFRα2. 
Importantly, this is the first time that biological functions of the GDNF precursor 
protein are reported. Further studies are required to investigate the role of 
proGDNF in aging and pathological conditions.   
Finally, we identified SorLA as an alternative sorting receptor for GDNF and its 
receptors (III). Results of our studies propose an important role for SorLA in the 
regulation of GDNF signaling both in vitro and in vivo.
 
The main conclusions from this work are: 
I. (β)pro-GDNF, but not (α)pro-GDNF, is secreted activity-dependently in 
neuronal-like PC6 cells 
II. GDNF precursor protein proGDNF is proteolytically cleaved into mature 
GDNF by furin, PACE4, PC5A, PC5B and PC7, but not by matrix 
metalloproteinases or plasmin. 
III. Recombinant proGDNF is biologically active; it can support the survival of 
sympathetic neurons and induce ureteric budding in embryonic kidney 
explants.  
IV. ProGDNF can signal through GFRα1 and RET but, unlike mature GDNF, it 
does not signal via GFRα2.  
V. SorLA is a novel sorting receptor for GDNF and a co-receptor for GFRα1. 
SorLA modulates GDNF signaling by targeting GDNF to lysosomal 
degradation, while internalized GFRα1 is recycled back to the cell 
membrane.  
VI. SorLA knock-out mice are hyperactive and respond abnormally to 
amphetamine. These features are most likely caused by increased striatal 




Abadpour S, Göpel SO, Schive SW, Korsgren O, Foss A, Scholz H (2017) Glial cell-line derived neurotrophic factor 
protects human islets from nutrient deprivation and endoplasmic reticulum stress induced apoptosis. Sci Rep 
7:1575. 
Afratis NA, Nikitovic D, Multhaupt HAB, Theocharis AD, Couchman JR, Karamanos NK (2017) Syndecans - key 
regulators of cell signaling and biological functions. FEBS J 284:27–41. 
Airaksinen MS, Saarma M (2002) The GDNF family: signalling, biological functions and therapeutic value. Nat Rev 
Neurosci 3:383–394. 
Airavaara M, Pletnikova O, Doyle ME, Zhang YE, Troncoso JC, Liu QR (2011) Identification of novel GDNF isoforms 
and cis-antisense GDNFOS gene and their regulation in human middle temporal gyrus of Alzheimer disease. J 
Biol Chem 286:45093–45102. 
Akerud P, Alberch J, Eketjäll S, Wagner J, Arenas E (1999) Differential effects of glial cell line-derived neurotrophic 
factor and neurturin on developing and adult substantia nigra dopaminergic neurons. J Neurochem 73:70–78. 
Al-Shawi R, Hafner A, Olson J, Chun S, Raza S, Thrasivoulou C, Lovestone S, Killick R, Simons P, Cowen T (2008) 
Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. 
Eur J Neurosci 27:2103–2114. 
Alemany S, Ribasés M, Vilor-Tejedor N, Bustamante M, Sánchez-Mora C, Bosch R, Richarte V, Cormand B, Casas 
M, Ramos-Quiroga JA, Sunyer J (2015) New suggestive genetic loci and biological pathways for attention 
function in adult attention-deficit/hyperactivity disorder. Am J Med Genet Part B Neuropsychiatr Genet 168:459–
470. 
Alfano I, Vora P, Mummery RS, Mulloy B, Rider CC (2007) The major determinant of the heparin binding of glial 
cell-line-derived neurotrophic factor is near the N-terminus and is dispensable for receptor binding. Biochem J 
404:131–140. 
Amiel J et al. (2008) Hirschsprung disease, associated syndromes and genetics: a review. J Med Genet 45:1–14. 
Amoresano A, Incoronato M, Monti G, Pucci P, de Franciscis V, Cerchia L (2005) Direct interactions among Ret, 
GDNF and GFRα1 molecules reveal new insights into the assembly of a functional three-protein complex. Cell 
Signal 17:717–727. 
Anastasia A, Barker PA, Chao M V., Hempstead BL (2015) Detection of p75NTR Trimers: Implications for Receptor 
Stoichiometry and Activation. J Neurosci 35:11911–11920. 
Anastasia A, Deinhardt K, Chao M V, Will NE, Irmady K, Lee FS, Hempstead BL, Bracken C (2013) Val66Met 
polymorphism of BDNF alters prodomain structure to induce neuronal growth cone retraction. Nat Commun 
4:2490. 
Anders J, Kjær S, Ibáñez CF (2001) Molecular Modeling of the Extracellular Domain of the RET Receptor Tyrosine 
Kinase Reveals Multiple Cadherin-like Domains and a Calcium-binding Site. J Biol Chem 276:35808–35817. 
Andersen OM, Reiche J, Schmidt V, Gotthardt M, Spoelgen R, Behlke J, von Arnim CAF, Breiderhoff T, Jansen P, 
Wu X, Bales KR, Cappai R, Masters CL, Gliemann J, Mufson EJ, Hyman BT, Paul SM, Nykjaer A, Willnow TE 
(2005) Neuronal sorting protein-related receptor sorLA/LR11 regulates processing of the amyloid precursor 
protein. Proc Natl Acad Sci U S A 102:13461–13466. 
Andersen OM, Schmidt V, Spoelgen R, Gliemann J, Behlke J, Galatis D, McKinstry WJ, Parker MW, Masters CL, 
Hyman BT, Cappai R, Willnow TE (2006) Molecular dissection of the interaction between amyloid precursor 
protein and its neuronal trafficking receptor SorLA/LR11. Biochemistry 45:2618–2628. 
Arighi E, Borrello MG, Sariola H (2005) RET tyrosine kinase signaling in development and cancer. Cytokine Growth 
Factor Rev 16:441–467. 
61 
 
Arimura N, Kimura T, Nakamuta S, Taya S, Funahashi Y, Hattori A, Shimada A, Ménager C, Kawabata S, Fujii K, 
Iwamatsu A, Segal RA, Fukuda M, Kaibuchi K (2009) Anterograde Transport of TrkB in Axons Is Mediated by 
Direct Interaction with Slp1 and Rab27. Dev Cell 16:675–686. 
Asai N, Fukuda T, Wu Z, Enomoto A, Pachnis V, Takahashi M, Costantini F (2006) Targeted mutation of serine 
697 in the Ret tyrosine kinase causes migration defect of enteric neural crest cells. Development 133:4507–
4516. 
Ascano M, Richmond A, Borden P, Kuruvilla R (2009) Axonal Targeting of Trk Receptors via Transcytosis 
Regulates Sensitivity to Neurotrophin Responses. J Neurosci 29:11674–11685. 
Baba T, Sakamoto Y, Kasamatsu A, Minakawa Y, Yokota S, Higo M, Yokoe H, Ogawara K, Shiiba M, Tanzawa H, 
Uzawa K (2015) Persephin: A potential key component in human oral cancer progression through the RET 
receptor tyrosine kinase-mitogen-activated protein kinase signaling pathway. Mol Carcinog 54:608–617. 
Baj G, Leone E, Chao M V., Tongiorgi E (2011) Spatial segregation of BDNF transcripts enables BDNF to 
differentially shape distinct dendritic compartments. Proc Natl Acad Sci 108:16813–16818. 
Baldwin AN, Shooter EM (1995) Zone mapping of the binding domain of the rat low affinity nerve growth factor 
receptor by the introduction of novel N-glycosylation sites. J Biol Chem 270:4594–4602. 
Baloh RH, Gorodinsky A, Golden JP, Tansey MG, Keck CL, Popescu NC, Johnson EM, Milbrandt J (1998a) GFRα3 
is an orphan member of the GDNF/neurturin/persephin receptor family. Proc Natl Acad Sci U S A 95:5801–
5806. 
Baloh RH, Tansey MG, Golden JP, Creedon DJ, Heuckeroth RO, Keck CL, Zimonjic DB, Popescu NC, Johnson 
EM, Milbrandt J (1997) TrnR2, a Novel Receptor That Mediates Neurturin and GDNF Signaling through Ret. 
Neuron 18:793–802. 
Baloh RH, Tansey MG, Johnson EM, Milbrandt J (2000) Functional mapping of receptor specificity domains of glial 
cell line- derived neurotrophic factor (GDNF) family ligands and production of GFRα1 RET-specific agonists. J 
Biol Chem 275:3412–3420. 
Baloh RH, Tansey MG, Lampe PA, Fahrner TJ, Enomoto H, Simburger KS, Leitner ML, Araki T, Johnson EM, 
Milbrandt J (1998b) Artemin, a novel member of the GDNF ligand family, supports peripheral and central 
neurons and signals through the GFRα3-RET receptor complex. Neuron 21:1291–1302. 
Barak S, Wang J, Ahmadiantehrani S, Hamida S Ben, Kells AP, Forsayeth J, Bankiewicz KS, Ron D (2015) Glial 
cell line-derived neurotrophic factor (GDNF) is an endogenous protector in the mesolimbic system against 
excessive alcohol consumption and relapse. Addict Biol 20:626–642. 
Barde YA, Edgar D, Thoenen H (1982) Purification of a new neurotrophic factor from mammalian brain. EMBO J 
1:549–553. 
Barford K, Deppmann C, Winckler B (2017) The neurotrophin receptor signaling endosome: Where trafficking meets 
signaling. Dev Neurobiol 77:405–418. 
Barnes P, Thomas KL (2008) Proteolysis of proBDNF Is a Key Regulator in the Formation of Memory Bartolomucci 
A, ed. PLoS One 3:e3248. 
Bartus RT, Johnson EM (2017) Clinical tests of neurotrophic factors for human neurodegenerative diseases, part 
2: Where do we stand and where must we go next? Neurobiol Dis 97:169–178. 
Bartus RT, Kordower JH, Johnson EM, Brown L, Kruegel BR, Chu Y, Baumann TL, Lang AE, Olanow CW, Herzog 
CD (2015) Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients 
with α-synucleinopathies. Neurobiol Dis 78:162–171. 
Baum AE et al. (2008) A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several 
other genes in the etiology of bipolar disorder. Mol Psychiatry 13:197–207. 
Bennett DL, Averill S, Clary DO, Priestley J V, McMahon SB (1996) Postnatal changes in the expression of the trkA 
high-affinity NGF receptor in primary sensory neurons. Eur J Neurosci 8:2204–2208. 
Berkemeier LR, Winslow JW, Kaplan DR, Nikolics K, Goeddel D V., Rosenthal A (1991) Neurotrophin-5: A novel 
neurotrophic factor that activates trk and trkB. Neuron 7:857–866. 
62 
 
Bespalov MM, Sidorova YA, Tumova S, Ahonen-Bishopp A, Magalhães AC, Kulesskiy E, Paveliev M, Rivera C, 
Rauvala H, Saarma M (2011) Heparan sulfate proteoglycan syndecan-3 is a novel receptor for GDNF, neurturin, 
and artemin. J Cell Biol 192:153–169. 
Borrello MG, Alberti L, Arighi E, Bongarzone I, Battistini C, Bardelli A, Pasini B, Piutti C, Rizzetti MG, Mondellini P, 
Radice MT, Pierotti MA (1996) The full oncogenic activity of Ret/ptc2 depends on tyrosine 539, a docking site 
for phospholipase C gamma. Mol Cell Biol 16:2151–2163. 
Borrello MG, Mercalli E, Perego C, Degl’Innocenti D, Ghizzoni S, Arighi E, Eroini B, Rizzetti MG, Pierotti MA (2002) 
Differential interaction of Enigma protein with the two RET isoforms. Biochem Biophys Res Commun 296:515–
522. 
Bothwell M (2014) NGF, BDNF, NT3, and NT4. In: Handbook of experimental pharmacology, pp 3–15. Springer 
International Publishing. 
Bradley LH, Fuqua J, Richardson A, Cholewo JT, Ai Y, Kelps KA, Glass JD, He X, Zhang Z, Grondin R, Littrell OM, 
Huettl P, Pomerleau F, Gash DM, Gerhardt GA (2010) Dopamine Neuron Stimulating Actions of a GDNF 
Propeptide. PLoS One 5. 
Bradshaw RA, Blundell TL, Lapatto R, McDonald NQ, Murray-Rust J (1993) Nerve growth factor revisited. Trends 
Biochem Sci 18:48–52. 
Breiderhoff T, Christiansen GB, Pallesen LT, Vaegter C, Nykjaer A, Holm MM, Glerup S, Willnow TE (2013) Sortilin-
Related Receptor SORCS3 Is a Postsynaptic Modulator of Synaptic Depression and Fear Extinction Mei L, ed. 
PLoS One 8:e75006. 
Brigadski T, Hartmann M, Lessmann V (2005) Differential Vesicular Targeting and Time Course of Synaptic 
Secretion of the Mammalian Neurotrophins. J Neurosci 25:7601–7614. 
Bronfman FC, Lazo OM, Flores C, Escudero CA (2014) Spatiotemporal Intracellular Dynamics of Neurotrophin and 
Its Receptors. Implications for Neurotrophin Signaling and Neuronal Function. In: Handbook of experimental 
pharmacology, pp 33–65. Springer International Publishing. 
Bruno MA, Cuello AC (2006) Activity-dependent release of precursor nerve growth factor, conversion to mature 
nerve growth factor, and its degradation by a protease cascade. Proc Natl Acad Sci U S A 103:6735–6740. 
Buj-Bello A, Adu J, Pinon LG, Horton A, Thompson J, Rosenthal A, Chinchetru M, Buchman VL, Davies AM (1997) 
Neurturin responsiveness requires a GPI-linked receptor and the Ret receptor tyrosine kinase. Nature 387:721–
724. 
Butte MJ, Hwang PK, Mobley WC, Fletterick RJ (1998) Crystal Structure of Neurotrophin-3 Homodimer Shows 
Distinct Regions Are Used To Bind Its Receptors. Biochemistry 37:16846–16852. 
Campbell C, Beug S, Nickerson PEB, Peng J, Mazerolle C, Bassett EA, Ringuette R, Jama FA, Morales C, Christ 
A, Wallace VA (2016) Sortilin regulates sorting and secretion of Sonic hedgehog. J Cell Sci 129:3832–3844. 
Canty AJ, Dietze J, Harvey M, Enomoto H, Milbrandt J, Ibanez CF (2009) Regionalized Loss of Parvalbumin 
Interneurons in the Cerebral Cortex of Mice with Deficits in GFR 1 Signaling. J Neurosci 29:10695–10705. 
Cao J-P, Yu J-K, Li C, Sun Y, Yuan H-H, Wang H-J, Gao D-S (2008) Integrin β1 is involved in the signaling of glial 
cell line-derived neurotrophic factor. J Comp Neurol 509:203–210. 
Carmillo P, Dago L, Day ES, Worley DS, Rossomando A, Walus L, Orozco O, Buckley C, Miller S, Tse A, Cate RL, 
Rosenblad C, Sah DW, Gronborg M, Whitty A (2005) Glial cell line-derived neurotrophic factor (GDNF) receptor 
alpha-1 (GFR alpha 1) is highly selective for GDNF versus artemin. Biochemistry 44:2545–2554. 
Carter MT, Yome JL, Marcil MN, Martin CA, Vanhorne JB, Mulligan LM (2001) Conservation of RET proto-oncogene 
splicing variants and implications for RET isoform function. Cytogenet Cell Genet 95:169–176. 
Chao CC, Ma YL, Chu KY, Lee EHY (2003) Integrin αv and NCAM mediate the effects of GDNF on DA neuron 
survival, outgrowth, DA turnover and motor activity in rats. Neurobiol Aging 24:105–116. 
Charlet-Berguerand N, Le Hir H, Incoronato M, Di Porzio U, Yu Y, Jing S, De Franciscis V, Thermes C (2004) 
Expression of GFRα1 receptor splicing variants with different biochemical properties is modulated during kidney 
development. Cell Signal 16:1425–1434. 
63 
 
Chen, Z.-Y., Ieraci A, Teng H, Dall H, Meng C, Herrera, DG, Nykjaer A, Hempstead, BL and Lee F (2005) Sortilin 
Controls Intracellular Sorting of Brain-Derived Neurotrophic Factor to the Regulated Secretory Pathway. J 
Neurosci 25:6156–6166. 
Chen Z-Y, Bath K, McEwen B, Hempstead B, Lee F (2008) Impact of genetic variant BDNF (Val66Met) on brain 
structure and function. Novartis Found Symp 289:180-8-95. 
Chen Z-Y, Ieraci A, Tanowitz M, Lee FS (2005a) A novel endocytic recycling signal distinguishes biological 
responses of Trk neurotrophin receptors. Mol Biol Cell 16:5761–5772. 
Chen Z-Y, Ieraci A, Teng H, Dall H, Meng C-X, Herrera DG, Nykjaer A, Hempstead BL, Lee FS (2005b) Sortilin 
Controls Intracellular Sorting of Brain-Derived Neurotrophic Factor to the Regulated Secretory Pathway. J 
Neurosci 25:6156–6166. 
Chen Z-Y, Jing D, Bath KG, Ieraci A, Khan T, Siao C-J, Herrera DG, Toth M, Yang C, McEwen BS, Hempstead BL, 
Lee FS (2006) Genetic Variant BDNF (Val66Met) Polymorphism Alters Anxiety-Related Behavior. Science (80- 
) 314:140–143. 
Chen Z, Patel P, Sant G, Meng C, Teng K, Hempstead B, Lee F (2004) Variant Brain-Derived Neurotrophic Factor 
(BDNF) (Met66) Alters the Intracellular Trafficking and Activity-Dependent Secretion of Wild-Type BDNF in 
Neurosecretory Cells and Cortical Neurons. J Neurosci 24:4401–4411. 
Christoforou A, McGhee KA, Morris SW, Thomson PA, Anderson S, McLean A, Torrance HS, Le Hellard S, Pickard 
BS, StClair D, Muir WJ, Blackwood DH, Porteous DJ, Evans KL (2011) Convergence of linkage, association 
and GWAS findings for a candidate region for bipolar disorder and schizophrenia on chromosome 4p. Mol 
Psychiatry 16:240–242. 
Chung H, Multhaupt HAB, Oh ES, Couchman JR (2016) Minireview: Syndecans and their crucial roles during tissue 
regeneration. FEBS Lett 590:2408–2417. 
Cik M (2000) Binding of GDNF and neurturin to human GDNF family receptor alpha 1 and 2. Influence of cRET and 
cooperative interactions. J Biol Chem 275:27505–27512. 
Clee SM, Yandell BS, Schueler KM, Rabaglia ME, Richards OC, Raines SM, Kabara EA, Klass DM, Mui ET-K, 
Stapleton DS, Gray-Keller MP, Young MB, Stoehr JP, Lan H, Boronenkov I, Raess PW, Flowers MT, Attie AD 
(2006) Positional cloning of Sorcs1, a type 2 diabetes quantitative trait locus. Nat Genet 38:688–693. 
Clewes O, Fahey MS, Tyler SJ, Watson JJ, Seok H, Catania C, Cho K, Dawbarn D, Allen SJ (2008) Human 
ProNGF: Biological effects and binding profiles at TrkA, P75 NTR and sortilin. J Neurochem 107:1124–1135. 
Clow C, Jasmin BJ (2010) Brain-derived Neurotrophic Factor Regulates Satellite Cell Differentiation and Skeltal 
Muscle Regeneration. Mol Biol Cell 21:2182–2190. 
Cohen S (1960) Purification of a Nerve-Growth Promoting Protein From the Mouse Salivary Gland and Its Neuro-
Cytotoxic Antiserum*. Proc Natl Acad Sci U S A 46:302–311. 
Cohen S, Levi-Montalcini R (1956) A NERVE GROWTH-STIMULATING FACTOR ISOLATED FROM SNAKE 
VENOM. Proc Natl Acad Sci U S A 42:571–574. 
Conner JM, Lauterborn JC, Gall CM (1998) Anterograde transport of neurotrophin proteins in the CNS--a 
reassessment of the neurotrophic hypothesis. Rev Neurosci 9:91–103. 
Conner JM, Lauterborn JC, Yan Q, Gall CM, Varon S (1997) Distribution of Brain-Derived Neurotrophic Factor 
(BDNF) Protein and mRNA in the Normal Adult Rat CNS: Evidence for Anterograde Axonal Transport. J 
Neurosci 17:2295–2313. 
Cosma MP, Cardone M, Carlomagno F, Colantuoni V (1998) Mutations in the extracellular domain cause RET loss 
of function by a dominant negative mechanism. Mol Cell Biol 18:3321–3329. 
Costa RO, Perestrelo T, Almeida RD (2017) PROneurotrophins and CONSequences. Mol Neurobiol:(Epub ahead 
of print). 
Coulson EJ, Reid K, Baca M, Shipham KA, Hulett SM, Kilpatrick TJ, Bartlett PF (2000) Chopper, a new death 




Creedon DJ, Tansey MG, Baloh RH, Osborne P a, Lampe P a, Fahrner TJ, Heuckeroth RO, Milbrandt J, Johnson 
EM (1997) Neurturin shares receptors and signal transduction pathways with glial cell line-derived neurotrophic 
factor in sympathetic neurons. Proc Natl Acad Sci U S A 94:7018–7023. 
Crupi MJF, Yoganathan P, Bone LN, Lian E, Fetz A, Antonescu CN, Mulligan LM (2015) Distinct Temporal 
Regulation of RET Isoform Internalization: Roles of Clathrin and AP2. Traffic 16:1155–1173. 
Davies JA, Millar CB, Johnson EM, Milbrandt J (1999) Neurturin: An autocrine regulator of renal collecting duct 
development. Dev Genet 24:284–292. 
De Graaff E, Srinivas S, Kilkenny C, D’Agati V, Mankoo BS, Costantini F, Pachnis V (2001) Differential activities of 
the RET tyrosine kinase receptor isoforms during mammalian embryogenesis. Genes Dev 15:2433–2444. 
Deinhardt K, Chao M V. (2014) Trk Receptors. In: Handbook of experimental pharmacology, pp 103–119. Springer 
International Publishing. 
Deinhardt K, Kim T, Spellman DS, Mains RE, Eipper BA, Neubert TA, Chao M V, Hempstead BL (2011) Neuronal 
growth cone retraction relies on proneurotrophin receptor signaling through Rac. Sci Signal 4:ra82. 
Deinhardt K, Reversi A, Berninghausen O, Hopkins CR, Schiavo G (2007) Neurotrophins redirect p75NTR from a 
clathrin-independent to a clathrin-dependent endocytic pathway coupled to axonal transport. Traffic 8:1736–
1749. 
Deinhardt K, Salinas S, Verastegui C, Watson R, Worth D, Hanrahan S, Bucci C, Schiavo G (2006) Rab5 and Rab7 
Control Endocytic Sorting along the Axonal Retrograde Transport Pathway. Neuron 52:293–305. 
Dieni S, Matsumoto T, Dekkers M, Rauskolb S, Ionescu MS, Deogracias R, Gundelfinger ED, Kojima M, Nestel S, 
Frotscher M, Barde Y-A (2012) BDNF and its pro-peptide are stored in presynaptic dense core vesicles in brain 
neurons. J Cell Biol 196:775–788. 
Durbec P, Marcos-Gutierrez C V., Kilkenny C, Grigoriou M, Wartiowaara K, Suvanto P, Smith D, Ponder B, 
Costantini F, Saarma M, Sariola H, Pachnis V (1996) GDNF signalling through the Ret receptor tyrosine kinase. 
Nature 381:789–793. 
Edelmann E, Leßmann V, Brigadski T (2014) Pre- and postsynaptic twists in BDNF secretion and action in synaptic 
plasticity. Neuropharmacology 76:610–627. 
Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, Zaitsev E, Gold B, Goldman D, Dean 
M, Lu B, Weinberger DR (2003) The BDNF val66met polymorphism affects activity-dependent secretion of 
BDNF and human memory and hippocampal function. Cell 112:257–269. 
Eide FF, Vining ER, Eide BL, Zang K, Wang XY, Reichardt LF (1996) Naturally occurring truncated trkB receptors 
have dominant inhibitory effects on brain-derived neurotrophic factor signaling. J Neurosci 16:3123–3129. 
Eigenbrot C, Gerber N (1997) X-ray structure of glial cell-derived neurotrophic factor at 1.9 A resolution and 
implications for receptor binding. Nat Struct Biol 4:435–438. 
Eketjall S, Fainzilber M, Murray-Rust J, Ibanez CF (1999) Distinct structural elements in GDNF mediate binding to 
GFRalpha1 and activation of the GFRalpha1-c-Ret receptor complex. EMBO J 18:5901–5910. 
Emmerson PJ et al. (2017) The metabolic effects of GDF15 are mediated by the orphan receptor GFRAL. Nat Med. 
Encinas M, Crowder RJ, Milbrandt J, Johnson EM (2004) Tyrosine 981, a novel ret autophosphorylation site, binds 
c-Src to mediate neuronal survival. J Biol Chem 279:18262–18269. 
Enokido Y, de Sauvage F, Hongo JA, Ninkina N, Rosenthal A, Buchman VL, Davies AM (1998) GFRα-4 and the 
tyrosine kinase Ret form a functional receptor complex for persephin. Curr Biol 8:1019–1022. 
Enomoto H, Araki T, Jackman A, Heuckeroth RO, Snider WD, Johnson EM, Milbrandt J (1998) GFRα1-Deficient 
Mice Have Deficits in the Enteric Nervous System and Kidneys. Neuron 21:317–324. 
Enomoto H, Crawford P a a, Gorodinsky A, Heuckeroth ROO, Johnson EMM, Milbrandt J (2001) RET signaling is 




Enomoto H, Heuckeroth RO, Golden JP, Johnson EM, Milbrandt J (2000) Development of cranial parasympathetic 
ganglia requires sequential actions of GDNF and neurturin. Development 127:4877–4889. 
Enomoto H, Hughes I, Golden J, Baloh RH, Yonemura S, Heuckeroth RO, Johnson EM, Milbrandt J (2004) GFRα1 
Expression in Cells Lacking RET Is Dispensable for Organogenesis and Nerve Regeneration. Neuron 44:623–
636. 
Ernfors P, Merlio J-P, Persson H (1992) Cells Expressing mRNA for Neurotrophins and their Receptors During 
Embryonic Rat Development. Eur J Neurosci 4:1140–1158. 
Ernfors P, Wetmore C, Eriksdotter-Nilsson M, Bygdeman M, Strömberg I, Olson L, Persson H (1991) The nerve 
growth factor receptor gene is expressed in both neuronal and non-neuronal tissues in the human fetus. Int J 
Dev Neurosci 9:57–66. 
Escudero C a, Lazo OM, Galleguillos C, Parraguez JI, Lopez-Verrilli M a, Cabeza C, Leon L, Saeed U, Retamal C, 
Gonzalez A, Marzolo M-P, Carter BD, Court F a, Bronfman FC (2014) The p75 neurotrophin receptor evades 
the endolysosomal route in neuronal cells, favouring multivesicular bodies specialised for exosomal release. J 
Cell Sci 127:1966–1979. 
Esposito D, Patel P, Stephens RM, Perez P, Chao M V, Kaplan DR, Hempstead BL (2001) The cytoplasmic and 
transmembrane domains of the p75 and Trk A receptors regulate high affinity binding to nerve growth factor. J 
Biol Chem 276:32687–32695. 
Evans SF, Irmady K, Ostrow K, Kim T, Nykjaer A, Saftig P, Blobel C, Hempstead BL (2011) Neuronal brain-derived 
neurotrophic factor is synthesized in excess, with levels regulated by sortilin-mediated trafficking and lysosomal 
degradation. J Biol Chem 286:29556–29567. 
Fahnestock M, Michalski B, Xu B, Coughlin MD (2001) The Precursor Pro-Nerve Growth Factor Is the Predominant 
Form of Nerve Growth Factor in Brain and Is Increased in Alzheimer’s Disease. Mol Cell Neurosci 18:210–220. 
Fahnestock M, Yu G, Michalski B, Mathew S, Colquhoun A, Ross GM, Coughlin MD (2004) The nerve growth factor 
precursor proNGF exhibits neurotrophic activity but is less active than mature nerve growth factor. J Neurochem 
89:581–592. 
Fayard B, Loeffler S, Weis J, Vögelin E, Krüttgen A (2005) The secreted brain-derived neurotrophic factor precursor 
pro-BDNF binds to TrkB and p75NTR but not to TrkA or TrkC. J Neurosci Res 80:18–28. 
Feng D, Kim T, Ozkan E, Light M, Torkin R, Teng KK, Hempstead BL, Garcia KC (2010) Molecular and structural 
insight into proNGF engagement of p75NTR and sortilin. J Mol Biol 396:967–984. 
Fenner BM (2012) Truncated TrkB: Beyond a dominant negative receptor. Cytokine Growth Factor Rev 23:15–24. 
Fields RD, Itoh K (1996) Neural cell adhesion molecules in activity-dependent development and synaptic plasticity. 
Trends Neurosci 19:473–480. 
Fjord-Larsen L, Johansen JL, Kusk P, Tornøe J, Grønborg M, Rosenblad C, Wahlberg LU (2005) Efficient in vivo 
protection of nigral dopaminergic neurons by lentiviral gene transfer of a modified Neurturin construct. Exp 
Neurol 195:49–60. 
Forge A, Taylor RR, Dawson SJ, Lovett M, Jagger DJ (2017) Disruption of SorCS2 reveals differences in the 
regulation of stereociliary bundle formation between hair cell types in the inner ear. Chen P, ed. PLoS Genet 
13:e1006692. 
Fukuda T, Kiuchi K, Takahashi M (2002) Novel mechanism of regulation of Rac activity and lamellipodia formation 
by RET tyrosine kinase. J Biol Chem 277:19114–19121. 
Fundin BT, Mikaels A, Westphal H, Ernfors P (1999) A rapid and dynamic regulation of GDNF-family ligands and 
receptors correlate with the developmental dependency of cutaneous sensory innervation. Development 
126:2597–2610. 
Gabreski NA, Vaghasia JK, Novakova SS, McDonald NQ, Pierchala BA (2016) Exon skipping in the RET gene 




Galuska C, Lütteke T, Galuska S (2017) Is Polysialylated NCAM Not Only a Regulator during Brain Development 
But also during the Formation of Other Organs? Biology (Basel) 6:27. 
Geng Z, Xu FY, Huang SH, Chen ZY (2011) Sorting protein-related receptor SorlA controls regulated secretion of 
glial cell line-derived neurotrophic factor. J Biol Chem 286:41871–41882. 
Gibon J, Barker PA (2017) Neurotrophins and Proneurotrophins. Neuroscientist:(Epub ahead of print). 
Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P (2003) 
Direct brain infusion of glial cell line–derived neurotrophic factor in Parkinson disease. Nat Med 9:589–595. 
Ginty DD, Segal RA (2002) Retrograde neurotrophin signaling: Trk-ing along the axon. Curr Opin Neurobiol 12:268–
274. 
Glerup S et al. (2014a) SorCS2 regulates dopaminergic wiring and is processed into an apoptotic two-chain receptor 
in peripheral glia. Neuron 82:1074–1087. 
Glerup S, Bolcho U, Mølgaard S, Bøggild S, Vaegter CB, Smith AH, Nieto-Gonzalez JL, Ovesen PL, Pedersen LF, 
Fjorback AN, Kjolby M, Login H, Holm MM, Andersen OM, Nyengaard JR, Willnow TE, Jensen K, Nykjaer A 
(2016) SorCS2 is required for BDNF-dependent plasticity in the hippocampus. Mol Psychiatry 21:1–12. 
Glerup S, Nykjaer A, Vaegter CB (2014b) Sortilins in Neurotrophic Factor Signaling. In: Handbook of experimental 
pharmacology, pp 165–189. Springer International Publishing. 
Golden JP, Baloh RH, Kotzbauer PT, Lampe PA, Osborne PA, Milbrandt J, Johnson EM (1998) Expression of 
neurturin, GDNF, and their receptors in the adult mouse CNS. J Comp Neurol 398:139–150. 
Golden JP, Demaro JA, Osborne PA, Milbrandt J, Johnson EM (1999) Expression of Neurturin, GDNF, and GDNF 
Family-Receptor mRNA in the Developing and Mature Mouse. Exp Neurol 158:504–528. 
Golden JP, Milbrandt J, Johnson EM (2003) Neurturin and persephin promote the survival of embryonic basal 
forebrain cholinergic neurons in vitro. Exp Neurol 184:447–455. 
Goodarzi MO, Lehman DM, Taylor KD, Guo X, Cui J, Quiñones MJ, Clee SM, Yandell BS, Blangero J, Hsueh WA, 
Attie AD, Stern MP, Rotter JI (2007) SORCS1: a novel human type 2 diabetes susceptibility gene suggested 
by the mouse. Diabetes 56:1922–1929. 
Goodman KM, Kjær S, Beuron F, Knowles PP, Nawrotek A, Burns EM, Purkiss AG, George R, Santoro M, Morris 
EP, McDonald NQ (2014) RET Recognition of GDNF-GFRα1 Ligand by a Composite Binding Site Promotes 
Membrane-Proximal Self-Association. Cell Rep 8:1894–1904. 
Grimes ML, Zhou J, Beattie EC, Yuen EC, Hall DE, Valletta JS, Topp KS, LaVail JH, Bunnett NW, Mobley WC 
(1996) Endocytosis of activated TrkA: evidence that nerve growth factor induces formation of signaling 
endosomes. J Neurosci 16:7950–7964. 
Grimm L, Holinski-Feder E, Teodoridis J, Scheffer B, Schindelhauer D, Meitinger T, Ueffing M (1998) Analysis of 
the human GDNF gene reveals an inducible promoter, three exons, a triplet repeat within the 3’-UTR and 
alternative splice products. Hum Mol Genet 7:1873–1886. 
Hallböök F, Ibáñez CF, Persson H (1991) Evolutionary studies of the nerve growth factor family reveal a novel 
member abundantly expressed in xenopus ovary. Neuron 6:845–858. 
Hamburger V, Levi-Montalcini R (1949) Proliferation, differentiation and degeneration in the spinal ganglia of the 
chick embryo under normal and experimental conditions. J Exp Zool 111:457–501. 
Harrington AW, Leiner B, Blechschmitt C, Arevalo JC, Lee R, Mörl K, Meyer M, Hempstead BL, Yoon SO, Giehl 
KM (2004) Secreted proNGF is a pathophysiological death-inducing ligand after adult CNS injury. Proc Natl 
Acad Sci U S A 101:6226–6230. 
Hart GW, Copeland RJ (2010) Glycomics Hits the Big Time. Cell 143:672–676. 
Hasan W, Pedchenko T, Krizsan-Agbas D, Baum L, Smith PG (2003) Sympathetic neurons synthesize and secrete 
pro-nerve growth factor protein. J Neurobiol 57:38–53. 
67 
 
He D-Y, McGough NNH, Ravindranathan A, Jeanblanc J, Logrip ML, Phamluong K, Janak PH, Ron D (2005) Glial 
cell line-derived neurotrophic factor mediates the desirable actions of the anti-addiction drug ibogaine against 
alcohol consumption. J Neurosci 25:619–628. 
He X, Garcia KC (2004) Structure of Nerve Growth Factor Complexed with the Shared Neurotrophin Receptor p75. 
Science (80- ) 304:870–875. 
Hempstead BL (2006) Dissecting the diverse actions of pro- and mature neurotrophins. Curr Alzheimer Res 3:19–
24. 
Hempstead BL, Martin-Zanca D, Kaplan DR, Parada LF, Chao M V. (1991) High-affinity NGF binding requires 
coexpression of the trk proto-oncogene and the low-affinity NGF receptor. Nature 350:678–683. 
Henderson CE, Phillips HS, Pollock RA, Davies AM, Lemeulle C, Armanini M, Simmons L, Moffet B, Vandlen RA, 
Simpson LC corrected to Simmons L, Koliatsos VE, Rosenthal A (1994) GDNF: a potent survival factor for 
motoneurons present in peripheral nerve and muscle. Science 266:1062–1064. 
Hermey G, Plath N, Hübner CA, Kuhl D, Schaller HC, Hermans-Borgmeyer I (2004) The three sorCS genes are 
differentially expressed and regulated by synaptic activity. J Neurochem 88:1470–1476. 
Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I (1999) Identification and Characterization of 
SorCS, a Third Member of a Novel Receptor Family. Biochem Biophys Res Commun 266:347–351. 
Hermey G, Sjøgaard SS, Petersen CM, Nykjaer A, Gliemann J (2006) Tumour necrosis factor alpha-converting 
enzyme mediates ectodomain shedding of Vps10p-domain receptor family members. Biochem J 395:285–293. 
Herskowitz JH, Offe K, Deshpande A, Kahn RA, Levey AI, Lah JJ (2012) GGA1-mediated endocytic traffic of 
LR11/SorLA alters APP intracellular distribution and amyloid-  production. Mol Biol Cell 23:2645–2657. 
Heuckeroth RO, Enomoto H, Grider JR, Golden JP, Hanke JA, Jackman A, Molliver DC, Bardgett ME, Snider WD, 
Johnson EM, Milbrandt J (1999) Gene targeting reveals a critical role for neurturin in the development and 
maintenance of enteric, sensory, and parasympathetic neurons. Neuron 22:253–263. 
Hibbert AP, Kramer BMR, Miller FD, Kaplan DR (2006) The localization, trafficking and retrograde transport of 
BDNF bound to p75NTR in sympathetic neurons. Mol Cell Neurosci 32:387–402. 
Hickey JG, Myers SM, Tian X, Zhu SJ, V. Shaw JL, Andrew SD, Richardson DS, Brettschneider J, Mulligan LM 
(2009) RET-mediated gene expression pattern is affected by isoform but not oncogenic mutation. Genes, 
Chromosom Cancer 48:429–440. 
Hidaka T, Ogawa E, Kobayashi EH, Suzuki T, Funayama R, Nagashima T, Fujimura T, Aiba S, Nakayama K, 
Okuyama R, Yamamoto M (2016) The aryl hydrocarbon receptor AhR links atopic dermatitis and air pollution 
via induction of the neurotrophic factor artemin. Nat Immunol 18:64–73. 
Hidalgo-Figueroa M, Bonilla S, Gutiérrez F, Pascual A, López-Barneo J (2012) GDNF is predominantly expressed 
in the PV+ neostriatal interneuronal ensemble in normal mouse and after injury of the nigrostriatal pathway. J 
Neurosci 32:864–872. 
Hienola A, Tumova S, Kulesskiy E, Rauvala H (2006) N-syndecan deficiency impairs neural migration in brain. J 
Cell Biol 174:569–580. 
Hillger F, Herr G, Rudolph R, Schwarz E (2005) Biophysical comparison of BMP-2, ProBMP-2, and the free pro-
peptide reveals stabilization of the pro-peptide by the mature growth factor. J Biol Chem 280:14974–14980. 
Hirata Y, Shimokawa N, Oh-hashi K, Yu ZX, Kiuchi K (2010) Acidification of the Golgi apparatus is indispensable 
for maturation but not for cell surface delivery of Ret. J Neurochem 115:606–613. 
Hofer M, Pagliusi SR, Hohn A, Leibrock J, Barde Y-A (1990) Regional distribution of brain-derived neurotrophic 
factor mRNA in the adult mouse brain-derived neurotrophic factor/hippocampus/ in situ hybridization/nerve 
growth factor/trophic interactions. EMBO J 9:2459–2464. 
Hohn A, Leibrock J, Bailey K, Barde Y-A (1990) Identification and characterization of a novel member of the nerve 
growth factor/brain-derived neurotrophic factor family. Nature 344:339–341. 
68 
 
Horger BA, Nishimura MC, Armanini MP, Wang L-C, Poulsen KT, Rosenblad C, Kirik D, Moffat B, Simmons L, 
Johnson E, Milbrandt J, Rosenthal A, Bjorklund A, Vandlen RA, Hynes MA, Phillips HS (1998) Neurturin exerts 
potent actions on survival and function of midbrain dopaminergic neurons. J Neurosci 18:4929–4937. 
Horton AC, Ehlers MD (2003) Neuronal polarity and trafficking. Neuron 40:277–295. 
Howe CL, Mobley WC (2005) Long-distance retrograde neurotrophic signaling. Curr Opin Neurobiol:40–48. 
Hsu J-Y et al. (2017) Non-homeostatic body weight regulation through a brainstem-restricted receptor for GDF15. 
Nature 550:255–259. 
Hulpiau P, van Roy F (2009) Molecular evolution of the cadherin superfamily. Int J Biochem Cell Biol 41:349–369. 
Ibanez CF (2013) Structure and Physiology of the RET Receptor Tyrosine Kinase. Cold Spring Harb Perspect Biol 
5:a009134. 
Ibáñez CF (2010) Beyond the cell surface: New mechanisms of receptor function. Biochem Biophys Res Commun 
396:24–27. 
Ikonen E, Simons K (1998) Protein and lipid sorting from the trans-Golgi network to the plasma membrane in 
polarized cells. Semin Cell Dev Biol 9:503–509. 
Immonen T, Alakuijala A, Hytönen M, Sainio K, Poteryaev D, Saarma M, Pasternack M, Sariola H (2008) A 
proGDNF-related peptide BEP increases synaptic excitation in rat hippocampus. Exp Neurol 210:793–796. 
Ioannou M, Fahnestock M (2017) ProNGF, but Not NGF, Switches from Neurotrophic to Apoptotic Activity in 
Response to Reductions in TrkA Receptor Levels. Int J Mol Sci 18:E599. 
Ip NY, Ibáñez CF, Nye SH, McClain J, Jones PF, Gies DR, Belluscio L, Le Beau MM, Espinosa R, Squinto SP 
(1992) Mammalian neurotrophin-4: structure, chromosomal localization, tissue distribution, and receptor 
specificity. Proc Natl Acad Sci U S A 89:3060–3064. 
Jacobsen L, Madsen P, Jacobsen C, Nielsen MS, Gliemann J, Petersen CM (2001) Activation and Functional 
Characterization of the Mosaic Receptor SorLA/LR11. J Biol Chem 276:22788–22796. 
Jacobsen L, Madsen P, Moestrup SK, Lund AH, Tommerup N, Nykjaer A, Sottrup-Jensen L, Gliemann J, Petersen 
CM (1996) Molecular characterization of a novel human hybrid-type receptor that binds the alpha2-
macroglobulin receptor-associated protein. J Biol Chem 271:31379–31383. 
Jacobsen L, Madsen P, Nielsen MS, Geraerts WPM, Gliemann J, Smit AB, Petersen CM (2002) The sorLA 
cytoplasmic domain interacts with GGA1 and -2 and defines minimum requirements for GGA binding. FEBS 
Lett 511:155–158. 
Jain S, Encinas M, Johnson EM, Milbrandt J (2006a) Critical and distinct roles for key RET tyrosine docking sites 
in renal development. Genes Dev 20:321–333. 
Jain S, Golden JP, Wozniak D, Pehek E, Johnson EM, Milbrandt J (2006b) RET Is Dispensable for Maintenance of 
Midbrain Dopaminergic Neurons in Adult Mice. J Neurosci 26:11230–11238. 
Jankowski MP, Baumbauer KM, Wang T, Albers KM, Davis BM, Koerber HR (2017) Cutaneous neurturin 
overexpression alters mechanical, thermal, and cold responsiveness in physiologically identified primary 
afferents. J Neurophysiol 117:1258–1265. 
Jaszai J, Farkas L, Galter D, Reuss B, Strelau J, Unsicker K, Krieglstein K (1998) GDNF-related factor persephin 
is widely distributed throughout the nervous system. J Neurosci Res 53:494–501. 
Jing S, Wen D, Yu Y, Holst PL, Luo Y, Fang M, Tamir R, Antonio L, Hu Z, Cupples R, Louis J-C, Hu S, Altrock BW, 
Fox GM (1996) GDNF–Induced Activation of the Ret Protein Tyrosine Kinase Is Mediated by GDNFR-α, a 
Novel Receptor for GDNF. Cell 85:1113–1124. 
Jing S, Yu Y, Fang M, Hu Z, Holst PL, Boone T, Delaney J, Schultz H, Zhou R, Fox GM (1997) GFR -2 and GFR -
3 Are Two New Receptors for Ligands of the GDNF Family. J Biol Chem 272:33111–33117. 
Jones KR, Reichardt LF (1990) Molecular cloning of a human gene that is a member of the nerve growth factor 
family. Proc Natl Acad Sci U S A 87:8060–8064. 
69 
 
Katoh-Semba R, Takeuchi IK, Semba R, Kato K (1997) Distribution of brain-derived neurotrophic factor in rats and 
its changes with development in the brain. J Neurochem 69:34–42. 
Kinnunen T, Kaksonen M, Saarinen J, Kalkkinen N, Peng HB, Rauvala H (1998) Cortactin-Src Kinase Signaling 
Pathway Is Involved in N-syndecan-dependent Neurite Outgrowth. J Biol Chem 273:10702–10708. 
Kjaer S, Hanrahan S, Totty N, McDonald NQ (2010) Mammal-restricted elements predispose human RET to folding 
impairment by HSCR mutations. Nat Struct Mol Biol 17:726–731. 
Kjær S, Kurokawa K, Perrinjaquet M, Abrescia C, Ibáñez CF (2006) Self-association of the transmembrane domain 
of RET underlies oncogenic activation by MEN2A mutations. Oncogene 25:7086–7095. 
Klein R, Jing S, Nanduri V, O’Rourke E, Barbacid M (1991a) The trk proto-oncogene encodes a receptor for nerve 
growth factor. Cell 65:189–197. 
Klein R, Lamballe F, Bryant S, Barbacid M (1992) The trkB tyrosine protein kinase is a receptor for neurotrophin-4. 
Neuron 8:947–956. 
Klein R, Nanduri V, Jing S, Lamballe F, Tapley P, Bryant S, Cordon-Cardo C, Jones KR, Reichardt LF, Barbacid M 
(1991b) The trkB tyrosine protein kinase is a receptor for brain-derived neurotrophic factor and neurotrophin-3. 
Cell 66:395–403. 
Klein RD et al. (1997) A GPI-linked protein that interacts with Ret to form a candidate neurturin receptor. Nature 
387:717–721. 
Knowles PP, Murray-Rust J, Kjaer S, Scott RP, Hanrahan S, Santoro M, Ibáñez CF, McDonald NQ (2006) Structure 
and chemical inhibition of the RET tyrosine kinase domain. J Biol Chem 281:33577–33587. 
Knudsen K, Haase A-M, Fedorova TD, Bekker AC, Østergaard K, Krogh K, Borghammer P (2017) Gastrointestinal 
Transit Time in Parkinson’s Disease Using a Magnetic Tracking System. J Parkinsons Dis 7:471–479. 
Kobe B, Kajava A V (2001) The leucine-rich repeat as a protein recognition motif. Curr Opin Struct Biol 11:725–
732. 
Kojima M, Mizui T (2017) BDNF Propeptide: A Novel Modulator of Synaptic Plasticity. In: Vitamins and Hormones, 
1st ed., pp 19–28. Elsevier Inc. 
Kopra J, Vilenius C, Grealish S, Härma M-A, Varendi K, Lindholm J, Castrén E, Võikar V, Björklund A, Piepponen 
TP, Saarma M, Andressoo J-O (2015) GDNF is not required for catecholaminergic neuron survival in vivo. Nat 
Neurosci 18:319–322. 
Kopra JJ, Panhelainen A, af Bjerkén S, Porokuokka LL, Varendi K, Olfat S, Montonen H, Piepponen TP, Saarma 
M, Andressoo J-O (2017) Dampened Amphetamine-Stimulated Behavior and Altered Dopamine Transporter 
Function in the Absence of Brain GDNF. J Neurosci 37:1581–1590. 
Koskela M, B??ck S, V??ikar V, Richie CT, Domanskyi A, Harvey BK, Airavaara M (2017) Update of neurotrophic 
factors in neurobiology of addiction and future directions. Neurobiol Dis 97:189–200. 
Kotzbauer PT, Lampe PA, Heuckeroth RO, Golden JP, Creedon DJ, Johnson Jr EM, Milbrandt J (1996) Neurturin, 
a relative of glial-cell-line-derived neurotrophic factor. Nature 384:467–470. 
Kraemer BR, Yoon SO, Carter BD (2014) The Biological Functions and Signaling Mechanisms of the p75 
Neurotrophin Receptor. In: Handbook of experimental pharmacology, pp 121–164. Springer International 
Publishing. 
Kramer ER, Aron L, Ramakers GMJ, Seitz S, Zhuang X, Beyer K, Smidt MP, Klein R (2007) Absence of Ret 
signaling in mice causes progressive and late degeneration of the nigrostriatal system. PLoS Biol 5:0616–0628. 
Kramer ER, Liss B (2015) GDNF-Ret signaling in midbrain dopaminergic neurons and its implication for Parkinson 
disease. FEBS Lett 589:3760–3772. 
Kumar A et al. (2015) GDNF Overexpression from the Native Locus Reveals its Role in the Nigrostriatal 
Dopaminergic System Function. PLoS Genet 11:1–24. 
70 
 
Kumar A, Varendi K, Peränen J, Andressoo J-O (2014) Tristetraprolin is a novel regulator of BDNF. Springerplus 
3:502. 
Kurowska Z, Kordower JH, Stoessl AJ, Burke RE, Brundin P, Yue Z, Brady ST, Milbrandt J, Trapp BD, Sherer TB, 
Medicetty S (2016) Is Axonal Degeneration a Key Early Event in Parkinson’s Disease? J Parkinsons Dis 6:703–
707. 
Lamballe F, Klein R, Barbacid M (1991) trkC, a new member of the trk family of tyrosine protein kinases, is a 
receptor for neurotrophin-3. Cell 66:967–979. 
Lang AE et al. (2006) Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor 
infusion in Parkinson disease. Ann Neurol 59:459–466. 
Larsen JV, Hansen M, Møller B, Madsen P, Scheller J, Nielsen M, Petersen CM (2010) Sortilin facilitates signaling 
of ciliary neurotrophic factor and related helical type 1 cytokines targeting the gp130/leukemia inhibitory factor 
receptor beta heterodimer. Mol Cell Biol 30:4175–4187. 
Larsen JV, Petersen CM (2017) SorLA in Interleukin-6 Signaling and Turnover. Mol Cell Biol 37:e00641-16. 
Ledda F, Paratcha G, Sandoval-Guzmán T, Ibáñez CF (2007) GDNF and GFRalpha1 promote formation of 
neuronal synapses by ligand-induced cell adhesion. Nat Neurosci 10:293–300. 
Lee R, Kermani P, Teng KK, Hempstead BL (2001) Regulation of cell survival by secreted proneurotrophins. 
Science 294:1945–1948. 
Leibrock J, Lottspeich F, Hohn A, Hofer M, Hengerer B, Masiakowski P, Thoenen H, Barde YA (1989) Molecular 
cloning and expression of brain-derived neurotrophic factor. Nature 341:149–152. 
Leitner ML, Molliver DC, Osborne PA, Vejsada R, Golden JP, Lampe PA, Kato AC, Milbrandt J, Johnson EM (1999) 
Analysis of the retrograde transport of glial cell line-derived neurotrophic factor (GDNF), neurturin, and 
persephin suggests that in vivo signaling for the GDNF family is GFRα coreceptor-specific. J Neurosci 19:9322–
9331. 
Lemmon MA, Schlessinger J (2010) Cell signaling by receptor tyrosine kinases. Cell 141:1117–1134. 
Leppänen V-M, Bespalov MM, Runeberg-Roos P, Puurand Ü, Merits A, Saarma M, Goldman A (2004) The structure 
of GFRα1 domain 3 reveals new insights into GDNF binding and RET activation. EMBO J 23:1452–1462. 
Leßmann V, Brigadski T (2009) Mechanisms, locations, and kinetics of synaptic BDNF secretion: An update. 
Neurosci Res 65:11–22. 
Levi-Montalcini R (1964) THE NERVE GROWTH FACTOR. Ann N Y Acad Sci 118:149–170. 
Li XZ, Yan J, Huang SH, Zhao L, Wang J, Chen ZY (2012) Identification of a key motif that determines the differential 
surface levels of RET and TrkB tyrosine kinase receptors and controls depolarization enhanced RET surface 
insertion. J Biol Chem 287:1932–1945. 
Lim KC, Tyler CM, Lim ST, Giuliano R, Federoff HJ (2007) Proteolytic processing of proNGF is necessary for mature 
NGF regulated secretion from neurons. Biochem Biophys Res Commun 361:599–604. 
Lin LF, Doherty DH, Lile JD, Bektesh S, Collins F (1993) GDNF: a glial cell line-derived neurotrophic factor for 
midbrain dopaminergic neurons. Science 260:1130–1132. 
Lindahl M, Danilova T, Palm E, Lindholm P, Võikar V, Hakonen E, Ustinov J, Andressoo J-O, Harvey BK, Otonkoski 
T, Rossi J, Saarma M (2014) MANF is indispensable for the proliferation and survival of pancreatic β cells. Cell 
Rep 7:366–375. 
Lindahl M, Poteryaev D, Yu L, Arumäe U, Timmusk T, Bongarzone I, Aiello A, Pierotti MA, Airaksinen MS, Saarma 
M (2001) Human Glial Cell Line-derived Neurotrophic Factor Receptor α4 is the Receptor for Persephin and is 
Predominantly Expressed in Normal and Malignant Thyroid Medullary Cells. J Biol Chem 276:9344–9351. 
Lindahl M, Saarma M, Lindholm P (2017) Unconventional neurotrophic factors CDNF and MANF: Structure, 
physiological functions and therapeutic potential. Neurobiol Dis 97:90–102. 
71 
 
Lindahl M, Timmusk T, Rossi J, Saarma M, Airaksinen MS (2000) Expression and alternative splicing of mouse 
Gfrα4 suggest roles in endocrine cell development. Mol Cell Neurosci 15:522–533. 
Lindfors PH, Lindahl M, Rossi J, Saarma M, Airaksinen MS (2006) Ablation of persephin receptor glial cell line-
derived neurotrophic factor family receptor α4 impairs thyroid calcitonin production in young mice. 
Endocrinology 147:2237–2244. 
Lindholm P, Saarma M (2010) Novel CDNF/MANF family of neurotrophic factors. Dev Neurobiol 70:360–371. 
Liu X, Vega QC, Decker RA, Pandey A, Worby CA, Dixon JE (1996) Oncogenic RET receptors display different 
autophosphorylation sites and substrate binding specificities. J Biol Chem 271:5309–5312. 
Lou H, Kim S, Zaitsev E, Snell CR, Lu B, Loh YP (2005) Sorting and Activity-Dependent Secretion of BDNF Require 
Interaction of a Specific Motif with the Sorting Receptor Carboxypeptidase E. Neuron 45:245–255. 
Ma GQ, Wang B, Wang HB, Wang Q, Bao L (2008) Short elements with charged amino acids form clusters to sort 
protachykinin into large dense-core vesicles. Traffic 9:2165–2179. 
Maisonpierre PC, Belluscio L, Friedman B, Alderson RF, Wiegand SJ, Furth ME, Lindsay RM, Yancopoulos GD 
(1990a) NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of 
expression. Neuron 5:501–509. 
Maisonpierre PC, Belluscio L, Squinto S, Ip NY, Furth ME, Lindsay RM, Yancopoulos GD (1990b) Neurotrophin-3: 
a neurotrophic factor related to NGF and BDNF. Science 247:1446–1451. 
Maness PF, Schachner M (2007) Neural recognition molecules of the immunoglobulin superfamily: signaling 
transducers of axon guidance and neuronal migration. Nat Neurosci 10:19–26. 
Marcusson EG, Horazdovsky BF, Cereghino JL, Gharakhanian E, Emr SD (1994) The sorting receptor for yeast 
vacuolar carboxypeptidase Y is encoded by the VPS10 gene. Cell 77:579–586. 
Marks C, Belluscio L, Ibanez CF (2012) Critical Role of GFR 1 in the Development and Function of the Main 
Olfactory System. J Neurosci 32:17306–17320. 
Marks WJ et al. (2010) Gene delivery of AAV2-neurturin for Parkinson’s disease: A double-blind, randomised, 
controlled trial. Lancet Neurol 9:1164–1172. 
Marks WJ, Baumann TL, Bartus RT (2016) Long-Term Safety of Patients with Parkinson’s Disease Receiving 
rAAV2-Neurturin (CERE-120) Gene Transfer. Hum Gene Ther 27:522–527. 
Masoudi R, Ioannou MS, Coughlin MD, Pagadala P, Neet KE, Clewes O, Allen SJ, Dawbarn D, Fahnestock M 
(2009) Biological activity of nerve growth factor precursor is dependent upon relative levels of its receptors. J 
Biol Chem 284:18424–18433. 
Masure S, Cik M, Hoefnagel E, Nosrat CA, Van der Linden I, Scott R, Van Gompel P, Lesage ASJ, Verhasselt P, 
Ibáñez CF, Gordon RD (2000) Mammalian GFRα-4, a Divergent Member of the GFRα Family of Coreceptors 
for Glial Cell Line-derived Neurotrophic Factor Family Ligands, Is a Receptor for the Neurotrophic Factor 
Persephin. J Biol Chem 275:39427–39434. 
Masure S, Cik M, Pangalos MN, Bonaventure P, Verhasselt P, Lesage  a S, Leysen JE, Gordon RD (1998) 
Molecular cloning, expression and tissue distribution of glial-cell-line-derived neurotrophic factor family receptor 
alpha-3 (GFRalpha-3). Eur J Biochem 251:622–630. 
Masure S, Geerts H, Cik M, Hoefnagel E, Van Den Kieboom G, Tuytelaars A, Harris S, Lesage ASJ, Leysen JE, 
Van Der Helm L, Verhasselt P, Yon J, Gordon RD (1999) Enovin, a member of the glial cell-line-derived 
neurotrophic factor (GDNF) family with growth promoting activity on neuronal cells. Existence and tissue-
specific expression of different splice variants. Eur J Biochem 266:892–902. 
Mauffray M, Domingues O, Hentges F, Zimmer J, Hanau D, Michel T (2015) Neurturin Influences Inflammatory 
Responses and Airway Remodeling in Different Mouse Asthma Models. J Immunol 194:1423–1433. 
McDonald NQ, Chao M V. (1995) Structural determinants of neurotrophin action. J Biol Chem 270:19669–19672. 
McDonald NQ, Lapatto R, Rust JM, Gunning J, Wlodawer A, Blundell TL (1991) New protein fold revealed by a 2.3-
Å resolution crystal structure of nerve growth factor. Nature 354:411–414. 
72 
 
Meeker RB, Williams KS (2015) The p75 neurotrophin receptor: At the crossroad of neural repair and death. Neural 
Regen Res 10:721–725. 
Meng X, Lindahl M, Hyvönen ME, Parvinen M, de Rooij DG, Hess MW, Raatikainen-Ahokas A, Sainio K, Rauvala 
H, Lakso M, Pichel JG, Westphal H, Saarma M, Sariola H (2000) Regulation of cell fate decision of 
undifferentiated spermatogonia by GDNF. Science 287:1489–1493. 
Meng X, Pata I, Pedrono E, Popsueva A, De Rooij DG, Jänne M, Rauvala H, Sariola H (2001) Transient disruption 
of spermatogenesis by deregulated expression of neurturin in testis. Mol Cell Endocrinol 184:33–39. 
Merighi A (2016) Targeting the glial-derived neurotrophic factor and related molecules for controlling normal and 
pathologic pain. Expert Opin Ther Targets 20:193–208. 
Messer CJ, Eisch AJ, Carlezon WA, Whisler K, Shen L, Wolf DH, Westphal H, Collins F, Russell DS, Nestler EJ 
(2000) Role for GDNF in biochemical and behavioral adaptations to drugs of abuse. Neuron 26:247–257. 
Milbrandt J et al. (1998) Persephin, a novel neurotrophic factor related to GDNF and neurturin. Neuron 20:245–
253. 
Miller IN, Cronin-Golomb A (2010) Gender differences in Parkinson’s disease: clinical characteristics and cognition. 
Mov Disord 25:2695–2703. 
Mitsou I, Multhaupt HAB, Couchman JR (2017) Proteoglycans, ion channels and cell–matrix adhesion. Biochem J 
474:1965–1979. 
Mizoguchi H, Nakade J, Tachibana M, Ibi D, Someya E, Koike H, Kamei H, Nabeshima T, Itohara S, Takuma K, 
Sawada M, Sato J, Yamada K (2011) Matrix Metalloproteinase-9 Contributes to Kindled Seizure Development 
in Pentylenetetrazole-Treated Mice by Converting Pro-BDNF to Mature BDNF in the Hippocampus. J Neurosci 
31:12963–12971. 
Mizui T, Ishikawa Y, Kumanogoh H, Lume M, Matsumoto T, Hara T, Yamawaki S, Takahashi M, Shiosaka S, Itami 
C, Uegaki K, Saarma M, Kojima M (2015) BDNF pro-peptide actions facilitate hippocampal LTD and are altered 
by the common BDNF polymorphism Val66Met. Proc Natl Acad Sci 112:E3067–E3074. 
Moore MW, Klein RD, Fariñas I, Sauer H, Armanini M, Phillips H, Reichardt LF, Ryan AM, Carver-Moore K, 
Rosenthal A (1996) Renal and neuronal abnormalities in mice lacking GDNF. Nature 382:76–79. 
Mowla SJ, Pareek S, Farhadi HF, Petrecca K, Fawcett JP, Seidah NG, Morris SJ, Sossin WS, Murphy RA (1999) 
Differential Sorting of Nerve Growth Factor and Brain-Derived Neurotrophic Factor in Hippocampal Neurons. J 
Neurosci 19:2069–2080. 
Mullican SE, Lin-Schmidt X, Chin C-N, Chavez JA, Furman JL, Armstrong AA, Beck SC, South VJ, Dinh TQ, Cash-
Mason TD, Cavanaugh CR, Nelson S, Huang C, Hunter MJ, Rangwala SM (2017) GFRAL is the receptor for 
GDF15 and the ligand promotes weight loss in mice and nonhuman primates. Nat Med. 
Mulligan LM (2014) RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 14:173–186. 
Murota H, Izumi M, Abd El-Latif MIA, Nishioka M, Terao M, Tani M, Matsui S, Sano S, Katayama I (2012) Artemin 
causes hypersensitivity to warm sensation, mimicking warmth-provoked pruritus in atopic dermatitis. J Allergy 
Clin Immunol 130:671–682.e4. 
Mwangi SM, Usta Y, Shahnavaz N, Joseph I, Avila J, Cano J, Chetty VK, Larsen CP, Sitaraman S V., Srinivasan 
S (2011) Glial Cell Line–Derived Neurotrophic Factor Enhances Human Islet Posttransplantation Survival. 
Transplantation 92:745–751. 
Myers SM, Eng C, Ponder BA, Mulligan LM (1995) Characterization of RET proto-oncogene 3’ splicing variants and 
polyadenylation sites: a novel C-terminus for RET. Oncogene 11:2039–2045. 
Nagappan G, Zaitsev E, Senatorov V V, Yang J, Hempstead BL, Lu B (2009) Control of extracellular cleavage of 
ProBDNF by high frequency neuronal activity. Proc Natl Acad Sci U S A 106:1267–1272. 
Naveilhan P, Baudet C, Mikaels A, Shen L, Westphal H, Ernfors P (1998) Expression and regulation of GFRalpha3, 
a glial cell line-derived neurotrophic factor family receptor. Proc Natl Acad Sci U S A 95:1295–1300. 
73 
 
Nickels JD, Chatterjee S, Stanley CB, Qian S, Cheng X, Myles DAA, Standaert RF, Elkins JG, Katsaras J (2017) 
The in vivo structure of biological membranes and evidence for lipid domains. PLOS Biol 15:e2002214. 
Nielsen J, Gotfryd K, Li S, Kulahin N, Soroka V, Rasmussen KK, Bock E, Berezin V (2009) Role of Glial Cell Line-
Derived Neurotrophic Factor (GDNF)-Neural Cell Adhesion Molecule (NCAM) Interactions in Induction of 
Neurite Outgrowth and Identification of a Binding Site for NCAM in the Heel Region of GDNF. J Neurosci 
29:11360–11376. 
Nielsen MS, Gustafsen C, Madsen P, Nyengaard JR, Hermey G, Bakke O, Mari M, Schu P, Pohlmann R, Dennes 
A, Petersen CM (2007) Sorting by the Cytoplasmic Domain of the Amyloid Precursor Protein Binding Receptor 
SorLA. Mol Cell Biol 27:6842–6851. 
Nielsen MS, Keat SJ, Hamati JW, Madsen P, Gutzmann JJ, Engelsberg A, Pedersen KM, Gustafsen C, Nykjær A, 
Gliemann J, Hermans-Borgmeyer I, Kuhl D, Petersen CM, Hermey G (2008) Different motifs regulate trafficking 
of SorCS1 isoforms. Traffic 9:980–994. 
Nielsen MS, Madsen P, Christensen EI, Nykjaer A, Gliemann J, Kasper D, Pohlmann R, Petersen CM (2001) The 
sortilin cytoplasmic tail conveys Golgi-endosome transport and binds the VHS domain of the GGA2 sorting 
protein. EMBO J 20:2180–2190. 
Nishino J, Mochida K, Ohfuji Y, Shimazaki T, Meno C, Ohishi S, Matsuda Y, Fujii H, Saijoh Y, Hamada H (1999) 
GFRα3, a Component of the Artemin Receptor, Is Required for Migration and Survival of the Superior Cervical 
Ganglion. Neuron 23:725–736. 
Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER, Lozano AM, Penn RD, Simpson RK, Stacy M, 
Wooten GF, ICV GDNF Study Group. Implanted intracerebroventricular. Glial cell line-derived neurotrophic 
factor (2003) Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. 
Neurology 60:69–73. 
Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, Jacobsen C, Kliemannel M, Schwarz E, Willnow 
TE, Hempstead BL, Petersen CM (2004) Sortilin is essential for proNGF-induced neuronal cell death. Nature 
427:843–848. 
Oetjen S, Mahlke C, Hermans-Borgmeyer I, Hermey G (2014) Spatiotemporal expression analysis of the growth 
factor receptor SorCS3. J Comp Neurol 522:3386–3402. 
Oh-hashi K, Ito M, Tanaka T, Hirata Y, Kiuchi K (2009) Biosynthesis, processing, and secretion of glial cell line-
derived neurotrophic factor in astroglial cells. Mol Cell Biochem 323:1–7. 
Ollila HM, Soronen P, Silander K, Palo OM, Kieseppä T, Kaunisto MA, Lönnqvist J, Peltonen L, Partonen T, Paunio 
T (2009) Findings from bipolar disorder genome-wide association studies replicate in a Finnish bipolar family-
cohort. Mol Psychiatry 14:351–353. 
Orozco OE, Walus L, Sah DWY, Pepinsky RB, Sanicola M (2001) GFRalpha3 is expressed predominantly in 
nociceptive sensory neurons. Eur J Neurosci 13:2177–2182. 
Pachnis V, Mankoo B, Costantini F (1993) Expression of the c-ret proto-oncogene during mouse embryogenesis. 
Development 119:1005–1017. 
Pang PT, Teng HK, Zaitsev E, Woo NT, Sakata K, Zhen S, Teng KK, Yung W-H, Hempstead BL, Lu B (2004) 
Cleavage of proBDNF by tPA/plasmin is essential for long-term hippocampal plasticity. Science 306:487–491. 
Paoletti F, Malerba F, Kelly G, Noinville S, Lamba D, Cattaneo A, Pastore A (2011) Conformational Plasticity of 
proNGF Tramontano A, ed. PLoS One 6:e22615. 
Paratcha G, Ledda F, Baars L, Coulpier M, Besset V, Anders J, Scott R, Ibáñez CF (2001) Released GFRα1 
Potentiates Downstream Signaling, Neuronal Survival, and Differentiation via a Novel Mechanism of 
Recruitment of c-Ret to Lipid Rafts. Neuron 29:171–184. 
Paratcha G, Ledda F, Ibáñez CF (2003) The neural cell adhesion molecule NCAM is an alternative signaling 
receptor for GDNF family ligands. Cell 113:867–879. 
Parkash V, Goldman A (2009) Comparison of GFL-GFRα complexes: Further evidence relating GFL bend angle to 
RET signalling. Acta Crystallogr Sect F Struct Biol Cryst Commun 65:551–558. 
74 
 
Parkash V, Leppänen VM, Virtanen H, Jurvansuu JM, Bespalov MM, Sidorova YA, Runeberg-Roos P, Saarma M, 
Goldman A (2008) The structure of the glial cell line-derived neurotrophic factor-coreceptor complex: Insights 
into RET signaling and heparin binding. J Biol Chem 283:35164–35172. 
Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J (2008) Absolute 
requirement of GDNF for adult catecholaminergic neuron survival. Nat Neurosci 11:755–761. 
Pasquin S, Sharma M, Gauchat JF (2016) Cytokines of the LIF/CNTF family and metabolism. Cytokine 82:122–
124. 
Paveliev M, Lume M, Velthut A, Phillips M, Arumae U, Saarma M (2007) Neurotrophic factors switch between two 
signaling pathways that trigger axonal growth. J Cell Sci 120:2507–2516. 
Pereira DB, Chao M V. (2007) The Tyrosine Kinase Fyn Determines the Localization of TrkB Receptors in Lipid 
Rafts. J Neurosci 27:4859–4869. 
Perrinjaquet M, Sjöstrand D, Moliner A, Zechel S, Lamballe F, Maina F, Ibáñez CF (2011) MET signaling in 
GABAergic neuronal precursors of the medial ganglionic eminence restricts GDNF activity in cells that express 
GFR{alpha}1 and a new transmembrane receptor partner. J Cell Sci 124:2797–2805. 
Petersen CM, Nielsen MS, Nykjaer A, Jacobsen L, Tommerup N, Rasmussen HH, Roigaard H, Gliemann J, Madsen 
P, Moestrup SK (1997) Molecular identification of a novel candidate sorting receptor purified from human brain 
by receptor-associated protein affinity chromatography. J Biol Chem 272:3599–3605. 
Peterziel H, Unsicker K, Krieglstein K (2002) TGFβ induces GDNF responsiveness in neurons by recruitment of 
GFRα1 to the plasma membrane. J Cell Biol 159:157–167. 
Piccinini E, Kalkkinen N, Saarma M, Runeberg-Roos P (2013) Glial cell line-derived neurotrophic factor: 
characterization of mammalian posttranslational modifications. Ann Med 45:66–73. 
Pichel JG, Shen L, Sheng HZ, Granholm A-C, Drago J, Grinberg A, Lee EJ, Huang SP, Saarma M, Hoffer BJ, 
Sariola H, Westphal H (1996) Defects in enteric innervation and kidney development in mice lacking GDNF. 
Nature 382:73–76. 
Pierchala BA, Milbrandt J, Johnson EM (2006) Glial Cell Line-Derived Neurotrophic Factor-Dependent Recruitment 
of Ret into Lipid Rafts Enhances Signaling by Partitioning Ret from Proteasome-Dependent Degradation. J 
Neurosci 26:2777–2787. 
Pioro EP, Cuello AC (1990) Distribution of nerve growth factor receptor-like immunoreactivity in the adult rat central 
nervous system. Effect of colchicine and correlation with the cholinergic system--I. Forebrain. Neuroscience 
34:57–87. 
Poteryaev D, Titievsky A, Sun YF, Thomas-Crusells J, Lindahl M, Billaud M, Arumäe U, Saarma M (1999) GDNF 
triggers a novel Ret-independent Src kinase family-coupled signaling via a GPI-linked GDNF receptor α1. FEBS 
Lett 463:63–66. 
Pozas E, Ibáñez CF (2005) GDNF and GFRα1 promote differentiation and tangential migration of cortical 
GABAergic neurons. Neuron 45:701–713. 
Pruunsild P, Kazantseval A, Aid T, Palm K, Timmusk T (2007) Dissecting the human BDNF locus: Bidirectional 
transcription, complex splicing, and multiple promoters. Genomics 90:397–406. 
Quartu M, Serra MP, Boi M, Sestu N, Lai ML, Del Fiacco M (2007) Tissue distribution of neurturin, persephin and 
artemin in the human brainstem at fetal, neonatal and adult age. Brain Res 1143:102–115. 
Quartu M, Serra MP, Manca A, Mascia F, Follesa P, Del Fiacco M (2005) Neurturin, persephin, and artemin in the 
human pre- and full-term newborn and adult hippocampus and fascia dentata. Brain Res 1041:157–166. 
Quistgaard EM, Madsen P, Grøftehauge MK, Nissen P, Petersen CM, Thirup SS (2009) Ligands bind to Sortilin in 
the tunnel of a ten-bladed β-propeller domain. Nat Struct Mol Biol 16:96–98. 
Rana AQ, Ahmed US, Chaudry ZM, Vasan S (2015) Parkinson’s disease: a review of non-motor symptoms. Expert 
Rev Neurother 15:549–562. 
Reichardt LF (2006) Neurotrophin-regulated signalling pathways. Philos Trans R Soc B Biol Sci 361:1545–1564. 
75 
 
Reitz C, Tokuhiro S, Clark LN, Conrad C, Vonsattel J-P, Hazrati L-N, Palotás A, Lantigua R, Medrano M, Z Jiménez-
Velázquez I, Vardarajan B, Simkin I, Haines JL, Pericak-Vance MA, Farrer LA, Lee JH, Rogaeva E, George-
Hyslop PS, Mayeux R (2011) SORCS1 alters amyloid precursor protein processing and variants may increase 
Alzheimer’s disease risk. Ann Neurol 69:47–64. 
Rezgaoui M, Hermey G, Riedel IB, Hampe W, Schaller HC, Hermans-Borgmeyer I (2001) Identification of SorCS2, 
a novel member of the VPS10 domain containing receptor family, prominently expressed in the developing 
mouse brain. Mech Dev 100:335–338. 
Richardson DS, Lai AZ, Mulligan LM (2006) RET ligand-induced internalization and its consequences for 
downstream signaling. Oncogene 25:3206–3211. 
Richardson DSS, Rodrigues DMM, Hyndman BDD, Crupi MJFJF, Nicolescu ACC, Mulligan LMM (2012) Alternative 
splicing results in RET isoforms with distinct trafficking properties. Mol Biol Cell 23:3838–3850. 
Rind HB, Butowt R, von Bartheld CS (2005) Synaptic Targeting of Retrogradely Transported Trophic Factors in 
Motoneurons: Comparison of Glial Cell Line-Derived Neurotrophic Factor, Brain-Derived Neurotrophic Factor, 
and Cardiotrophin-1 with Tetanus Toxin. J Neurosci 25:539–549. 
Robinson RC, Radziejewski C, Stuart DI, Jones EY (1995) Structure of the Brain-Derived Neurotrophic 
Factor/Neurotrophin 3 Heterodimer. Biochemistry 34:4139–4146. 
Rodriguez-Tébar A, Dechant G, Barde YA, Johnson EM, Yasukawa K, Matsuda T, Hirano T, Kishimoto T (1990) 
Binding of brain-derived neurotrophic factor to the nerve growth factor receptor. Neuron 4:487–492. 
Rodríguez-Tébar A, Dechant G, Götz R, Barde YA (1992) Binding of neurotrophin-3 to its neuronal receptors and 
interactions with nerve growth factor and brain-derived neurotrophic factor. EMBO J 11:917–922. 
Rolan PE, O’Neill G, Versage E, Rana J, Tang Y, Galluppi G, Aycardi E (2015) First-In-Human, Double-Blind, 
Placebo-Controlled, Randomized, Dose-Escalation Study of BG00010, a Glial Cell Line-Derived Neurotrophic 
Factor Family Member, in Subjects with Unilateral Sciatica. PLoS One 10:e0125034. 
Rosenthal  a, Goeddel D V, Nguyen T, Lewis M, Shih  a, Laramee GR, Nikolics K, Winslow JW (1990) Primary 
structure and biological activity of a novel human neurotrophic factor. Neuron 4:767–773. 
Rossi J, Luukko K, Poteryaev D, Laurikainen  a, Sun YF, Laakso T, Eerikäinen S, Tuominen R, Lakso M, Rauvala 
H, Arumäe U, Pasternack M, Saarma M, Airaksinen MS (1999) Retarded growth and deficits in the enteric and 
parasympathetic nervous system in mice lacking GFR alpha2, a functional neurturin receptor. Neuron 22:243–
252. 
Rossi J, Santamäki P, Airaksinen MS, Herzig KH (2005) Parasympathetic innervation and function of endocrine 
pancreas requires the glial cell line-derived factor family receptor α2 (GFRα2). Diabetes 54:1324–1330. 
Rossi J, Tomac A, Saarma M, Airaksinen MS (2000) Distinct roles for GFRα1 and GFRα2 signalling in different 
cranial parasympathetic ganglia in vivo. Eur J Neurosci 12:3944–3952. 
Ruiz-Ferrer M, Torroglosa A, Luzón-Toro B, Fernández RM, Antiñolo G, Mulligan LM, Borrego S (2011) Novel 
mutations at RET ligand genes preventing receptor activation are associated to Hirschsprung’s disease. J Mol 
Med 89:471–480. 
Runeberg-Roos P, Piccinini E, Penttinen A-M, Mätlik K, Heikkinen H, Kuure S, Bespalov MM, Peränen J, Garea-
Rodríguez E, Fuchs E, Airavaara M, Kalkkinen N, Penn R, Saarma M (2016) Developing therapeutically more 
efficient Neurturin variants for treatment of Parkinson’s disease. Neurobiol Dis 96:335–345. 
Runeberg-Roos P, Virtanen H, Saarma M (2007) RET(MEN 2B) is active in the endoplasmic reticulum before 
reaching the cell surface. Oncogene 26:7909–7915. 
Saavedra A, Baltazar G, Duarte EP (2008) Driving GDNF expression: The green and the red traffic lights. Prog 
Neurobiol 86:186–215. 
Safina DR, Surin AM, Pinelis VG, Kostrov S V. (2015) Effect of neurotrophin-3 precursor on glutamate-induced 
calcium homeostasis deregulation in rat cerebellum granule cells. J Neurosci Res 93:1865–1873. 
76 
 
Sainio K, Suvanto P, Davies J, Wartiovaara J, Wartiovaara K, Saarma M, Arumae U, Meng X, Lindahl M, Pachnis 
V, Sariola H (1997) Glial-cell-line-derived neurotrophic factor is required for bud initiation from ureteric 
epithelium. Development 124:4077–4087. 
Sánchez-Sánchez J, Arévalo J (2017) A Review on Ubiquitination of Neurotrophin Receptors: Facts and 
Perspectives. Int J Mol Sci 18:630. 
Sanicola M, Hession C, Worley D, Carmillo P, Ehrenfels C, Walus L, Robinson S, Jaworski G, Wei H, Tizard R, 
Whitty  a, Pepinsky RB, Cate RL (1997) Glial cell line-derived neurotrophic factor-dependent RET activation 
can be mediated by two different cell-surface accessory proteins. Proc Natl Acad Sci U S A 94:6238–6243. 
Schmidt V, Sporbert A, Rohe M, Reimer T, Rehm A, Andersen OM, Willnow TE (2007) SorLA/LR11 regulates 
processing of amyloid precursor protein via interaction with adaptors GGA and PACS-1. J Biol Chem 
282:32956–32964. 
Schmidt V, Subkhangulova A, Willnow TE (2017) Sorting receptor SORLA: cellular mechanisms and implications 
for disease. Cell Mol Life Sci 74:1475–1483. 
Schmutzler BS, Roy S, Pittman SK, Meadows RM, Hingtgen CM (2011) Ret-Dependent and Ret-Independent 
Mechanisms of Gfl-Induced Sensitization. Mol Pain 7:1744-8069-7–22. 
Schuchardt A, D’Agati V, Larsson-Blomberg L, Costantini F, Pachnis V (1994) Defects in the kidney and enteric 
nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 367:380–383. 
Scott RP, Eketjäll S, Aineskog H, Ibáñez CF (2005) Distinct turnover of alternatively spliced isoforms of the RET 
kinase receptor mediated by differential recruitment of the Cbl ubiquitin ligase. J Biol Chem 280:13442–13449. 
Scott RP, Ibanez CF (2001) Determinants of Ligand Binding Specificity in the Glial Cell Line-derived Neurotrophic 
Factor Family Receptor  s. J Biol Chem 276:1450–1458. 
Seidah NG, Benjannet S, Pareek S, Chrétien M, Murphy RA (1996a) Cellular processing of the neurotrophin 
precursors of NT3 and BDNF by the mammalian proprotein convertases. FEBS Lett 379:247–250. 
Seidah NG, Benjannet S, Pareek S, Savaria D, Hamelin J, Goulet B, Laliberte J, Lazure C, Chrétien M, Murphy RA 
(1996b) Cellular processing of the nerve growth factor precursor by the mammalian pro-protein convertases. 
Biochem J 314 ( Pt 3:951–960. 
Seidah NG, Mayer G, Zaid A, Rousselet E, Nassoury N, Poirier S, Essalmani R, Prat A (2008) The activation and 
physiological functions of the proprotein convertases. Int J Biochem Cell Biol 40:1111–1125. 
Sendtner M (2014) Motoneuron Disease. In: Handbook of experimental pharmacology, pp 411–441. Springer 
International Publishing. 
Sergaki MC, López-Ramos JC, Stagkourakis S, Gruart A, Broberger C, Delgado-García JM, Ibáñez CF (2017) 
Compromised Survival of Cerebellar Molecular Layer Interneurons Lacking GDNF Receptors GFRα1 or RET 
Impairs Normal Cerebellar Motor Learning. Cell Rep 19:1977–1986. 
Shakya R, Jho EHH, Kotka P, Wu Z, Kholodilov N, Burke R, D’Agati V, Costantini F (2005) The role of GDNF in 
patterning the excretory system. Dev Biol 283:70–84. 
Sidorova YA, Mätlik K, Paveliev M, Lindahl M, Piranen E, Milbrandt J, Arumäe U, Saarma M, Bespalov MM (2010) 
Persephin signaling through GFRα1: The potential for the treatment of Parkinson’s disease. Mol Cell Neurosci 
44:223–232. 
Simons K, Ikonen E (1997) Functional rafts in cell membranes. Nature 387:569–572. 
Sjostrand D, Ibanez CF (2008) Insights into GFR 1 Regulation of Neural Cell Adhesion Molecule (NCAM) Function 
from Structure-Function Analysis of the NCAM/GFR 1 Receptor Complex. J Biol Chem 283:13792–13798. 
Sjöstrand D, Carlsson J, Paratcha G, Persson B, Ibáñez CF (2007) Disruption of the GDNF binding site in NCAM 
dissociates ligand binding and homophilic cell adhesion. J Biol Chem 282:12734–12740. 
Skeldal S, Matusica D, Nykjaer A, Coulson EJ (2011) Proteolytic processing of the p75 neurotrophin receptor: A 
prerequisite for signalling?: Neuronal life, growth and death signalling are crucially regulated by intra-membrane 
proteolysis and trafficking of p75NTR. BioEssays 33:614–625. 
77 
 
Skeldal S, Sykes AM, Glerup S, Matusica D, Palstra N, Autio H, Boskovic Z, Madsen P, Castrén E, Nykjaer A, 
Coulson EJ (2012) Mapping of the interaction site between sortilin and the p75 neurotrophin receptor reveals 
a regulatory role for the sortilin intracellular domain in p75 neurotrophin receptor shedding and apoptosis. J Biol 
Chem 287:43798–43809. 
Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B (2005) Improvement of bilateral motor functions 
in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived 
neurotrophic factor. J Neurosurg 102:216–222. 
Sofroniew M V, Howe CL, Mobley WC (2001) Nerve Growth Factor Signaling, Neuroprotection, and Neural Repair. 
Annu Rev Neurosci 24:1217–1281. 
Song M, Giza J, Proenca CC, Jing D, Elliott M, Dincheva I, Shmelkov S V., Kim J, Schreiner R, Huang SH, Castrén 
E, Prekeris R, Hempstead BL, Chao M V., Dictenberg JB, Rafii S, Chen ZY, Rodriguez-Boulan E, Lee FS (2015) 
Slitrk5 Mediates BDNF-Dependent TrkB Receptor Trafficking and Signaling. Dev Cell 33:690–702. 
Spencer A, Yu L, Guili V, Reynaud F, Ding Y, Ma J, Jullien J, Koubi D, Gauthier E, Cluet D, Falk J, Castellani V, 
Yuan C, Rudkin B (2017) Nerve Growth Factor Signaling from Membrane Microdomains to the Nucleus: 
Differential Regulation by Caveolins. Int J Mol Sci 18:693. 
Sun XL, Chen BY, Duan L, Xia Y, Luo ZJ, Wang JJ, Rao ZR, Chen LW (2014) The proform of glia cell line-derived 
neurotrophic factor: A potentially biologically active protein. Mol Neurobiol 49:234–250. 
Suo D, Park J, Harrington AW, Zweifel LS, Mihalas S, Deppmann CD (2014) Coronin-1 is a neurotrophin endosomal 
effector that is required for developmental competition for survival. Nat Neurosci 17:36–45. 
Suter-Crazzolara C, Unsicker K (1994) GDNF is expressed in two forms in many tissues outside the CNS. 
Neuroreport 5:2486–2488. 
Suter U, Heymach J V, Shooter EM (1991) Two conserved domains in the NGF propeptide are necessary and 
sufficient for the biosynthesis of correctly processed and biologically active NGF. EMBO J 10:2395–2400. 
Suvanto P, Hiltunen JO, Arumäe U, Moshnyakov M, Sariola H, Sainio K, Saarma M (1996) Localization of glial cell 
line-derived neurotrophic factor (GDNF) mRNA in embryonic rat by in situ hybridization. Eur J Neurosci 8:816–
822. 
Suvanto P, Wartiovaara K, Lindahl M, Arumae U, Moshnyakov M, Horelli-Kuitunen N, Airaksinen MS, Palotie A, 
Sariola H, Saarma M (1997) Cloning, mRNA distribution and chromosomal localisation of the gene for glial cell 
line-derived neurotrophic factor receptor beta, a homologue to GDNFR-alpha. Hum Mol Genet 6:1267–1273. 
Tahira T, Ishizaka Y, Itoh F, Sugimura T, Nagao M (1990) Characterization of ret proto-oncogene mRNAs encoding 
two isoforms of the protein product in a human neuroblastoma cell line. Oncogene 5:97–102. 
Takahashi M, Asai N, Iwashita T, Isomura T, Miyazaki K, Matsuyama M (1993a) Characterization of the ret proto-
oncogene products expressed in mouse L cells. Oncogene 8:2925–2929. 
Takahashi M, Ritz J, Cooper GM (1985) Activation of a novel human transforming gene, ret, by DNA rearrangement. 
Cell 42:581–588. 
Takahashi S, Kasai K, Hatsuzawa K, Kitamura N, Misumi Y, Ikehara Y, Murakami K, Nakayama K (1993b) A 
Mutation of Furin Causes the Lack of Precursor-Processing Activity in Human Colon Carcinoma LoVo Cells. 
Biochem Biophys Res Commun 195:1019–1026. 
Tanaka M, Ito S, Matsushita N, Mori N, Kiuchi K (2000) Promoter analysis and characteristics of the 5’-untranslated 
region of the mouse glial cell line-derived neurotrophic factor gene. Brain Res Mol Brain Res 85:91–102. 
Tanaka T, Shinoda M, Feng B, Albers KM, Gebhart GF (2011) Modulation of visceral hypersensitivity by glial cell 
line-derived neurotrophic factor family receptor -3 in colorectal afferents. AJP Gastrointest Liver Physiol 
300:G418–G424. 
Tansey MG, Baloh RH, Milbrandt J, Johnson EM (2000) GFRalpha-mediated localization of RET to lipid rafts is 
required for effective downstream signaling, differentiation, and neuronal survival. Neuron 25:611–623. 
Tatsumi N, Miki R, Katsu K, Yokouchi Y (2007) Neurturin-GFRα2 signaling controls liver bud migration along the 
ductus venosus in the chick embryo. Dev Biol 307:14–28. 
78 
 
Teitelman G, Guz Y, Ivkovic S, Ehrlich M (1998) Islet injury induces neurotrophin expression in pancreatic cells and 
reactive gliosis of peri-islet Schwann cells. J Neurobiol 34:304–318. 
Tenenbaum L, Humbert-Claude M (2017) Glial Cell Line-Derived Neurotrophic Factor Gene Delivery in Parkinson’s 
Disease: A Delicate Balance between Neuroprotection, Trophic Effects, and Unwanted Compensatory 
Mechanisms. Front Neuroanat 11:1–12. 
Teng HK, Teng KK, Lee R, Wright S, Tevar S, Almeida RD, Kermani P, Torkin R, Chen Z, Lee FS, Kraemer RT, 
Nykjaer A, Hempstead BL (2005) ProBDNF Induces Neuronal Apoptosis via Activation of a Receptor Complex 
of p75 NTR and Sortilin. J Neurosci 25:5455–5463. 
Teng KK, Felice S, Kim T, Hempstead BL (2010) Understanding proneurotrophin actions: Recent advances and 
challenges. Dev Neurobiol 70:350–359. 
Thompson J, Doxakis E, Pinon LG, Strachan P, Buj-Bello A, Wyatt S, Buchman VL, Davies AM (1998) GFRα-4, a 
new GDNF family receptor. Mol Cell Neurosci 11:117–126. 
Tinholt M, Stavik B, Louch W, Carlson CR, Sletten M, Ruf W, Skretting G, Sandset PM, Iversen N (2015) Syndecan-
3 and TFPI colocalize on the surface of endothelial-, smooth muscle-, and cancer cells. PLoS One 10:1–17. 
Tomac AC, Agulnick AD, Haughey N, Chang C-F, Zhang Y, Bäckman C, Morales M, Mattson MP, Wang Y, 
Westphal H, Hoffer BJ (2002) Effects of cerebral ischemia in mice deficient in Persephin. Proc Natl Acad Sci U 
S A 99:9521–9526. 
Tomac AC, Grinberg A, Huang SP, Nosrat C, Wang Y, Borlongan C, Lin S-Z, Chiang Y-H, Olson L, Westphal H, 
Hoffer BJ (1999) Glial cell line-derived neurotrophic factor receptor α1 availability regulates glial cell line-derived 
neurotrophic factor signaling: evidence from mice carrying one or two mutated alleles. Neuroscience 95:1011–
1023. 
Tongiorgi E, Baj G (2008) Functions and mechanisms of BDNF mRNA trafficking. Novartis Found Symp 289:136-
47-51, 193–195. 
Tongiorgi E, Righi M, Cattaneo A (1997) Activity-dependent dendritic targeting of BDNF and TrkB mRNAs in 
hippocampal neurons. J Neurosci 17:9492–9505. 
Treanor JJS et al. (1996) Characterization of a multicomponent receptor for GDNF. Nature 382:80–83. 
Trevaskis JL et al. (2017) Neurturin and a GLP-1 Analogue Act Synergistically to Alleviate Diabetes in Zucker 
Diabetic Fatty Rats. Diabetes 66:2007–2018. 
Trupp M, Arenas E, Fainzilber M, Nilsson A-S, Sieber B-A, Grigoriou M, Kilkenny C, Salazar-Grueso E, Pachnis V, 
Arumäe U, Sariola H, Saarma M, Ibáñez CF (1996) Functional receptor for GDNF encoded by the c-ret proto-
oncogene. Nature 381:785–789. 
Trupp M, Belluardo N, Funakoshi H, Ibáñez CF (1997) Complementary and overlapping expression of glial cell line-
derived neurotrophic factor (GDNF), c-ret proto-oncogene, and GDNF receptor-alpha indicates multiple 
mechanisms of trophic actions in the adult rat CNS. J Neurosci 17:3554–3567. 
Trupp M, Raynoschek C, Belluardo N, Ibáñez CF (1998) Multiple GPI-anchored receptors control GDNF-dependent 
and independent activation of the c-Ret receptor tyrosine kinase. Mol Cell Neurosci 11:47–63. 
Trupp M, Rydén M, Jörnvall H, Funakoshi H, Timmusk T, Arenas E, Ibáñez CF (1995) Peripheral expression and 
biological activities of GDNF, a new neurotrophic factor for avian and mammalian peripheral neurons. J Cell 
Biol 130:137–148. 
Tsui-Pierchala BA, Ahrens RC, Crowder RJ, Milbrandt J, Johnson EM (2002a) The long and short isoforms of Ret 
function as independent signaling complexes. J Biol Chem 277:34618–34625. 
Tsui-Pierchala BA, Encinas M, Milbrandt J, Johnson EM (2002b) Lipid rafts in neuronal signaling and function. 
Trends Neurosci 25:412–417. 
Tsui CC, Pierchala BA (2010) The Differential Axonal Degradation of Ret Accounts for Cell-Type-Specific Function 
of Glial Cell Line-Derived Neurotrophic Factor as a Retrograde Survival Factor. J Neurosci 30:5149–5158. 
79 
 
Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J (1995) Spatial and temporal expression of the 
ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 10:191–198. 
Underwood CK, Reid K, May LM, Bartlett PF, Coulson EJ (2008) Palmitoylation of the C-terminal fragment of 
p75NTR regulates death signaling and is required for subsequent cleavage by γ-secretase. Mol Cell Neurosci 
37:346–358. 
Vaegter CB, Jansen P, Fjorback AW, Glerup S, Skeldal S, Kjolby M, Richner M, Erdmann B, Nyengaard JR, 
Tessarollo L, Lewin GR, Willnow TE, Chao M V, Nykjaer A (2011) Sortilin associates with Trk receptors to 
enhance anterograde transport and neurotrophin signaling. Nat Neurosci 14:54–61. 
van Weering DH, Moen TC, Braakman I, Baas PD, Bos JL (1998) Expression of the receptor tyrosine kinase Ret 
on the plasma membrane is dependent on calcium. J Biol Chem 273:12077–12081. 
Varendi K, Kumar A, Härma MA, Andressoo JO (2014) MIR-1, miR-10b, miR-155, and miR-191 are novel regulators 
of BDNF. Cell Mol Life Sci 71:4443–4456. 
Vieira P, Thomas-Crusells J, Vieira A (2003) Internalization of glial cell-derived neurotrophic factor receptor GFR 
alpha 1 in the absence of the ret tyrosine kinase coreceptor. Cell Mol Neurobiol 23:43–55. 
Virtanen H, Yang J, Bespalov MM, Hiltunen JO, Leppänen V-M, Kalkkinen N, Goldman A, Saarma M, Runeberg-
Roos P (2005) The first cysteine-rich domain of the receptor GFRalpha1 stabilizes the binding of GDNF. 
Biochem J 387:817–824. 
Wang Y, Geng Z, Zhao L, Huang SH, Sheng AL, Chen ZY (2008) GDNF isoform affects intracellular trafficking and 
secretion of GDNF in neuronal cells. Brain Res 1226:1–7. 
Warren Olanow C et al. (2015) Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A 
double-blind, randomized, controlled trial. Ann Neurol 78:248–257. 
West AE, Pruunsild P, Timmusk T (2014) Neurotrophins: Transcription and Translation. In: Handbook of 
experimental pharmacology, pp 67–100. Springer International Publishing. 
Westergaard UB, Kirkegaard K, Sørensen ES, Jacobsen C, Nielsen MS, Petersen CM, Madsen P (2005) SorCS3 
does not require propeptide cleavage to bind nerve growth factor. FEBS Lett 579:1172–1176. 
Whittle AJ, Jiang M, Peirce V, Relat J, Virtue S, Ebinuma H, Fukamachi I, Yamaguchi T, Takahashi M, Murano T, 
Tatsuno I, Takeuchi M, Nakaseko C, Jin W, Jin Z, Campbell M, Schneider WJ, Vidal-Puig A, Bujo H (2015) 
Soluble LR11/SorLA represses thermogenesis in adipose tissue and correlates with BMI in humans. Nat 
Commun 6:8951. 
Widenfalk J, Nosrat C, Tomac  a, Westphal H, Hoffer B, Olson L (1997) Neurturin and glial cell line-derived 
neurotrophic factor receptor-beta (GDNFR-beta), novel proteins related to GDNF and GDNFR-alpha with 
specific cellular patterns of expression suggesting roles in the developing and adult nervous system and in 
periphera. J Neurosci 17:8506–8519. 
Willnow TE, Andersen OM (2013) Sorting receptor SORLA - a trafficking path to avoid Alzheimer disease. J Cell 
Sci 126:2751–2760. 
Willnow TE, Petersen CM, Nykjaer A (2008) VPS10P-domain receptors — regulators of neuronal viability and 
function. Nat Rev Neurosci 9:899–909. 
Wilson CM, Naves T, Al Akhrass H, Vincent F, Melloni B, Bonnaud F, Lalloué F, Jauberteau M-O (2016) A new role 
under sortilin’s belt in cancer. Commun Integr Biol 9:e1130192. 
Wilson CM, Naves T, Vincent F, Melloni B, Bonnaud F, Lalloue F, Jauberteau MO (2014) Sortilin mediates the 
release and transfer of exosomes in concert with two tyrosine kinase receptors. J Cell Sci 127:3983–3997. 
Worby CA, Vega QC, Chao HH-J, Seasholtz AF, Thompson RC, Dixon JE (1998) Identification and Characterization 
of GFRα-3, a Novel Co-receptor Belonging to the Glial Cell Line-derived Neurotrophic Receptor Family. J Biol 
Chem 273:3502–3508. 
Wu P-L, Lee M, Huang T-T (2017) Effectiveness of physical activity on patients with depression and Parkinson’s 
disease: A systematic review. PLoS One 12:e0181515. 
80 
 
Yan Q, Matheson C, Lopez OT (1995) In vivo neurotrophic effects of GDNF on neonatal and adult facial motor 
neurons. Nature 373:341–344. 
Yanez A, Harrell T, Sriranganathan H, Ives A, Bertke A (2017) Neurotrophic Factors NGF, GDNF and NTN 
Selectively Modulate HSV1 and HSV2 Lytic Infection and Reactivation in Primary Adult Sensory and Autonomic 
Neurons. Pathogens 6:5. 
Yang J, Siao C-J, Nagappan G, Marinic T, Jing D, McGrath K, Chen Z-Y, Mark W, Tessarollo L, Lee FS, Lu B, 
Hempstead BL (2009) Neuronal release of proBDNF. Nat Neurosci 12:113–115. 
Yang L et al. (2017) GFRAL is the receptor for GDF15 and is required for the anti-obesity effects of the ligand. Nat 
Med. 
Yano H, Torkin R, Martin LA, Chao M V., Teng KK (2009) Proneurotrophin-3 Is a Neuronal Apoptotic Ligand: 
Evidence for Retrograde-Directed Cell Killing. J Neurosci 29:14790–14802. 
Ye H, Kuruvilla R, Zweifel LS, Ginty DD (2003) Evidence in Support of Signaling Endosome-Based Retrograde 
Survival of Sympathetic Neurons. Neuron 39:57–68. 
Yu T, Scully S, Yu Y, Fox GM, Jing S, Zhou R (1998) Expression of GDNF family receptor components during 
development: implications in the mechanisms of interaction. J Neurosci 18:4684–4696. 
Yuzwa SA, Yang G, Borrett MJ, Clarke G, Cancino GI, Zahr SK, Zandstra PW, Kaplan DR, Miller FD (2016) 
Proneurogenic Ligands Defined by Modeling Developing Cortex Growth Factor Communication Networks. 
Neuron 91:988–1004. 
Zanin JP, Abercrombie E, Friedman WJ (2016) Proneurotrophin-3 promotes cell cycle withdrawal of developing 
cerebellar granule cell progenitors via the p75 neurotrophin receptor. Elife 5:1–21. 
Zanin JP, Unsain N, Anastasia A (2017) Growth factors and hormones pro-peptides: the unexpected adventures of 
the BDNF prodomain. J Neurochem 141:330–340. 
Zinman L, Cudkowicz M (2011) Emerging targets and treatments in amyotrophic lateral sclerosis. Lancet Neurol 
10:481–490. 
Zuo T, Qin JY, Chen J, Shi Z, Liu M, Gao X, Gao D (2013) Involvement of N-cadherin in the protective effect of glial 
cell line-derived neurotrophic factor on dopaminergic neuron damage. Int J Mol Med 31:561–568. 
Zweifel LS, Kuruvilla R, Ginty DD (2005) Functions and mechanisms of retrograde neurotrophin signalling. Nat Rev 
Neurosci 6:615–625.  
  
